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Physikalisch-chemische Aspekte
immunologischer und anderer
reversibler Assoziations-Reaktionen1)
(Thermodynamics) "is such a marvel-
ous tool: you don't understand what
you put in, and you don't understand
what you get out. But you know it must
be right."
Aharon Katchalsky
äs quoted
by G. Oster (1984)
Nature 309, 95
Von E. KUSS
L Frauenklinik der Universität München
(Eingegangen am 27. Dezember 1983)
Herrn Professor Dr. Dr. L Trautschold, dem Organisator und Moderator dieser Konferenz,
zum ehrenden Andenken
Zusammenfassung: Es werden die grundlegenden Begriffe, Symbole und Formeln reversibler Assoziationsre-
aktionen am Beispiel von Immunreaktionen zusammenfassend und im Hinblick auf ihre Anwendung im
Bereich der Analytik dargestellt (Kapitel 1). Die Enthalpien und Entropien der Aktivierung und Reaktion
werden unter Berücksichtigung der Ergebnisse neuerer Untersuchungen gedeutet (Kapitel 2). Die gängigen,
auch in den üblichen klinisch-chemischen Laboratorien durchführbaren Verfahren zur Ermittlung physika-
lisch-chemischer Kenngrößen auch komplexer Assoziationsreaktionen werden diskutiert (Kapitel 3); zur
Auswertung der Meßdaten wird auf die kürzlich in dieser Zeitschrift erschienene Übersicht verwiesen (E.
KUSS, J. Clin. Chem. Clin. Biochem. 20, 227-234 (1982)). Die Anwendung physikalisch-chemischer Kenn-
größen in der analytischen Praxis wird an Beispielen aufgezeigt (Kapitel 4).
Physical chemical äspects of immunological reactions and other reversible associations
Summary: The Standard concepts, Symbols, and formulae of reversible association reactions are comprehen-
sively illustrated with the aid of the immune reaction, and presented in the context of their use in analysis
(section 1). The enthalpy and entropy values of activation arid reaction are interpreted in the light of the
results of recent investigations (section 2). Common methods that can be performed in the ordinary clinical
chemical laboratory are discussed for the determination of physical chemical constants, including those of
complicated association reactions (section 3); Processing of experimental data was recently reviewed in this
Journal (E. KUSS, J. Clin. Chem. Clin. Biochem. 20, 227-234 (1982)). The use of physical chemical constants
in analysis is illustrated with examples (section 4).
1. Definitionen
Als immunologische Reaktionen werden die reversi-
blen Assoziatioösreaktionen bezeichnet, die zwi-
schen hydratisierten Irnmunglobulinen und ihren
ebenfalls hydratisierten Antigenen (oder deren spe-
zifischen Kompetitoren) ablaufen, und die zu Ifn-
munkomplexen führen. Die bipolaren Zentren der
Reaktionen sind in den Bindungsplätzen Qj der va-
riablen Domäne des Immunglobulins, den mögli-
cherweise unscharf begrenzten Regionen vom Aus-
maß etwa l nm2, lokalisiert und in den Bindungs-
plätzen Pi, den Immundeterminanten oder Epitopen
des Antigens, den von etwa 5 Aminosäuren oder
Hexosen oder von etwa einem Steroidmolekül aus-
gefüllten Raumstrukturen. Der endgültige Abstand
der sterisch und funktional komplementären Mole-
külgruppen der beiden Reaktionszentren im Köm-
]) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983. t
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plex wird auf einige 0,1 nm gesch tzt. Sterische und
funktionale Komplementarit t bedingen sich gegen-
seitig, da die molekularen attraktiven Kr fte nur
ber kurze Distanzen wirken (1—8).
Die physikalisch chemischen Aspekte der Immunre-
aktion werden auf die Analytik ausgerichtet, die der
Charakterisierung der zwei Gruppen von „Reaktan-
den", „Bindungsklassen" oder „Bindungsordnun-
gen"
Pi mit den „Ordnungen" i = l, 2, ... m;
Qj mit den „Ordnungen" j = l, 2, ... n;
und den daraus in reversiblen Reaktionen entste-
henden oder entstandenen Komplexen, Produkten,
j dient:
(Formel 1) P,· + Qj P.Q, .
k-iij
„Charakterisierung" beinhaltet die Bestimmung von
Qualit ten und Quantit ten der Reaktanden und
Produkte. Der Zusammenhang zwischen Qualit ten
und Quantit ten zeigt sich im Massenwirkungsgesetz
(Gl. 1) und in den damit zusammenh ngenden reak-
tionskinetischen und thermodynamischen Gleichun-
gen. Die m glichen Reaktionspartner Pi, Qj und ihre
Produkte PiQj sind in der Reaktionsmatrix (Abb. 1)
aufgef hrt. Aus den Spalten und Zeilen der Matrix
ergeben sich die Definitionen von pj und qy; die Defi-
nitionsgleichungen entsprechen dem Massenerhal-
tungsgesetz (Gl. 2).
i
 - κ -
"
 Κϋ
 "
(Gl. 2a) p, = [Pi] + [PiQj
l +Σ
V lf£* J^-ai
a=l *
(Gl. 2b) q, = [QJ + [Ρφ
l + Σi = l ή
Σ Kai [Qa],
[ ]: Aktivit ten im Reaktionsgleichgewicht (= Konzentratio-
nen mit Aktivit tsfaktor etwa 1)
KJJ·: Gleichgewichtskonstante der reversiblen Assoziationsreak^
tioii PJ + Qj -& PjQj
k+iij: Geschwindigkeitskonstante der Hinre ktion Pj -h Qj —»
R:
T:
e:
ΔΗ5:
Δ5?:
_ΔΟ; ^ΔΗ; ASJ
= e RT = e RT e R
Geschwindigkeitskonstante der R ckreaktion PjQj —» Pj -l·
QJ
Gaskonstante = 8,314 j mol"1 K"1
= molare Boltzmann^Konstante Nk,
N = Avogadro-Zahl == 6 Χ 1023 mo]"1;
k = Zto/rzma/z/i-Konstante
= 1,4 x 10~23 J K"1
Thermodynamische Temperatur (TEispunkt ^ 273,15 K)
lim (l + l/n)n = 2,718
n—»ac
(y = ex, dann In y = x)
Standard- nderung der G/^/w-Energie
Standard- nderung der Enthalpie
Standard- nderung der Entropie
l, 2, ... m
l, 2, ... n
Qi
Q2
Qn
Pi
PiQi
PiQ2
PlQn
P, + Σ P,Qj = p,
j-i
P2
P2Qi
P2Q2
P2Qn
P2 + Σ P2Qj = p2
Pm
PmQi
PmQ2
PmQn '
r
j
n
Pm + Σ PmQj == Pm
Qi 4- Σ PiQi = φ
Q2 Hr Σ P,Q2 = q2
Qn -H 2 PjQn = qn
Abb. 1. Reaktionsmatrix.
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In den Reaktionsansätzen, die als thermodynami-
sche Systeme mit konstantem Druck und konstanter
Temperatur betrachtet werden, können P\ und/oder
Qj hinsichtlich ihrer Mengen und Affinitäten regel-
mäßig oder unregelmäßig verteilt sein. Als regelmä-
ßig wird eine Verteilung bezeichnet, wenn sich die
Mengen symmetrisch um eine Menge mittlerer Affi-
nität verteilen.
Beispiel für regelmäßige Verteilung:
a) monoklonale Antikörper; identische Molekülspezies Qj mit
Anti Pj-Aktivität
b) polyklonale Antikörper mit Causs- oder Sips- Verteilung der n
verschiedenen Affinitäten der verschiedenen Molekülspezies
Qj mit Anti Pj-Aktivitäten (9).
Beispiel für unregelmäßige multimodale Verteilung:
n diskrete Antikörper-Ordnungen Qj mit Anti-Pj-Aklivitäten
(10).
Der Begriff Affinität bleibt thermodynamisch defi-
nierten Systemen vorbehalten. Die (relative) Bin-
dungsstärke von Antiseren als Resultante verschie-
dener, zum Teil gegenläufiger Effekte wird als Avi-
dität bezeichnet.
In PJ und/oder Qj können Ordnungen enthalten sein,
deren Elemente zu Aggregaten, z.B. der Art nQ
(oder mP) zusammengeschlossen sind. Von diesen
Aggregaten können sequentiell bis zu maximal n P
(bzw. bis zu maximal m Q) gebunden werden; in die-
sen Fällen bezeichnen m p und nq die Konzentratio-
nen der Bindungsplätze und p sowie q die Konzen-
trationen der Aggregate.
Beispiel für Aggregate:
m = 4: Ribonuclease (MT == 14000) mit 4 verschiedenen Bin-
dungsplätzen, Immundeterminanten pro Molekül; (5)
m = 106:Erythrocyt mit 106 identischen Bindungsplätzen, 1m-
mundetermirianten, vom (Blutgruppen-) Typ A pro
150 lim2.
n = 2: Immunglobulin G (Mr = 150000) mit 2 identischen
Bindungsplätzen pro Molekül; Abstand etwa 10 nm
n = 10: Immunglobulin M (Mr = 900000) mit 10 identischen
Bindungsplätzen pro Molekül; Abstand bis etwa 30
nm.
Die Besetzung eines der Biridungsplätze der Art "Q
kann die n - l restlichen Bindungsstellen des Ag-
gregates für den gleichen Reaktionspartner unbeein-
flußt lassen (Unabhängigkeit der Bindüngsstellen)
oder die restlichen Bindüngsstellen so beeinflussen
(homotrope Kooperativität), daß entweder deren
Affinität größer wird (positive homotrope Koopera-
tivität) oder kleiner wird (negative homotrope Ko-
operativität). Ordnungen von Pi oder Qj, die meßbare
Signale geben (Indikatoren) werden mit * gekenn-
zeichnet. Besonders für diese gelten Definitionsglei-
chungen und Ableitungen folgender Art (Beispiel
P*, markiertes Antigen; für Q*, markierte Antikör-
per, kann Analoges definiert werden):
[P*] = F; [P*Q] = B; p* m [P*] + [P*Q] ;
B B R
 = B
F ' T ~~ l + R; " q
F freie Bindungsplätze;
B besetzte Bindungsplätze;
T Gesamtzahl der eingesetzten Bindungsplätze
R Response, Wirkung einer bestimmten Dosis p oder q auf die
Verteilung des „Indikators"
r Anteil der besetzten Bindungsplätze an der Gesamtzahl der
Bindungsplätze (r' s B/p).
2. Reaktions-Energien
*
In einem System kann eine Assoziation von P·, und
Qj prinzipiell dann stattfinden, wenn
1. einzelne Elemente (z.B. Moleküle) des Systems
hinreichend große Energien besitzen, deren Summe
in einer Größe E ^ EQ (Schwellenenergie) zusam-
mengefaßt wird, und wenn diese Moleküle hinrei-
chend häufig richtige Orientierungen zueinander
eingehen, deren Wahrscheinlichkeit in einer Größe
A enthalten ist. E und A können mit Hilfe der expe-
rimentell zugänglichen Reaktions-Geschwindig-
keitskonstante k charakterisiert werden (11).
2. die mit der Reaktion verbundene Änderung der
G/öfoschen Energie , der Differenz aus Reak-
tions-Enthalpie-Glied und Reaktions-Entropie-
Glied 8, des gesamten Systems einen negativen
Wert erhält ( < 0). , und 8 können mit
Hilfe der experimentell zugänglichen Konzentratio-
nen der Reaktionspartner und deren Quotient K
charakterisiert werden. Ein Reaktionsgleichgewicht
ist dann erreicht, wenn die G/&fosche Funktion ein
Minimum erreicht hat (12).
Die Aussagen 1) und 2) sind in Gleichung l enthal-
ten.
Zu 1): Die Theorie der molekularen Übergangszustände (z.B.
PiQ^ in Pj + QJ «± PiQ* <± PjQj) führte zu Gl. 3; die Theorie der
Molekül-Kollisionen ergab ähnliche Ausdrücke (siehe z.B. J. H.
Knox> Molecular Thermodynamics, Chichester 1978).
Die strukturelle Analogie von Gleichung 3 zur empi-
rischen mit üblichen Labortechniken experimentell
nachprüfbaren Gleichung 4 ist offensichtlich. Des-
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wegen kann Gleichung 3 zur Deutung, Gleichung 4
zur Bestimmung der unbekannten Parameter heran-
gezogen werden (11, 13, 14).
kT(Gl. 3) k = -^e
ASAi
R
A
RT
(Gl. 4) k = Aexpe RT
1 1 1 A EeXpIn k = In Aexp - -^
k + n j oder k-uj von Gleichung l
Planck-Wirkungsquantum 6,6 x 10~34 Js
Entropie der Aktivierung
AHAki: Enthalpie der Aktivierung
Aexp: Präexponentialfaktor
ECxP: experimentelle Aktivierungsenergie
ic, T, e, R: s. Gl. l, Legende
Zur Ermittlung Von Aexp und Eexp werden im allge-
meinen die Werte der Reaktions-Geschwindigkeits-
konstanten k bei verschiedenen Temperaturen be-
stimmt. Diese liegen im >l/T/zemMS-Diagramm (In k
vs. l/T) nach Gleichung 4 auf einer Geraden. In der
Praxis gilt der Anstieg der Geraden als Quotient
Eexp/R und der Ordinatenabschnitt bei l/T —» 0 als
In Aexp. Da zumeist von Reaktionen mit Proteinen
nur die k-Werte eines engen Temperaturbereiches
eingesetzt werden können, sind insbesondere die
durch Extrapolation gewonnenen Werte von Aexp
mit großen Fehlern behaftet. Die ermittelten Werte
sind innerhalb des Meßbereiches und innerhalb der
Meßgenauigkeit konstant, d.h. anscheinend unab-
hängig von der Temperatur, wogegen die Theorie ei-
ne Temperaturabhängigkeit der Aexp und Eexp zu-
grundeliegenden molekularen Werte einschließt.
Zur Deutung von Eexp und Aexp bzw. zur Bestim-
mung von « und ASAkt werden die Gleichungen
3 und 4 verglichen; offensichtlich entspricht die Ak-
tivierungs-Enthalpie dem Wert Eexp-RT
und die Aktivierungs-Entropie ASAkt dem Wert R In
(AexpNh/RT)-R. Aus der Gleichung folgt ferner-
hin, daß die Geschwindigkeit einer Reaktion um so
größer ist, je kleiner die Enthalpiezunahme und je
größer die Entropiezunahme beim Übergang vom
Grundzustand Pj + Qj oder PjQj zum Übergangszu-
stand PjQ* der Reaktion ist.
Ein großes positives Enthalpieglied wird als Deh-
nung oder Stauchung chemischer Bindungen bei
Ausbildung des Ubergangszustandes gedeutet. Ein
großes negatives Entropieglied gilt als Ausdruck der
geringen Wahrscheinlichkeit der Ausbildung präzi-
ser komplementärer Konformationen und Berüh-
rungswinkel der Reaktanden Pj und Qj. Von Protein-
Bindungsreaktionen wird angenommen, daß sich die
Aktivierungsentropie ASAkt nicht wesentlich von der
Reaktionsentropie 8 (siehe Gleichung 5) unter-
scheidet, d.h., daß die Entropie von PjQj* der Entn>
pie von PjQj etwa gleich ist. Die wenigen bisher vor-
liegenden experimentellen Befunde sind nicht ganz
einheitlich. Aus der Tatsache, daß k+i kaum tempe^
raturabhängig ist und zumeist nicht wesentlich unter
den für diffusionskontrollierte Reaktionen zu erwar-
bt/rAemws-Gleichung tenden Werten liegt (109 l mol""^"1), wurde ge-
schlossen, daß zur Assoziation von Liganden an Pro-
teine keine großen Aktivierungsenergien benötigt
werden (13, 14); Beispiele für offenbar nicht-diffu-
sionskontrollierte Assoziationsreaktion siehe z.B.
I.e. (6), (15). Die Aktivierungsenergie zur Dissozia-
tion steroidaler Haptene von Antikörpern lag mit
42—63 kJ/mol (10—15 kcal/mol) deutlich unter dem
für die Dissoziation von Cortisol-Transcortin gemes-
senen Wert von 151 kJ/mol (36 kcal/mol). Für die-
sen Komplex ist auch eine relativ hohe Aktivie-
rungsenergie der Assoziation gemessen worden (109
kJ/mol = 26 kcal/mol). Dagegen wird die Konfor-
mation eines Immunglobulins durch die Assoziation
eines stefoidalen Haptens offenbar nur geringfügig
verändert (6, 16, 17).
Zu 2): Die mit Gleichung l definierte Änderung der Gibbsschen
Standardenergie AG° gilt für Standardreaktionen. Die allgemein
mit Fortschreiten einer Reaktion verbundene Änderung der
Gibbsschcn Energie AG wird durch die Gleichungen 5 und 6 fest-
gelegt.
Nach Gleichung 5 wird die Negjativität von G umso
größer und somit auch die Triebkraft einer Reaktion
um so größer, je kleiner die Enthalpiezunahme ist
(durch größeres negatives ) und je größer die
Entropiezunahme ist (durch größeres positives
TAS); sie ist abhängig von den Ausgangs-Konzen-
trationen der Reaktionspartner (zum chemischen
Potential des gebundenen Liganden, dG/dn, siehe
I.e. (18)).
Zur Normierung der in Gleichung 5 und Gleichung 6
enthaltenen Größen AG, und 8 wurden die
Standardreaktionen definiert, an deren Beginn alle
Reaktionspartner in der Konzentration l (z.B. l
mol/1) und an deren Ende alle Reaktionspartner in
den jeweiligen Gleichgewichtskonzentrationen vor-
liegen. Durch diese Normierung wird In · \ s= In l =
0 und In Kf^ = In K (K == Gleichgewichtskonstante)
und somit Gleichung 6 zu Gleichung 7 und Glei-
chung 8, den logarithmierten Formen der Gleichung
1. Die zugehörigen Potentialdifferenzen werden als
Standardpötentiale °, ° und 8° bezeichnet.
Durch Differenzierung wird Gleichung 9a erhalten.
Gleichung 9a kann integriert werden, wenn im inter-
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essierenden Bereich ΔΗ° von der Temperatur unab-
h ngig ist. Als Folge davon erh lt man die Gleichung
9b, ein Analogon der ,4n7ien/Hs-Gleichung (GL 4).
( l. 5) AG = ΔΗ - ΤΔ5
Gibbs-Helmholtz-Gleichung
(Gl 6) ΔΟ = RT In ^
(GL 7) ΔΟ° = - RT In K = - RT In ±i
(Gl. 9a) van't //o//-Gleichung
(Gl. 9b) In K = - ΔΗ° ^ = + C
(GL 10) = Δθρ° /CJrc/z0//-Gleichung
ΔΟ: nderung der G/6 s-Energie
ΔΗ: nderung der Enthalpie
AS: nderung der Entropie
Δ Cp: nderung der W rmekapazit t
Κ™: Quotient der initialen Konzentrationen der Reaktionspart-
ner [ Jini
Kfin: Quotient der finalen Konzentrationen der Reaktionspartner
l l f i n
Z hler der Quotienten: kontinuierliche Multiplikation der
Konzentrationen der Reaktionsprodukte; st chiometrische
Koeffizienten als Exponenten.
Nenner der Quotienten: kontinuierliche Multiplikation der
Konzentrationen der Reaktanden; st chiometrische Koeffi-
zienten als Exponenten.
z.B. f r: 1P -l· IQ ^± 1PQ
Kir
κKf in
~ [P]UQ]in
Die Zahlenwerte f r Δθ° (bzw. ΔΟ) lassen sich un-
mittelbar aus den Werten von K (bzw. von Kini und
Κίίη) errechnen (GL 6 bzw. GL 7). Theoretische
Sch tzung ber Van der Waa/s-Interaktion///awfl-
for-Konstanten der Assoziation von P und Q kl der
Gasphase mit nachfolgender Hydratation f hrt als
kleine Differenz gro er Zahlen erwartungsgem
nur ungef hr in den Bereich der experimentell er-
mittelten ΔΟ° Werte (8).
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Die Zahlenwerte von ΔΗ° lassen sich nach Glei-
chung 9b aus der Temperaturabh ngigkeit der K-
Werte ermitteln. Hiernach liegen die K-Werte im
van91 //^//-Diagramm (In K vs. l/T) auf einer Gera-
den. In der blichen Laborpraxis gilt der Anstieg der
Geraden als Quotient ΔΗ°/Κ. Da aber im strengen
Sinne sowohl ΔΗ° wie auch Δ8° von der Temperatur
abh ngen, sind die Voraussetzungen f r den ber-
gang von Gleichung 9a zu Gleichung 9b nicht gege-
ben und im van't Ho/jf-Diagramm ist ein nicht-linea-
rer Verlauf der K-Werte zu erwarten. In der tempe-
raturabh ngigen nderung von ΔΗ° dr ckt sich
ACp aus, der Unterschied der Summen der spezifi-
schen W rmen von Reaktanden und Produkten
(Kirchoff-Salz). Die Zahlenwerte von ΔΗ (= W r-
met nung der Reaktion) lassen sich auch, und bei
Temperaturabh ngigkeit von ΔΗ richtiger, direkt im
Kalorimeter bestimmen. L t man die Reaktion im
Kalorimeter bei verschiedenen Temperaturen ablau-
fen, kann man aus der Temperaturabh ngigkeit der
W rmet nung den Wert von Δ€£ berechnen, bei li-
nearem Verlauf als ΔΗ°/ΔΤ, sonst ber quadrati-
sche Regression (z.B. ΔΗ° = A + BT + CT2; C£ =
B + 2CT).
Die Zahlenwerte von Δ8° werden nach Gleichung 5
durch Differenzenbildung aus den Werten von ΔΟ°
und ΔΗ° berechnet oder aus dem Achsenabschnitt,
in Analogie zur Aktivierungsentropie (GL 4).
F r konkrete Reaktionen sind die numerischen
Werte der Potentiale zumindest n herungsweise ex-
perimentell bestimmbar. Wegen der unvermeidli-
chen Abweichung der experimentellen Bedingungen
von „Standardbedingungen" (z.B. In [H+] = 0!)
k nnen nur „apparente" Werte ermittelt werden,
was durch z.B. ΔΟ0/, ΔΗ0', und Δ8°' gekennzeich-
net werden sollte; die experimentellen Bedingungen
sind anzugeben (z.B. 25 °C (298,15 K); pH 7,6 lo-
nenst rke 0,1 mol/1) (19).
Die Gz' foschen Potentiale der Immunreaktionen
egen bei -21 bis -63 kJ/mol (-5 bis -15 kcal/
mol). Immunreaktionen erwiesen sich zum Teil als
berwiegend Enthalpie-getrieben, zum Teil als
berwiegend Entropie-getrieben; es wurden sowohl
positive wie auch negative Werte f r ΔΟ° publiziert
(4, 6, 13, 20). Auch die Frage, ob die Dispersion der
Δθ°-Werte einer „nat rlichen" Antik rperpopula-
tion auf die Streuung des Enthalpie- oder des Entro-
pie-Gliedes zur ckzuf hren ist, bleibt offen, auch
wenn zuletzt das Enthalpie-Glied als Ursache der
Streuung von Δθ° favorisiert wurde (21). Zumin-
dest an einigen Hapten-Antik rper-Paaren wurde
eine Enthalpie-Entropie-Kompensation nachgewie-
sen. Mit steigender Temperatur ging der Einflu des
Enthalpie-Anteils zugunsten des Entropie-Anteils
zur ck (22).
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Die Deutung von °, 8° und AC£ als Ergebnis
molekularer Vorgänge muß Änderungen der Reak-
tanden und des Lösungsmittels berücksichtigen, da
sich mit der Reaktion auch die Solvatationszustände
ändern (statt Formel l besser:)
PI(N + m H20) + Qj(y + n H20) *=*· PiQj(m + n H2O)
+ ( + y) H2o
Die vorliegenden Deutungen sind unvollständig, da
die thermodynamischen Potentiale die Summe aller
molekularen Prozesse repräsentieren und da der
Nachweis von Änderungen einzelner Molekülspe-
zies mit Hilfe von z.B. Röntgen- oder NMR-Spek-
troskopie noch nicht abgeschlossen ist. Lediglich ei-
ne Struktur-unabhängige und somit unspezifische
Komponente des Entropie-Terms, eine Mischungs-
entropie, kann aus der Standard-Entropie-Ände-
rung 5° einfach eliminiert werden. Hierdurch wer-
den Werte für die „unitarische" Entropie-Änderung
ÄSU und für die entsprechend abgeleitete „unitari-
sche" Änderung des Gibbsschen Potentials AGU er-
halten, mit denen die Stabilität des Komplexes bes-
ser charakterisiert werden kann.
ASU = 5° + R In 1/[H2O]
AGU = ° - R In 1/[H2O]T
(R In 1/[H20] = 33,5 J mol'1 K"1
= 7,98 cal mor1 K-1
(3, 7, 8, 12, 14, 22, 23).
[H2O] = 55,6 mol/I
Der Energiegewinn, der mit der Assoziationsreak-
tion verbunden ist, d.h. die Negativität von AG°,
wird auf die Summation zahlreicher, im einzelnen
schwacher und z.T. gegensinnig wirkender Kräfte
zurückgeführt, die aus den Wechselwirkungen ver-
schiedener Molekülgruppen resultieren, überwie-
gend sind dies die van der Wßöfc-Kräfte, die Wasser-
stoffbrücken-Bindungen und die hydrophoben
Wechselwirkungen, d. h. die Minimierung der Expo-
sition unpolarer Gruppen und die Maximierung der
Exposition polarer und ionischer Gruppen.
Beim Lösen unpolarer Gase in Wasser (25 °C) wird
wegen der Neuorientierung der Wassermoleküle an
den Grenzflächen (Ausbildung „eisartiger" Struktu-
ren) die negative Entropie-Änderung das Gibbsschc
Potential bestimmen und wegen der Ausbildung von
Wasserstoff-Brücken wird eine positive Änderung
der Wärmekapazität erwartet („Schmelzen" der eis-
artigen Strukturen). Beim Lösen von Ionen in Was-
ser wird wegen der -Dipol-Wechselwirkung die
positive Enthalpie-Änderung das Gibbssche Poten-
tial bestimmen und wegen der Verminderung von
Wasserstoff-Brücken wird eine negative Änderung
der Wärmekapazität erwartet. Die Umkehr derarti-
ger Effekte bei der Assoziation von P und Q im Be-
reich der Kontaktregionen von P und Q, die zusätzli-
chen intermolekularen Wechselwirkungen zwischen
P und Q und die Energiebeiträge? durch intramole-
kulare Konformationsänderungen von P und Q er-
geben als Summe die meßbaren Änderungen AG°,
°, AS° und AC°. Die oben genannte Enthalpie-
Entropie-Kompensation könnte wie folgt verlaufen.
Bei niedrigen Temperatüren wird die negative Ge-
samt-Enthalpie- und -Entropie-Änderung überwie-
gend durch die „intrinsische" Enthalpie- und Entro-
pie-Änderung der Komplexbildung bestimmt. Die
mit steigender Temperatur zunehmende Verminde-
rung der Negativität mit Übergang zu positiven Wer-
ten der Gesamtpotentiale wäre eine Folge der Ent-
halpie- und Entropie-Änderung durch Vorgänge im
Lösungsmittel. Aus dem gegensinnigen Einfluß der
Enthalpie- und Entropie-Änderungen resultiert eine
im Meßbereich ungefähr konstante Änderung des
Gibbsschen Potentials.
3. Reaktions-Geschwindigkeitskonsfanten und Re-
aktions-GIeichgewiditskonstanten
Die Berechnung von Aexp, Eexp, °, ° und AS°
setzt die Kenntnis der Geschwindigkeitskonstanten
k+i, k-i und/oder die Kenntnis der Gleichgewichts-
konstanten K = k+]/k_] bei verschiedenen Tempe-
raturen voraus. Die Größen k und K können unab-
hängig voneinander experimentell bestimmt werden,
k über die Reaktionsgeschwindigkeiten, K über die
Gleichgewichts-Konzentrationen. Als Quotient von
k+i und k_i kann K auch über die Reaktionsge-
schwindigkeiten ermittelt werden. Da beide Verfah-
ren mit systematischen experimentellen Fehlern be-
haftet sein können, empfiehlt sich der Vergleich der
nach beiden Verfahren gewonnenen Ergebnisse. Für
eine subtilere Behandlung der Reaktionskinetik
auch mehrwertiger und trägerfixierter Reaktions-
partner mit Unterscheidung der diffusiven und reak-
tiven Anteile von k und K siehe z.B. I.e. (24).
Reakt ions-Geschwindigkei tskonstanten
Die durch Formel l definierte reversible Reaktion
setzt sich aus den Partialreaktionen nach Formel
und l" zusammen.
c>
(Formel l') P{ + Qj -^-»PiQ,
(Formel l") PiQj -^->Pi + Qj
[ ] bedeutet im folgenden „Konzentration zur Zeit t", also nicht
mehr „Gleichgewichtskonzenträtion" [ ]&,.
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Wird die Reaktion nach Formel gestartet, findet
zur Zeit t0 ausschließlich die Assoziationsreaktion
statt (v_i = 0), deren Geschwindigkeit v+i durch
Gleichung 11 definiert, zur Zeit t0 maximal ist.
( ,, ) v„ - - ÜB - --ßl- SSIdt dt dt
Wird die Reaktion nach Formel l" gestartet, findet
zur Zeit t0 ausschließlich die Dissoziationsreaktion
statt (v+i = 0), deren Geschwindigkeit v_i, durch
Gleichung 12 definiert, zur Zeit t0 maximal ist.
«a«,
Zu irgendeinem Zeitpunkt zwischen t0 und täq sind
beide Geschwindigkeiten, v+1 und v_i von Null ver-
schieden und es gilt Gleichung 13 (Analytische Lö-
sung: I.e. (26).
(Gl. 13) d[PQ] _ d[P] = d[Q]dt dtdt
= k+1[P] [Q] - k-,[PQ] 0
Zur Zeit täq hat sich das kinetische Gleichgewicht der
Reaktion eingestellt. Von diesem Zeitpunkt an gilt
Gleichung 14 a—c.
(G,.14a)«91=-ffl,-^l
(Gl. 14b)
= k+i[P] [Q] - k_,[PQ] = 0
[Q] = k_![PQ]
Zur experimentellen Bestimmung einer der beiden
Geschwindigkeitskonstanten der Gleichung 13 kann
durch geeignete Versuchsbedingung die jeweils ge-
genläufige Reaktion unterdrückt werden, so daß
nach Gleichung 11 oder Gleichung 12 gerechnet
werden kann (6, 25, 26, siehe aber auch I.e. 24).
Bestimmung von k+j
Unter der Voraussetzung v+J > v_i ist k+i schwieri-
ger zu bestimmen als k-i. Als maximale Assozia-
tionsgeschwindigkeit gilt die diffusionskontrollierte
Reaktion mit k = 109 l
l
(t]/2 =
k[P]o = 10
 9
 s bei Konzentrationen von
l mol/1). Im allgemeinen liegen Bestimmungen die-
ser Art außerhalb der Möglichkeiten der üblichen
Labortechnik; es werden z.B. Strömlings- und Rela-
xationsmethoden notwendig (16, 27). Bei niederen
Konzentrationen und hohen Affinitäten der Reak-
tanden ist es jedoch möglich, mit den üblichen La-
bormethoden auch für die Geschwindigkeitskon-
stanten der Assoziationsreaktionen Näherungswerte
zu erhalten, selbst wenn kein „inneres Signal" der
Moleküle eine Unterscheidung von P* und P*Q er-
möglicht, sondern zu ihrer Bestimmung eine Tren-
nung dieser Molekülspezies erforderlich ist (6, 2.5).
Wenn v+i > v-j, dann kann, zumindest in der Initial-
phase der Reaktion, statt Gleichung 13 die Glei-
chung 11 verwendet werden. Sie wird zur Gleichung
15 umgewandelt.
(Gl. 15)
k+, dt =
= k+1(p - [PQ]) (q - [PQ])
d[PQ]
(p - (q -
Durch Integration erhält man die Gl. 16 und 17
(25).
16) k t 1 in PÜ ~ tPQ»• 6) +l t - _ p In ( _ [pQ])
P
q(Gl. 17) k+1 t(q - p) = In £ + i„ * _ |^ |
Gleichung 17 zeigt, daß die Steigung der beim Auf-
tragen von
. q - [PQ]
gegen die Zeit t erhaltenen Geraden k+i(q - p) be-
trägt. Es ist also prinzipiell möglich, k+i zu bestim-
men, wenn die Konstanten p und q bekannt sind und
die Veränderung von PQ zuverlässig bestimmt wer-
den kann.
Wählt man im Experiment ein Verhältnis p/q « ^
10 oder ^ ^ 1/10, dann wird von Gleichung 15 der
Ausdruck p — PQ « p oder es wird der Ausdruck q
— PQ « q: die Meßdaten können dann als Daten
einer pseudo-monomolekularen Reaktion behandelt
werden (siehe GL 18).
Weichen die transformierten Meßdaten von der Li-
nearität ab, kann die Richtigkeit des gewählten Mo-
dells überprüft werden; in Anbetracht der Schnellig-
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keit der Reaktion dürften Fehler in der Versuchsan-
ordnung oder Messung als Ursache für die Abwei-
chung von der Linearität wahrscheinlicher sein. Es
kann auch auf eine apparente Geschwindigkeitskon-
stante kapp übergegangen werden:
'
Bäq (B,,- B,) (28)-
Bestimung von k-1
Da nach Voraussetzung v_j <^ v+i, muß die Rück-
Assoziation P -l· Q —> PQ unterbunden werden.
Wenn dies möglich ist (kompetitive Hemmung der
Bindung von P, Adsorption von P), kann von Formel
l" und somit auch von Gleichung 12 ausgegangen
werden; Gleichung 12 wird umgeformt zu Gleichung
18 (siehe z.B. I.e. (6), (25), (26)).
(Gl. 18) k-, dt = -
-i t = - In [PQ], - In [PQ]0 = - In [PQ]t[PQ]o ·
Die Gleichung 18 zeigt, daß beim Auftragen des lo-
garithmierten Quotienten (PQ-Konzentrationen zu
verschiedenen Reaktionszeiten t dividiert durch die
PQ-Konzentration zur Zeit t = 0) gegen die Reak-
tionszeit t eine Gerade mit der Steigung k-i erhalten
wird.
Weichen die transformierten Meßdaten von der Li-
nearität ab und können Fehler in der Versuchsa-
nordnung und Messung ausgeschlossen werden, so
ist zu prüfen, ob nicht statt Qj = Q, z.B. das Modell
QJ (j = l, 2, . . . n) den Daten besser anzupassen ist
(26, 28). Über scheinbare negative Kooperativität
siehe I.e. (24). Wenn es die Dissoziations-Geschwin-
digkeitskonstante ist, die den Wert der Gleichge-
wichts-Konstante im wesentlichen bestimmt, dann
liegen die Werte für k_i von Immunkomplexen zwi-
schen 10~5 s"1 (eine Dissoziation pro Monat) und
l O6 s"1 (eine Dissoziation pro $) (14).
Einklang zu bringen ist. Als diagnostisches Hilfsmit-
tel empfiehlt sich die Transformation der Gleichung
l, mit i = l, j = l,
a) nach Langmuir^Michaelis-Menten
_ q K F
B
 ~ l + K F
b) nach Scatchard
r/F = - Kr + K
c) nach Sips-Hill-Nernst
ln(B/(q - B)) = aln K + aln F
Aus der Lage der Meßpunkte in den Diagrammen B
vs. F, r/F vs. r, ln(B/(q - B)) vs. F, wird auf Abwei-
chungen vom einfachsten Modell, i = l, j = l, K,j =
K, geschlossen; je nach Plausibilität wird eines der
folgenden Modelle den realen Versuchsbedingungen
unterlegt (26, 29, 30).
1. Modell·, m Ordnungen von unabhängigen Anti-
gen-Bindungsplätzen
n Ordnungen Von unabhängigen Anti-
körper-Bindungsplätzen
(Modell konkurrierender Reaktionen)
Die in Gleichung l enthaltenen n x m Gleichungen
und die in Gleichung 2 enthaltenen n -l· m Gleichun-
gen lassen sich durch Substitution von \P\ Qj] in Glei-
chung 2 komprimieren zu den -Gleichungen der
Gleichung 2a oder zu den m-Gleichungen der Glei-
chung 2b, mit denen die n x m Gleichgewichte der
Matrix (Abb. 1) determiniert sind.
Zur weiteren Rechnung wird die Gleichung bevor-
zugt, die die wenigsten Indices beinhaltet. Wenn also
m < n, wird Gleichung 2a bevorzugt und zur Glei-
chung 19 umgewandelt (31).
Da
B T - F
gilt die Scatchard Transformation (Gl. 19).
Reaktion s-Gleich gewichtskonstanten
Zur Berechnung der Gleichgewichtskonstanten aus
bekannten Größen (z.B. p) und den gemessenen
Konzentrationen (z.B. B, F) sind Vorkenntnisse
über Eigenschaften der Reaktionspartner erforder-
lich. Aus diesen Vorkenntnissen werden Mödellvor-
stellungen entwickelt und es wird geprüft, wie weit
das hypothetische Modell mit den Meßwerten in
(01.19) . - - i .
l + 21 Kaj [Pa]
Die Parameter pi, qj und Kij können mit Hilfe elek-
tronischer Datenverarbeitung an die Ergebnisse ex-
perimenteller Versuchsreihen angepaßt werden, die
im allgemeinen aus den Gleichgewichts-Konzentra-
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tionen eines markierten Antigens bestehen, dessen
Dosis pj variiert wird. Gleichung 19 kann nicht ana-
lytisch gelöst werden, sondern nur numerisch z.B.
mit Hilfe von Iterationsverfahren. Da die Anzahl be-
rechenbarer Parameter durch die Anzahl informati-
ver Meßpunkte begrenzt ist, können selten für mehr
als 5 Parameter Zahlenwerte ermittelt werden, für
die bereits über 25 Meßpunkte gefordert werden
(26, 29).
2. Modell: m = l Ordnung von Antigen-Bindungs-
platzen
n Ordnungen von Antikörper-Bindungs-
plätzen
(Modell zur Charakterisierung einer An-
tikörper- oder, allgemeiner, einer „Re-
zeptor'Topulation)
Wenn Pi zu P oder P* wird, vereinfacht sich Glei-
chung 19 zu Gleichung 19b.
(Gl. 19b) R = ij qj KI qil + Kj[F]
KZ qi
l + K2[F] + ...+
qn
l + K„[F]
a) Wenn das System neben den Antikörper-Bin-
dungsplätzen („spezifische Binder") einen „Binder"
Qm mit niedriger Affinität und hoher Kapazität (z.B.
„unspezifische Adsorption") enthält, dann wird
Kn[F] -» 0 und somit Knqn/(l + Kn[F]) zur Konstan-
ten Knqn = N
b) Wenn für das System eine Ordnung von Antikör-
per-Bindungsplätzen mit einer mittleren Bindungs-
energie
0° = RT In K
n
 n IC
K = ^-^·
definiert werden kann, dann verteilen sich alle
symmetrisch um ÄG°. Das Maß für die Breite der
Verteilung, d.h. für die Heterogenität der Antikör-
per, ist
, wenn eine Gauss-Verteilung angenommen wird
a, wenn eine Sips-Verteilung angenommen wird.
Die Annahme einer Gauss^Verteilung führt zu Glei-
chung 20, die Annahme einer Sips-Verteilung zu
Gleichung 21 (32).
(01.20) ..i- ß =
(Gl. 21) r = KF«l + KF" In l - r = K F;
(a = 0 s£ a =£ 1)
Sips-Hiü Transformation
Zusammenhang zwischen und a:
o = 2 V3F cot (r)
Konkrete Bedeutung von o und a:
Bereich mit 75% der Bindungsstellen
0,5 4,3 0,0025 bis 40 K
0,7 2,4 0,16 6
0,8 * 1,8 0,27 3,7
1,0 0,0 alle Bindungsstellen l x K
d.h.Kj = K
Zur Berechnung des Heterogenitäts-Index wird nach Gleichung
21 ln(r/(l - r)) gegen F aufgetragen (5/pJ-/////-Diagramm); hier-
zu muß q bereits bekannt sein, ggf. aus dem Scatchard-Diagramm
ermittelt sein. Der Anstieg der Geraden ergibt a; zur Bedeutung
der Asymptoten bei nicht-linearem Sips-/////-Graph, siehe z.B.
I.e. (30); neuere Behandlung der Verteilungsfunktion siehe z.B.
I.e. (9).
Für jedes und gilt, daß die mittlere intrinsische Assoziations-
konstante K den reziproken Wert von [P] bei Halbsättigung von q
(bzw. n x q) entspricht; dieser Wert ist im So7/c/zfl/Y/-Diagramm
unmittelbar zugänglich.
c) Wenn die Bindungsplätze Pi und/oder Qj des An-
tigens und/oder des Antikörpers zu Aggregaten zu-
sammengefaßt sind, z.B. mehrwertiges Antigen und/
oder mehrwertiger Antikörper, deren Bindungsplät-
ze sequentiell besetzt werden, dann können deren
intrinsische Affinitäten und damit deren intrinsischej
Gleichgewichtskonstanten K identisch oder nicht-
identisch sein. Bei ungleichen intrinsischen Affinitä-
ten kann die Verschiedenheit von vornherein vorge-
geben sein oder durch die vorangegangene Bindung
induziert worden sein.
Im folgenden wird Q(nQ) als mehrwertig, n wertig,
behandelt; die Indices (j = l, 2 ... n) von P bedeu-
tend abweichend vom bisherigen Gebrauch die stö-
chiometrischen Faktoren und nq die Gesamtzahl der
Bindungsplätze.
J. Clin. Chem. Clin, Biochem. / Vol. 22,1984 / No. 12
860 KUSS: Physikalisch-chemische Aspekte reversibler Assoziations-Reaktionen
(Gl. 22)
P + "Q = P"Q; K, = n K;
P + P«Q = P2"Q; K2 = K;
KJ: thermodynamische (experimentelle) Gleichgewichts-Kon-
stante des jtcn Liganden.
B
r ss —q
Im Scatchard-OiagTamm r/F = /(r) werden die Meß-
werte aufgetragen. Die Differenzierung von Glei-
chung 24 ergibt folgende Grenzwerte
Pj-,nQ = PjnQ; _ n - j F-»0 und für F-*
Pn-inQ = PnnQ; K n =
Bei n wertigen Einheiten wird das Verhältnis der
„experimentellen" Gleichgewichtskonstanten KJ zuj
den „intrinsischen" Gleichgewichtskonstanten K
durch den „statistischen" Faktor ausgedrückt
(Gl. 23).
(Gl. 23) n - j -h l _ KJ
K
Statistischer Faktor: Die Wahrscheinlichkeit, daß P
mit einer n-wertigen Einheit, von deren n Bindungs-j
stellen mit K = K noch keine besetzt ist, an einer der
n Stellen assoziiert, ist -mal wahrscheinlicher, als
daß nach Besetzung von n - l Stellen die letzte, also
die nte Stelle besetzt wird. Deswegen wird KI zu nK.
Der initiale Anstieg des Graphen ist also durch die
Parameter der beiden ersten Bindungen charakteri-
siert, der finale Anstieg des Graphen ist durch die
Parameter der letzten Bindung charakterisiert (30)
 ?
Die Gleichung 24 ist die allgemeine Form der Adair-
Gleichung, die 1925 entwickelt wurde, um die Bin-
dung von Ü2 an Hb zu beschreiben (n = 4)
Die Adair-Gltichung ist u.a. geeignet, um folgende
Probleme zu behandeln:
l
K
2
K
n
. < K
positive
Kooperativität:
negative
Kooperativität:
gemischte
Kooperativität:
gleichwertige
unabhängige ,
 2 n
Bindungsstellen: K = K = . . . = K.
l 2 n
K > K > . . . > K
l 2 i i+1
K < K ... K > K .
n
. . K
Die Wahrscheinlichkeit, daß P von einer n-wertigenj
Einheit, von deren n Bindungsstellen mit K = K alle
mit P besetzt sind, PnnQ> von einer der n Stellen ab-
dissoziiert, ist -fach wahrscheinlicher, als daß P von
einer nQ Einheit abdissoziert, von der erst eine der n
Stellen besetzt ist. Deswegen wird Kn zu l/n K.
Die Gruppe Gleichung 22 kann unter Verwendung
von Gleichung 23 zur Adair-Funktion (Gl. 24)
transformiert werden (14, 30).
j ,
(G1.24) r = i=1
n
l + P
• : >ldm>-Konstanten, deren molekular-physikalische Bedeu^
tung vom Typ der Assoziations-Reaktion abhängt.
K, x K2 . . . K) j
Gleichung 24 kann durch Si/?s-/fi//-Afernsr-Transfor-
mation (Gl. 21) umgewandelt werden in einen Aus-
druck der Art
log = log (-
Dieser Ausdruck geht für sehr kleine Werte von [P]
über in
log K + log [P]
und für sehr große Werte von [P] über in
log K 4- log [P],
diese Ausdrücke definieren Asymptoten der durch
Gleichung 24 definierten Funktion y = /(x). Sie er-
n l
geben (y -» 0) Werte für K und K. Diese Werte ste-
hen in Zusammenhang mit der. empirisch gefunde-
nen Funktion (Gl. 25),
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log = log K + log [P]
Sips- Hill-Nernst-Gleichung
a: 5/p$-///7/-Koeffizient:
l < a ^  n: positive Kooperation
0 < < l : negative Kooperation, Heterogenität,
(Quervernetzung, s. Modell 3b)
1 = gleichwertige unabhängige Bindungs-
stellen
(Über den Zusammenhang zwischen Adair-Glei-
chung (Gl. 24) und /////-Gleichung (Gl. 25) siehe 1. c.
(30).
l 2 n
Wenn (in Gleichung 24) K = K = . . . = K gesetzt
wird, vereinfacht sich die Gleichung zu Glei-
chung 26.
also wird bei nQ mit n unabhängigen gleichwertigen
Bindungsstellen für P pro Einheit das Ausmaß der
Bindung von P n mal größer als für Q mit einer ein-
zelnen Bindungsstelle pro Einheit mit der gleichen
inneren Gleichgewichtskonstanten K.
3. Modell: m Ordnungen von Antigen-Bindungs-
plätzen, zu mP aggregiert.
2 Ordnungen von Antikörper-Bindungs-
plätzen, zu 2Q aggregiert (z.B. IgG)
(Modell der Präzipitation und Aggluti-
nation).
a) m = 2: Die Interaktion von zweiwertigem, im
Unterschied zu *P makromolekularem 2P mit
zweiwertigem 2Q führt, in Abhängigkeit von den
Verhältnissen der Konzentrationen von 2p und
2q, zu linearen, gegebenenfalls zirkulären Poly-
meren. Unter der Annahme, daß identische und
unabhängige Bindungsstellen mit intrinsischen
i
Assoziationskonstanten K vorliegen, ergeben
sich die stöchiometrischen Assoziationskonstan-
ten K aus den in Abbildung 2 zusammengestell-
ten Faktoren (33); über entsprechende Reaktio-
nen mit fixierten Reaktionspartnern siehe I.e.
(34).
'P + 2Q ^
2P + 2Q
2P + 2P„2Qn
2Q + 2P„2Qn
2P + 2P„2Q„+1
2Q + 2P„+,2Qn
2P„2Qn
lp2Q
2p2Q
2P„-H2Qn
2Pn2Q„
 + l
2Pn+l2Qn+ l
Pn+1 Qn+1
2P„2Q„
2
4
1
1
4
4
l/2n
—
M
M
M
M
M
Z„V/N
Abb. 2. Faktoren der intrinsischen Gleichgewichtskonstanten
zweiwertiger Reaktionspartner (nach I.e. (33))
Erste Zeile: Reaktion des einwertigen JP
n: Anzahl der im Komplex vorliegenden Moleküle
l/2n, l, 2, 4: Statistische Faktoren (s. Gleichung .29)
M: Korrekturfaktor für den Übergang von ]P zum ma-
kromolekularen 2P bei gleicher intrinsischer Assozia-
i
tionskonstante K
Zn: Korrekturfaktor für Ringschluß-Reaktion
V/N, (Volumen/Teilchenzahl): Korrekturfaktor für den
Übergang von der bimolekularen zur monomolekularen
Reaktion.
b) m > 2: Die Interaktion mehrwertiger Reaktions-
partner, von denen einer mehr als zweiwertig ist,
führt in Abhängigkeit von den Verhältnissen der
Konzentrationen zur Ausbildung räumlich ver-
netzter Polymerer. Im Gleichgewicht können ne-
ben freiem mP und 2Q die Komplexe mPj 2Qj vor-
liegen, mit den stöchiometrischen Indizes
i = l, 2, . . ., oo
und
j = (i - 1),
(i).
(i + D,
(. - - ·),
(i(m - 1) + 1).
Die möglichen Komplexe lassen sich in einer Matrix
anordnen, deren erste Zeile formal der Assoziation
eines monovalenten Liganden (*Q) an einen polyva-
lenten Binder (mP) entspricht (s. Modell 2c) und de-
ren erste Kolonne der Ausbildung linearer Polyme-
rer durch Assoziation zweiwertiger Reaktionspart-
ner entspricht (s. Modell 3a). Jeder dieser linearen
Komplexe kann sequentiell bis zur Sättigung weite-
res 2Q binden, analog den in der ersten Zeile formu-
lierten Vorgängen.
Über die Einführung der Wahrscheinlichkeitsfunk-
tion WP, definiert als die Wahrscheinlichkeit, daß ei-
ne Bindungsstelle auf dem mP-Aggregat mit einer
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TrQo mPi2Qi mPi2Q2
mP22Qi mP22Q2 mP22Q3
mP32Q2 n>P32Q3 mP32QK
...
 mPi2Qm
...
 mP22Chm-l
...
 mP32Q3m-i
Abb. 3. Komplexe (Immunkomplexe), die durch Assoziation von
m-wertigen mP und 2-wertigen 2Q neben freiem 2Q
(= mPo2Qi) im Gleichgewicht vorliegen können (nach
I.e. (35)).
Bindungsstelle auf dem 2Q-Aggregat reagiert hat
und der Wahrscheinlichkeitsfunktion WQ, definiert
als die Wahrscheinlichkeit, daß eine Bindungsstelle
auf dem 2Q-Aggregat mit einer Bindungsstelle auf
dem mP-Aggregat reagiert hat und der intrinsischen,
identischen, unabhängigen, Assoziationskonstanten
i
K lassen sich Bindungsfunktionen aufstellen, z.B.
[2q] - [2Q1die Scatchard-Funkuon in der Form ' = -—=-
Aus den Bindungsfunktionen läßt sich ableiten (35),
daß
1. die Titrationskurve von der vorgelegten Menge
mP abhängt, und daß sich die Titrationskurven bei
r' = m/2 schneiden, wenn K[2Q] = 1/2. Solange
[2Q] < 1/2 K, also vor dem Schnittpunkt der Ti-
trationskurven, ist die Bindung von polyvalenten
Reaktionspartner effektiver als die von nicht-ag-
gregierten P und Q mit gleichen intrinsischen As-
soziationskonstanten. Nichtlinearität des Seat-
c/zarrf-Graphen ist beim Auftreten von querver-
netzten Polymeren mit der Äquivalenz und Un-
abhängigkeit der Bindungsplätze vereinbar.
2. der Grenzwert lim r' wird m, das heißt unter die-
i2QH«
sen Bedingungen liegen nur noch Komplexe der
Art mPi2Qm vor. Das heißt, mit steigendem [2Q]
wird die Konzentration aller anderen Komplexe
(Abb. 3) zunächst ansteigen, ein Maximum errei-
chen, um dann auf 0 zurückzugehen. Alle Kom-
plexe mPi2Qj außer mPi2Qm haben ihre Maximal-
i
werte, die mit j/i = m/2 bei [2Q] = 1/2 K. Diese
analytischen Ergebnisse entsprechen den Über-
lieferungen der empirischen Immunologie zur
Deutung von Präzipitations- und Agglutinatioris-
Reaktionen (Prozonenphänomen, Äquivalenz-
punkt).
4. Modell: m Ordnungen von Antigen-Bindungs-
plätzen (z.B. mit Pj = P*)
n = l Ordnungen von Antikörper-Bin-
dungsplätzen
(Modell zur Beschreibung des Prinzips
der Bestimmung von p mit Hilfe der Be-
ziehung [P*Q]/[P*] = R = /(p) (quanti-
tative Bestimmung von p mit Hilfe eines
der „Bindungsverfahren", z.B. Radio-
immunoassay) oder auch Prüfung des
Ausmaßes und der Spezifität der Bin-
dung von P* an Q, wenn P* als „mar-
kierte" Form von P vorliegt und Q als
spezifischer Rezeptor für P (z.B. P: Im-
mundeterminante oder Hormon; Q: An-
tikörper oder Rezeptor)).
In diesem Modell wird in Gleichung 19
Ri = [PiQ][Pi]
somit entsteht Gleichung 27
(Gl. 27) R = Kiql + 4- K2[P2]
Gleichung 27 wurde nach B hin entwickelt (31), so
daß sie in der Form von Gleichung 28 einer Seat-
c/za/Y/-Analyse zugänglich wurde.
= 0
(Gl. 28) K2RB + K2R2/Ki
+ (l + K2 (P2 "- q)) R -
Die Entwicklung von Gleichung 27 nach p hin wurde
zur Basis der theoretischen Behandlung von Sätti-
gungsverf ahren/Kompetitionsverf ahren (26 , 29 ,
31).
(Gl. 29) R2 + R(l + K
, P2K2 (R 1)R
(K2/KO R + l = 0;
Ekins-Gleiclnung
Wenn mit Bö die Konzentration von PiQ bei p2 == 0
bezeichnet wird, dann gibt es für jeden beliebigen
Wert von B/Bö zwischen 1,0 und 0,0 eine zugehörige
Dosis p2 > 0. Die Dosis der Substanz P2, die zum
Wert B/Bö = 0,5 führt, wird als ID50 (Inhibitionsdo-
sis 50%) der Substanz P2 bezeichnet. Werden anstel-
le der bekannten Mengen der bekannten Substanz P2
Unbekannte Mengen unbekannter Substanzen (Pa,
P4 . . .) eingesetzt, so entspricht ein Vergleich der
jeweiligen Dosis-Wirkungsbeiiehungen dem Ver-
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gleich der Dosis-Wirkungsbeziehungen zwischen ei-
nem Standard und unbekannten Proben. Parallelität
der Dosis-Wirkungsbeziehung zwischen Standard
und Probe ist eine notwendige, aber keine hinrei-
chende Bedingung für die Annahme der strukturel-
len Identität von Standard und Probe. Diese Identi-
tät ist Voraussetzung dafür, aus der Wirkung R der
Probe auf die P2-Konzentration der Proben (P3,
?4...) zu schließen.
Das Verhältnis äquipotenter Dosen verschiedener
Substanzen, zumeist ausgedrückt als deren ID5o,
wird als Kreuzreaktivität der betreffenden interfe-
rierenden Substanzen bezeichnet. Das Verhältnis
der Kreuzreaktivitäten verschiedener Substanzen
zueinander ist abhängig von den Affinitäten dieser
Substanzen zu Q, d. h., von K2, K3, ¥U ... und von R,
und somit von der Zusammensetzung des Systems.
Wenn K2 bekannt ist (meist geht man von der An-
nahme aus, daß K2 = KI = K*), dann kann aus dem
Verhältnis der äquipotenten Mengen p3 zu p2 nach
Gleichung 30 die Assoziationskonstante für die Sub-
stanz P3 errechnet werden.
(Gl. 30) K3 = K2(El - * )Vp2 i + R; R)
K2, KS . . . haben hier die gleiche Bedeutung wie KI
in der Enzymologie. Die dort üblichen Verfahren
zur Bestimmung von KI (z.B. Dm?n-Transforma-
tion) sind jedoch nicht übertragbar, da im allgemei-
nen (P2) ( 2) (26).
Gleichung 30 impliziert, daß die Spezifität der analy-
tischen Bestimmung mit Hilfe von immunreaktionen
von der Affinität, einer inhärenten Eigenschaft des
Reagenz, und von den frei wählbaren Konzentra-
tionsverhältnissen der Reaktionspartner abhängt.
Dies wird auch offensichtlich, wenn man die Wahr-
scheinlichkeiten der Bindungen heranzieht. Die
Wahrscheinlichkeit WT einer „richtigen" Bindung
(PiQ) in Relation zu den möglichen Bindungen (PiQ
+ P2Q , . . *h PmQ) wird durch Gleichung 31 defi-
niert, bzw. durch Wf,, die Wahrscheinlichkeit einer
„falschen" Bindung (Wr + Wf = 1) (36).
(Gl. 31) Wr = [PiQ] + [P2Q] H-
i + [P2]K2 + .
(Pt - [PiQ])Ki
(Pi - PiQDKi + (P2 - [P2Q]K2 +
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1. Wenn pj + p2 -f . .
Wr =
q, dann pj - (PiQ)
P2 - (P2Q) p2
H- p2K2 +
Wr - l = - Wf = Ei £!p2 K2
. . oder,
da K = e "W
_(AG?- AG;)
RT
P2
Also ist die Wahrscheinlichkeit des Auftretens von
(PiQ) bei Einsetzen äquimolarer Mengen von pi und
— « 11 von der Relation der Assoziationskon-
stanten bzw. von der Differenz der Gibbsschen Po-
tentiale abhängig. Bei realen Ansätzen wird die ap-
parente Wahrscheinlichkeit durch das Verhältnis p\l
p2 beeinflußt.
2. Wenn pi + p2 H- . . q, dann wird [PiQ]
[P2Q] P2
Somit wird Wr unabhängig von Ki/K2 und das Auf-
treten der Komplexe PiQ und P2Q wird proportional
den eingesetzten Mengen von pi und p2, sofern KI,
K2 Mindestwerte überschreiten.
Um hochspezifische Reaktionsergebnisse zu erzie-
len, ist es also erforderlich, daß die Differenzen der
G/ö&sschen Reaktionspotentiale der Assoziationen
von Q mit dem „richtigen" Liganden PI und dem
„falschen" Liganden P2 groß genug sind, und daß pi
4. Anwendung physikalisch-chemischer Kenngrößen
in der analytischen Praxis
Wenn die physikalisch-chemischen Kenngrößen der
Immunreaktion bekannt sind, können mit Hilfe der
Reaktions-Geschwindigkeits- und Gleichgewichts-
Konstanten Formeln entwickelt werden, nach denen
die Meßdaten der nach „Bindungsverfahren" durch-
geführten quantitativen Bestimmungen ausgewertet
werden können („Standardkurven'4). Derartige
Auswertungsverfahren erweisen sich dann als vor-
teilhaft gegenüber phänomenologischen Dosis-Wir-
kungs-Kurven, die ausschließlich über statistische
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Interpolations- und Regressionsverfahren gewonnen
werden (deren Algorithmus keinen funktionalen
Zusammenhang mit Reaktionsmechanismen besitzt,
wie z.B. polygonale Interpolation, Spline Approxi-
mation), wenn die Modellvorstellungen über die Re-
aktion weitgehend den realen Reaktionsbedingun-
gen entsprechen. Tatsächlich konnten bewährte
Auswertungsverfahren, die zunächst empirisch ge-
wonnen worden waren, schließlich auf die Thermo-
dynamik der Reaktion zurückgeführt werden (37).
Analoge Überlegungen gelten für die Optimierung
der Reaktanden-Konzentrationen und Reaktionsbe-
dingungen. Auf der Basis der Reaktionsgleichungen
und der Fehleranalysen können Strategien zur Opti-
mierung entwickelt werden, womit zumeist eine Ma-
ximierung der Empfindlichkeit einer Bestimmung
gemeint ist; auf die Möglichkeit der Maximierung
der Spezifität durch Berücksichtigung thermodyna-
mischer Parameter wurde bereits hingewiesen (s. 4.
Modell). Die Praktikabilität, sofern damit die Ro-
bustheit der Bestimmung und ihr Zeitaufwand ge-
meint ist, wird ebenfalls durch thermodynamische
Daten determiniert. Reaktionsabbrüche vor Errei-
chen des Gleichgewichtszustandes (z.B. beim Se-
quentialverfahren) führen im allgemeinen zu Meß-
werten, die stärker mit Fehlern behaftet sind, als
wenn Gleichgewichts-Konzentrationen gemessen
werden. Schließlich ist die Kinetik und' damit auch
die Enthalpie der Reaktion, und zwar sowohl die der
Reaktion mit dem Analyten wie auch die der Reak-
tion mit anderen Kompetitoren cles Indikators, aus-
schlaggebend dafür, wie weit die Inkubationszeit ab-
gekürzt werden kann und wie weit bei höheren Tem-
peraturen inkubiert werden kann, ohne daß unver-
tretbare Einbußen an Empfindlichkeit und Spezifität
die Folge sind (26, 38—42). Eine Optimierung der
„Bindungsverfahren" durch „trial and error" ist
zwar auch möglich und letztlich unvermeidbar, aber
ohne Kenntnis der thermodynamischen und reak-
tionskinetischen Zusammenhänge nicht planvoll ein-
zusetzen.
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Summary: Conventionally prepared polyclonal antibodies have been used for a long time in biomedical re-
search and in clinical-chemical diagnosis. The hybridoma technology introduced by Köhler & Milstein ((1975)
Nature 256, 495—497), has opened the way to a new dimension in serology. It is now possible to prepare
monoclonal antibodies to any determinant on any component of biological matter. Such monoclonal and thus
specific antibodies can be obtained even against previously unknown antigens which had not been available in
purified or enriched form. Thus the dreams of immunologists and clinical scientists who were searching for
new disease-related markers, have become a reality.
The present impact and the predictable future influence of these new developments on biomedical research
and especially on clinical-chemical diagnosis, äs well äs their potential, limitations and problems, will be
critically reviewed in this paper. As an example of the potential of the new technology, recent results of tests
on the quantitation of urinary kidney-derived antigens with the help of monoclonal antibodies are presented.
With these monoclonal antibodies, which are specific for antigens in defined regions of the nephron of the
human kidney, recognition of the location and extent of primary damage at the cellular level will be possible
without invasive techniques.
Polyklonale und monoklonale Antikörper als Reagenzien in der biochemischen und klinisch-chemischen Ana-
lytik
Zusammenfassung: Konventionell hergestellte polyklonale Antikörper haben schon seit langer Zeit ihren
festen Platz als Reagenzien in der biomedizinischen Forschung und in der klinisch-chemischen Diagnostik.
Die Hybridomtechnologie mit der sich ergebenden Möglichkeit zur Herstellung monoklonaler Antikörper
gegen jede Determinante jedes denkbaren Antigenmoleküls hat das Spektrum der Anwendungsmöglichkei-
ten serologischer Techniken in unvorstellbarer Weise erweitert. So ist es jetzt möglich geworden, monoklo-
nale und damit spezifische Antikörper auch gegen Determinanten bisher unbekannter Antigene zu gewinnen,
ohne das entsprechende Antigenmolekül gereinigt oder angereichert zu haben. Die Wunschträume der Im-
munologen und klinischen Forscher, die nach neuen diagnostischen Markern, vor allem in der Tumorfor-
schung, suchten, würden greifbare Wirklichkeit.
Die vorliegende Veröffentlichung soll diese neuen Entwicklungen mit ihren - bereits heute vorhandenen und
in Zukunft absehbaren - Auswirkungen auf die biomedizinische Grundlagenforschung, vor allem aber auf
die klinische Diagnostik darstellen und ihre Möglichkeiten, Grenzen und Probleme kritisch diskutieren. Die
Möglichkeiten werden exemplarisch am Beispiel von Tests gegen Antigene der menschlichen Niere gezeigt.
In diesen Tests werden monoklonale Antikörper gegen Antigene aus genau lokalisierten Bereichen des
Nephrons eingesetzt, um die entsprechenden Antigene bei pathologischen Veränderungen im Harn von Pa-
tienten nachzuweisen. Solche Tests eröffiaen die Möglichkeit zur Erkennung von Lokalisation und Ausmaß
einer Schädigung im Nierenparenchym ohne die Anwendung invasiver Techniken.
l), Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
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Introduction
Substances defined by their immunological rather
than by their enzymatic activity, and therefore desig-
nated "antigens", have played a minor role in clini-
cal chemistry and diagnosis. The sprectrum of tests
available for such antigens has been very limited and
still is today. This is mainly due to technical prob-
lems in the development of tests for marker substan-
ces without known biological activities.
In the first seven decades of this Century, basic bio-
chemical research concentrated on substances with
known biological activities such äs enzymes and hor-
mones. Most of the enzyme tests in use today in bio-
medical research and in clinical diagnosis were
known from the outset. With such tests, it was rela-
tively easy to identify organ or tissue distribution of a
large number of marker substances and to determine
their concentration in body fluids under normal and
pathological conditions.
The development of tests for proteins or other cellu-
lar components without known biological activities
has been hampered by the fact that these substances
do not exhibit any known measurable biological
function. It is, however, possible to characterize
these, äs well äs any other biological marker, by their
reaction with specific antibodies. Preparation of spe-
cific antibodies depends on the availability of the
corresponding pure antigens. For the purification of
antigens recognition Systems are required. Tests
based on specific antibodies could serve äs such re-
cognition Systems. Since, however, specific antibo-
dies require pure antigens and, since the preparation
of pure antigens requires specific antibodies, we find
ourselves lost in a vicious circle.
In a few cases it has been possible to prepare specific
antibodies against antigens not known before and
not available in pure form; -foetoprotein is an ex-
ample for such an antigen. Furthermore, specific an-
tibodies have been prepared against constituents of
human serum rather early in the history of clinical
chemistry. These antigens were, however, so
"prominent" that no special recognition Systems
were required to identify them.
In principle, it should be possible to prepare specific
antisera for any known antigen in a way similar to
the procedure used for the preparation of antibodies
to -foetoprotein: after immunization of a laborato-
ry animal with the serum of a patient suffering from
a defined disease and absorption of the antibodies to
normal serum components with normal human se-
rum, an antiserum specific for those markers that are
released under this specific pathological condition
should be obtained.
In reality, however, this is impossible, since in con-
trast to -foetoprotein, which is present in the sera
of foetuses and patients with liver carcinoma in eon-
siderable concentration, most of the marker antigens
of interest are present only in minute concentrations,
in the ränge of l g/l to l mg/1, äs we know from
clinical enzymology. To raise specific antibodies
against such "minor contaminants" in the serum is
almost always impossible. The laboratory animaPs
immune system confronted with hundreds or even
thousands of different antigens most of them in very
low concentrations, remains unresponsive to most of
them.
Nevertheless, we know that large numbers of such
antigens must be present in the sera of patients, re-
leased from cells äs the result of pathological altera-
tions or lesions. The exploitation of this väst pool of
diagnostically valuable molecules has recently be-
come possible by the development of a new technol-
ogy for the preparation of monoclonal antibodies.
The hybridoma technolpgy, developed by Köhler &
Milstein (1) in 1975 has opened the way to the prep-
aration of monoclonal antibodies with predefined
specificities against any determinant of any antigen
of biological matter. Such reagents have been the
dream of immunologists. Therefore, many research
groups have concentrated their efforts on the prepa-
ration of such monoclonal antibodies to a variety of
antigens in many fields of biomedical research. In
this paper, the advantages of ;monoclonal antibodies,
their future applications in various fields of research,
and, last but not least, their limitations will be dis-
cussed. The üse of monoclonal antibodies for the de-
velopment of new strategies in kidney diagnosis, us-
ing ürine, will be discussed äs an example of these
future developmerits.
The Polyclonal Antibody Response
Conventionally prepared antibodies have been used
for many decades in biology and medicine for re-
search äs well äs for diagnostic and theräpeutic pur-
poses. Although they have many uses, their applica-
tion has been limited by their inherent biocheinical
properties. During its development, the immune Sys-
tem was exposed to an uncountable number of chal-
lenges from its antigenic environment and has ac-
quired, äs a result, the ability to respond with an
equally complex diversity of antibodies. Even
against a very simple chemic$\ly homogeneous de-
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terminant like the dinitrophenyl group, artificially
introduced into a carrier molecule, a population of
antibodies with different affinities and fine specifici-
ties is induced.
Immunization of an animal with a substance foreign
to its immune System — therefore called "immuno-
gen" or "antigen" - produces a very specific poly-
clonal cellular and humoral response. Individual
cells of the immune System recognize antigenic "de-
terminants" or "epitopes", individual molecular
structures on the surface of the antigenic particle.
Consequently, they are stimulated to produce large
numbers of antibodies, protein molecules comple-
mentary to the corresponding epitopes. Since each
antigenic particle exposes an undeterminable
number of individual epitopes on its surface, this
Stimulation will result in an undeterminable number
of individual antibodies, a polyclonal antibody popu-
lation. This antibody population is found in the se-
rum of the immunized animals.
Each antibody has a binding site, a molecular struc-
ture by which it can recognize the complementary
structure on the antigen particle, the epitope, and
bind to it. Binding of antibodies to an antigen can
have several consequences: Inhibition of biological
activities of the antigen (toxin, enzyme, bacteria, vi-
rus); complex formation (precipitation, agglutina-
tion); removal or destruction of the antigen by acces-
sory biological Systems (macrophages, complement).
Since the animal's immune System will be stimulated
in an unpredictable way by each of the epitopes pres-
ent on each of the antigens and, in additiön, by each
cöntaminatioii in the antigen preparation used for
immunization, high purity of the antigen is one of the
most important preconditions for the preparation of
specific antisera. Very often it is difficult or impossi-
ble to obtain highly purified antigens. Sometimes, äs
is the case with membrane integrated antigens, puri-
fication of the antigen is not possible without de-
struction of its native structure. Preparation of anti-
sera specific for subunits of complex biological mole-
cules like enzymes is equally difficult since the native
biological structure is often preserved only in the in-
tegrated native molecule. The preparation of antibo-
dies to previously unknown biological molecules was
not possible at all through conventional immuniza-
tion procedures.
The Hybridoma Technology
The hybridoma technology has opened a new dimen-
sion in the field of immunology and provided a way
of solving some of the problems inherent in polyclo-
nal antisera. Through in vitro fusion of sensitized B-
lymphocytes, the precursors of antibody producing
plasma cells, with "immortal" plasmacytoma cells,
i.e. continuously dividing transformed plasma cells,
it became possible to dissect the animal's polyclonal
immune response into its monoclonal components
and thus to prepare monoclonal antibodies.
The technological inventions necessary for the de-
velopment of the hybridoma technology had been
made a long time previously. Continuously dividing
immortal plasmacytoma cell lines of the mouse
were first developed by Potter (2), adapted to tissue
culture conditions in 1970 by Horibata (3) and fur-
ther developed by others (4) including Köhler, Howe
& Mustern (5).
For selection of fused from unfused cells, mutant
plasmacytoma cell lines had to be developed that are
deficient in an enzyme present in normal mouse
cells. A mutant deficient in the salvage pathway en-
zyme hypoxanthine-guanine phosphoribosyl transfe-
rase (HGPRT) was developed by Cotton et al. (6)
and by Köhler et al. (5). Hypoxanthine-guanine
phosphoribosyl transferase, a membrane bound en-
zyme, allows the cell to take up hypoxanthine, a nu-
cleotide precursor, from the culture medium through
transmembrane transport and convert it into the nu-
cleotides needed for DNA synthesis (7). In general,
this pathway is not important for the celPs survival
because nucleotides can equally well be acquired by
de novo synthesis. If, however, the DNA de novo
synthesis pathway is blocked, the cells are bound to
make use of the external nucleotide precursor hypo-
xanthine. In the hypoxanthine-aminopterine-thymi-
dine (HAT) selection medium developed by Linie-
field in 1964 (8), the de novo synthesis pathway is
blocked by aminopterine and only cells with an in-
tact hypoxanthine-guanine phosphoribosyl transfe-
rase salvage pathway enzyme can survive. Unfused
hypoxanthine-guanine phosphoribosyl transferase
deficient plasmacytoma cells, although immortal in
principle, cannot survive under these conditions.
Unfused lymphocytes, mortal in vitro, will only sur-
vive a few days although their hypoxanthine-guanine
phosphoribosyl transferase enzyme is fully active.
Only hybrids between the hypoxanthine-guanine
phosphoribosyl transferase deficient plasmacytoma
cells and normal mouse lymphocytes will survive in
vitro. Thus, by means of fusion, two genetic factors
can be combined in one cell: the immortality and
capability for unlimited growth of the plasmacytoma
cell and the capacity to produce one individual mo-
noclonal antibody of the plasma cell.
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Originally K hler & Milstein used Sendai virus s the
fusing agent (1). Later, however, polyethyleneglyc-
ol (PEG), a fusiogen found by plant cytologists, was
adapted for fusion because of its higher fusion rate
and easier application (9, 10). In practice, fusion is
done by mixing, in the presence of the fusing agent,
the spieen lymphocytes of an immunized mouse with
mouse plasmacytoma cells harvested from in vitro
culture. Fusion takes place randomly within a few
minutes. After removal of the fusing agent the cells
are distributed into the wells of culture plates and
fed with HAT selective medium. After 1—2 weeks
unfused plasmacytoma and spieen cells s well s in-
ter-plasmacytoma and inter-lymphocyte fusion pro-
ducts will have died, and rapid cell growth will be
observed only in those wells that contained at least
one hybrid cell in the cell mixture seeded after fu-
sion. After 2—3 weeks the selective medium is re-
placed by normal culture medium and the cell sam-
ples can be further processed. The rapidly growing
hybrid cells, called hybridomas, secrete monoclonal
antibodies into the culture fluid. Their specificities
can be tested by suitable tests.
• t
Details of the fusion protocols and mouse myeloma
cell lines available for fusion have been published in
various technical papers (11—15). The principle is
depicted in figure 1.
Immunization procedures vary greatly from l bora-
tory to laboratory. In our experience, a long term
hyperimmunization procedure with p to 12 injec-
tions of the antigen mixture in complete Freund's ad-
juvent has led to promising results for the production
of monoclonal antibodies to epitopes of tissue com-
ponents so far unknown.
^ —-
Polycional
antiserum
Plasmocytoma
cells
Hybridomos
Ιο0ο0ο0ο°ο
Cloning on sott agar
*
| Β β ι I Q « ι i e „
i^LsJ U ·.
Moss production of monoclonal antibodies
Fig. 1. Schematic presentation of preparation of monoclonal antibodies to membrane antigens. Taken from:* Falkenberg et al.(68).
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Production and Purification of Monoclonal Antibo-
dies
Monoclonal antibodies excreted into tissue culture
fluid by hybridoma cells can be detected by suitable
techniques. In most cases, antibody concentration in
culture fluid is high enough (10—50 mg/1) for rou-
tine tests such äs RIA, ELISA, indirect immunofluo-
rescence, staining with peroxidase-labelled antibo-
dies, autoradiography. Those hybrid cell samples
that secrete a monoclonal antibody of desired speci-
ficity have to be checked for monoclonality. The
probability of monoclonality depends on the set-up
of the experiment and especially on the frequency of
wells with cell growth and can be calculated accord-
ingly (16, 17). However, in most cases, cloning will
be necessary, either by limiting dilution or on soft
agar. Mass production of monoclonal antibodies is
then possible either from cell culture supernatant or
from ascitic fluid of hybridoma tumour bearing mice.
For purification of monoclonal antibodies several
methods can be applied:
- affinity chromatography on protein A columns
(18) (applicable only to monoclonal antibodies of
some IgG-subclasses)
— immunospecific affinity chromatography on anti-
gen columns or on antimouse-Ig-columns: Care-
ful selection of the dissociating agent is important
to prevent irreversible damage to the antibody
molecules
- conventional biöchemical techiüques such äs ion
exchange and gel permeation chromatography.
The HPLC technique has recently been applied
successfully to monoclonal antibody purification
(19, 20).
Problems with Monoclonal Antibodies
However, it has turned out to be rather difficult to
obtain monoclonal antibodies of high purity. Mono-
clonal antibodies in ascitic fluid are contaminated
with normal mouse seriim proteins, iiicluding normal
mouse IgG's which cannot always be removed by the
purification prpcedüres rnentioned above. Monoclo-
nal antibodies in tissue culture fluid are free of other
mouse proteins. They are, however, heavily contam-
inated with proteins from horse serum or from foetal
calf serum (e.g. 10 g of monoclonal antibodies in
5000 g of horse serum proteins).
The affinity and specificity of monoclonal antibodies
are not always adequate. Since each monoclonal
antibody is just one of the total popuiation of antibo-
dies elicited against each of the epitopes of a multi-
epitope-antigen, it might not show the desired epi-
tope specificity and affinity which makes it suitable
for a certain test (e.g. RIA, ELISA, Immunofluores-
cence, etc.). Recently (21, 22) it was reported that
monoplonal antibodies might exhibit a kind of "as-
say-specificity", indicating that a given monoclonal
antibody might perform excellently in one assay but
give poor or negative results in another. Therefore,
large screening programs have to be performed to
identify those monoclonal antibodies that exhibit the
desired specificity and sufficient affinity for their an-
tigen(s).
In our experience, there is no problem in testing mo-
noclonal antibodies, even those of low affinity, with
techniques in which one of the reaction partners is
fixed to a solid phase (e.g. solid phase RIA, ELISA,
Immunofluorescence, Immunoperoxidase).
Further problems might arise from the "cross-reac-
tivity" of monoclonal antibodies (23). The binding
site of a monoclonal antibody is complementary to a
three dimensional molecular structure on the antigen
molecule, the epitope. On protein molecules such
structures might be determined by the primary se-
quence of a few amino acids or by a steric configura-
tion of several closely or distantly located amino acid
residues. Since the molecular area forming such epi-
topes is rather small, the same or similarly construct-
ed molecular areas might be present on other related
or non-related proteins. This "blurred vision" of the
monoclonal antibodies causes considerable problems
for their use. Although these considerations are also
valid for each of the antibodies that form a polyclo-
nal antiserum, these problems are not encountered
because all the antibodies of the serum react with
one target antigen for which a high specificity is thus
obtained. It might be necessary in the future to com-
bine several monoclonal antibodies to form artificial
antisera-like oligoclonal mixtures.
Due to the individual structure in the constant (class
and subclass specific sequences) and variable (idio-
typic sequences) regions each monoclonal antibody
is a distinct Individuum and has to be treated äs such.
Techniques and procedures developed for the biö-
chemical and immunochemical manipulation of an-
tibodies from conventionally prepared polyclonal
antisera cannot always be applied to these "capri-
cious primadonnas" of monoclonal antibodies. Di-
gestion with proteases to produce Fab-fragments or
conjugation with marker molecules do not always
work äs expected and cause problems in the prepara-
tion of derivatives of monoclonal antibodies (24).
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Application of Monoclonal Antibodies Instead of
Conventional Sera
Monoclonal antibodies have many advantages over
conventional polyclonal antisera. Nearly everything
that has been done with antisera might be done bet-
ter with monoclonal antibodies. The most important
advantages and disadvantages of working with mo-
noclonal antibodies are summarized below:
Advantages
— No pure antigen needed: total cells, unfractionat-
ed cell extracts or partially enriched fractions can
be used
— Purification of antigens on immunosorbent co-
lumns possible
— Unlimited supply of each monoclonal antibody
— High reproducibility over unlimited periods of
time
— Worldwide standardization possible for the first
time
— Useful for all kinds of binding techniques, espe-
cially in solid phase Systems
— Localization of individual membrane determi-
nants on the cell (topography)
— during cell cycle and cell differentiation
— in relation to other membrane antigens
— Localization of individual determinants of an an-
tigen (external or internal part of the antigen)
— Determination of the shed (physiological condi-
tion) or solubilized (pathological condition) anti-
gen or of antigen fragments in extracellular fluids
Disadvantages
- Affinity of monoclonal antibodies is often low
- Precipitation often not possible
— Expansion of work
— High costs
Scientists around the world have prepared monoclo-
nal antibodies against nearly every antigen one can
thihk of. The Information collected is immense and
growing day by day.
Industry has followed the trend. Many tests, pre-
viously performed with conventional antisera, are
now on the market using monoclonal antibodies.
Predictions from the economic sector point to the
development of a 2 billion dollar industry world wide
by 1990 (25). At this time a 50% replacement of
polyclonal antibodies by monoclonal antibodies in
diagnostic tests is forecasted (26).
In the fbrst instance, development 'was aimed at re-
placing polyclonal antisera by monoclonal antibo-
dies. By this approach new and better reagents for
research and clinical-analytical purposes were deve-
loped. However, the high costs of the technique and
the unavoidable large screening programmes result-
ed in sales prices often prohibitive for the reduced
budget of the university research worker. In many
cases it is questionable whether a cheap polyclonal
antiserum should be replaced by an expensive mo-
noclonal antibody.
There are, however, problems in which monoclonal
antibodies due to their specificity and biochemical
homogeneity have definite advantages over polyclo-
nal antisera. Since monoclonal antibodies are specif-
ic for individual antigenic epitopes, tests for haptens
and peptide hormones built on monoclonal antibo-
dies might be better and more specific than conven-
tional tests applying absorbed polyclonal antisera. If
a hybridoma producing an antibody with the desired
properties has been found, production of the mono-
clonal antibody is always simpler and cheaper than
the production of polyclonal antisera which each
have to be rendered specific by tedious absorption
procedures. Hormones that exhibit partial structural
identities or homologies in their peptide chains, e.g,
thyrotropin, follitropin, humaii chorionic gonado-
tropin and lutropin, are examples of this approach.
In tests for the quantitation of such hormones in
body fluids monoclonal antibodies will compete with
absorbed polyclonal antisera on the market.
For the determination of haptens like digoxin and
structurally related compounds and breakdown pro-
ducts thereof, monoclonal antibodies might be better
than polyclonal antisera (27). In this case, high affin-
ity of the antibodies is, however, of greatest impor^
tance for the development of suitable tests. Al-
though the search for a monoclonal antibody that
fulfils all the conditions might be long and tedious,
the chances of finding it are better than the chanees
of finding a polyclonal antiserum with the desired
properties.
The evaluation of isoenzymes, microhieterogeneous
forms and genetic variants of enzymes by immuno-
logical techniques is another field of applicätiofi of
monoclonal antibodies. Polyclonal antisera might be
äs good or better than monoclonal antibodies äs was
shown with the creatine kinase MB isoenzyme. Inhi-
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bition obtained with monoclonal antibodies (28) to
the B subunit was nearly äs high äs with polyclonal
antibodies.
There are other isoenzymes which so far can be rec-
ognized only by electrophoretic techniques. Since
the difference in electrophoretic mobüity must have
a structural basis, it should be possible to prepare
monoclonal antibodies with the power to identify in-
dividual isoenzymes. The amylase isoenzymes are
examples of this kind. Differentiation between the
pancreas-type and the saliva-type isoenzyme is pos-
sible by electrophoretic mobility, not by polyclonal
antisera (29). In this case monoclonal antibodies will
be useful reagents.
Several groups have prepared monoclonal antibo-
dies against prostatic acid phosphatase (PAP). Mo-
noclonal antibodies seem to have advantages over
polyclonal antisera in test Systems, since some of the
monoclonal antibodies do not cross-react with non-
prostatic acid phosphatases (30). A "tandem" assay
using two monoclonal antibodies specific for two ep-
itopes of the prostatic acid phosphatase molecule
was found to be specific exclusively for the prostatic
enzyme and useful for prostatic acid phosphatase
measurement (31). The properties of monoclonal
versus polyclonal antibodies to prostatic acid phos-
phatase in histochemical staining are compared in a
recent publication by Shevchuk et al. (32). Most car-
cinomas were positive with a goat antiserum, fewer
with a rabbit antiserum, and only about 50% were
positive with the monoclonal antibodies. This might
reflect the heterogeneity of the antigens used for
preparation of the antisera. For clinical testing, a
broad spectrum antiserum might be most useful. For
research purposes, however, where absolute speci-
ficity is needed to gäin new Information, monoclonal
antibodies may be more useful.
In test Systems developed for carcinoembryonic anti-
gen (CEA), two site-directed monoclonal antibodies
are used. Since "tionspecific eross-reacting antigens
l and 2 (NCA-1 and NCA-2)" are not recognized,
such a test System based on monoclonal antibodies
offers advantages over conv4entional test Systems
(33). The seiisitivity and specificity of 3 different
forms of solid phase EIA using 5 different monoclo-
nal antibodies against 4 distinct epitopes of the CEA
molecule were compared by Buchegger et al. (34). In
two further recent publications, the detection of
"epitope heterogeneity" of CEA from various ori-
gins was reported. Eshhar et al. (35) found that a se-
ries of 50 monoclonal anti-CEA antibodies could be
divided into four groups according to their reactivity
with individual epitopes in CEA preparations from
tissues and tumours of various origins. Similar obser-
vations were made by Wagner et al. (36) who found
that 5 monoclonal antibodies directed against the
protein moiety of the CEA molecule were helpful in
differentiating between 5 epitopes on CEA and/or
different CEA related antigens in normal and malig-
nant tissues.
"Silent" enzymes, i.e. inactive (e.g. proteases) or in-
activated forms or breakdown products of biologi-
cally active molecules are another field of applica-
tion of monoclonal antibodies. Monoclonal antibo-
dies to phenylalanine hydroxylase have been pre-
pared in our laboratory (37) in order to differentiate
between various genetic variants of the enzyme and
thus provide a means of classifying the hereditary
disease phenylketonuria.
Modulation of enzyme activity by antibodies is a well
known phenomenon. With monoclonal antibodies, it
is now possible to draw conclusions concerning the
molecular site involved in enzyme activity regulation
and modulation by antibodies. The activation of a
defective enzyme, ß-galactosidase of E. coli carrying
Z-gene point mutations, by individual monoclonal
antibodies has been reported recently (38) and indi-
cates that a "single hit" modification of protein con-
formation is possible. In our University, Hessova et
al. (39) have prepared monoclonal antibodies to the
oligomeric enzyme phosphorylase kinase which al-
lows characterization of the function of the a- and
subunits. Whereas most of the monoclonal antibo-
dies inhibited the AI or the Aa or both activities,
some were shown to activate the AO or the AI activi-
ties. Informative relationships were observed be-
tween the binding to a specific subunit and the en-
zyme activity.
Monoclonal antibodies to markers of classes and
subclasses of human and murine immunoglobulins
have already become important tools in research, es-
pecially in hybridoma research, äs well äs in clinical
diagnosis. Problems arising from unexpected and so
far uiiexplained reactions and cross-reactions (21,
22) of monoclonal antibodies specific for immuno-
globulins of the IgG subclasses are being investigat-
ed in a collaborative study, organized under the aus-
pices of the IUIS and the WHO. During the 6th Eu-
ropean Immunology Meeting in Interlaken in Sep-
tember 1984, the colloquium on "Monoclonal anti-
bodies to human Immunoglobulins — Specificity and
application" is devoted to this question.
A whole generation of new test Systems has become
possible by the introduction of monoclonal antibo-
dies: "enzyme channeling" (40) or "proximal link-
age" (41) immunometric assay s in which a measur-
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able Substrate turnover is observed only when two
monoclonal antibodies, each specific for one individ-
ual epitope of the same particle, and each labelled
vvith another enzyme react with the antigen. The
"sandwich ELISA" with two monoclonal antibodies
directed against two different epitopes of the anti-
gen, one bound to the solid phase ("catcher") the
other labelled with a marker enzyme ("indicator")
can be done in a "one step" mode: the antigen-con-
taining specimen and the enzyme labelled monoclo-
nal "indicator" antibody can be added to the solid
phase bound "catcher" in a mixture. This saves time
and costs in the clinical laboratory.
In this context a paper published 1980 by Kohen et
al. (42) should be mentioned. In this paper the au-
thors reported that a monoclonal antibody directed
against the dinitrophenyl (DNP) hapten exhibited
quasi-enzymatic properties if the DNP-group was
conjugated covalently through an ester bond with
the fluoresceht compound 7-hydroxy-coumarin
(DNP-CU). The antibody-enhanced esterolysis of
DNP-CU results from the interaction of the labile
ester with a nucleophilic group in a proper position
within the antibody combining site.
Exploitation of the Advantage of the Hybridoma
Technology: Tissue Antigens
Most of these applications of monoclonal antibodies
are not of great interest to immunologists, since the
new technology is only used instead of the conven-
tional forms of antibody production, exploiting only
part of the manifold advantages of the new technol-
ogy. In these developments, however, the usefulness
of the new technology has been tested and the ques-
tion answered whether the advantages compensate
for the enormous costs of development.
In order to exploit all the possibilities of the hybrido-
ma technology, new approaches and strategies had
to be devised. With monoclonal antibodies it is pos-
sible to detect new antigens or antigenic determi-
nants which, for technical reasons, have not been ac-
cessible betöre. Monoclonal antib.odies can be raised
against any determinant of a cell, a membrane frac-
tion, or a tissue extract. In very tedious and expen-
sive screening procedures, those have to be selected
that are specific for disease-relevant tissue marker
antigens. With these antibodies, the purification and
characterization of the corresponding antigens are
then possible.
Monoclonal Antibodies to Lymphocyte Differentia-
tion Antigens
One of the most important developments in this field
concerns the recognition of subsets of the lymphoid
cell population in human blood (43). A series of mo-
noclonal antibodies has been prepared, each direct-
ed against a differentiation antigen by which a cer-
tain T-cell type is characterized. Thus, the detenni-
nation of total T-cell, T-suppressor- and T-helper
cell counts in blood has nöw become possible. Mo-
noclonal antibodies together with the new fluores-
cence-activated cell sorting and counting technique
(44) will in future enable the haematologists to ob-
tain Information on the cellular immune Status of a
patient. Such diagnostic tools might in future enable
the clinician to draw conclusions on the state of a
disease and help him to decide oii appropriate thera·^
peutic measures. In urology these new reagents al-
ready have diagnostic äs well äs therapeutic conse-
quences, e.g. in kidney transplantation. Determina-
tion of helper to süppressor T-cell ratio might help to
predict the survival of a transplant in a recipient (45,
46). The süccessful treatment of rejection episodes
in kidney transplant recipients with monoclonal anti-
T-cell antibodies has been reported recently (47).
Cosimi et al. (48) treated cadaver doriof renal allo-
graft recipients at the time of diagnosis of acute re-
jection with monoclonal OKT3 antibody (reactive
with all mature peripheral blood T-cells). In all 8
cases loss of essentiälly all detectable peripheral
blood OKT3-reactive cells was observed within 5
minutes of i. v. iiifüsion ofr 1—5 mg of OKT3 anti-
body, and the established rojectiön episodes were
reversed in all cases within 2 to 7 days without any
treatment other than OKT3 antibody. Jönker et al.
(49) used a rhesus monkey skin allograft model to
study the effects of administration of monoclonal an-
tibodies in detail. They found that tfie monoclonal
OKT4 and OKT4A antibodies specific for T-helper-
cells successfully prolonged allograft survival where-
as the monoclonal OKT8 antibody specific for cyto-
toxic/suppressor T cells did not.
It can be expected that monoclonal antibodies
against clearly defined T-cell-subpopulations will re-
place the previously used horse anti^human-thymo-
cyte globulin (ATG) with its unselective T cell killing
capacity (50).
Since malignaiit lymphocytes express normal äs well
äs disease-related antigens on their sürface, the char-
acterization of leukaemic cells, the categorization of
leukaemias, and, finally, new therapeutic approaches
have become possible with monoclonal antibodies
'
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Currently, a simple test for the quantitation of T-cell
marker antigens on peripheral lymphocytes is under
development at Boehringer Mannheim (52): In this
test, which can be performed in a normal clinical la-
boratory following routine procedures, T-lympho-
cyte antigens are determined with galactosidase la-
belled monoclonal antibodies using the lymphocytes
themselves äs solid phase. By this test, the determi-
nation of T-cell subset patterns which previously was
possible only in laboratories equipped with highly
sophisticated machinery (fluorescence activated cell
sorter, FACS) or in tedious manual cell counting un-
der the fluorescence microscope, becomes available
to every laboratory which is equipped with a centri-
fuge and a photometer.
Monoclonal Antibodies to Tumour Antigens
The ability to prepare monoclonal antibodies to pre-
viously unknown biological marker molecules initial-
ly raised many hopes in the field of tumour immu-
nology. Monoclonal antibodies, directed to tumour-
specific or tumour-associated marker molecules,
were thought to offer the ultimate solution to the
cancer problem. The main obstacle to this approach
lies in the animaPs undifferentiated immune re-
sponse to everything that is foreign in the sample
used for immunization. Thus immunization with hu-
man tumour cells, tumour cell extracts, or fractions
thereof will yield, after fusipn, monoclonal antibo-
dies directed against whatever is recognized äs for-
eign by the animal's immune System. Considering
the vast complexity of tissue antigens, monoclonal
antibodies to real tumour ajitigens can be found only
by chance.
As discussed earlier, monoclonal antibodies to well
known tumour markers like carcinoembryonic aiiti-
gen (CEA) or prostatic acid phosphatase (PAP)
seem to offer advantäges over conventionally pre-
pared antisera. The literature on new tumour marker
antigens detected by monoclonal antibodies is grow-
ing day by day. Most of these reports have, however,
to be taken with great reseryation. So far, none of
the new markers has become part of clinical diagnos-
tic routine procedures. It is hoped that the efforts
undertaken iii many research laboratories around
the world will lead to the development of new diag-
nostic tools that will allow early detection and better
prognosis of cancer diseases. In several papers (53—
57) and monographs (58, 5-9) the new developments
have been described in detail and critically reviewed.
The future prospects of the use of targeted monoclo-
nal antibodies for radioimmunoimaging (RII (60,
61)) and for radioimmunotherapy (RIT (61,62)) are
equally promising. Paul Ehrlich's view (63) of tar-
geted antibodies used äs "Zauberkugeln" (magic
bullets) or, in modern terms äs "guided missiles"
against cancer might become reality in the near fu-
ture.
Monoclonal Antibodies to Kidney Tissue Antigens
Diagnosis of kidney damage is generally obtained
from the results of tests of renal glomerular or tubu-
lar function. Changes in function, however, indicate
the existence of severe lesions or irreversible tissue
necrosis. Thus, function parameters allow recogni-
tion of late phase reactions occurring during kidney
injury but they are in most cases inadequate for the
determination of minor early phase alterations. The
latter can be reversible and disappear when the ag-
gression on the tissue ends. They consist of modifica-
tions at the level of the renal cell surface accompan-
ied by release of membrane components in the urine.
Such early phase lesions can sometimes be recog-
nized by electron microscopic examination of biopsy
specimens. Most of the tests performed on urine in
use today yield Information on late phase events on-
ly. The recent establishment of assays for quantifica-
tion of the urinary ß2-microglobulin (64) and for
measurement of the urinary alanine aminopeptidase
activity (65) has allowed recognition of early phase
alterations. The determination of other kidney-de-
rived components in urine may in addition facilitate
the localization of damage to particular sites of the
nephron. In order to search for kidney-derived com-
ponents in urine we have prepared monoclonal an-
tibodies against human kidney antigens (66, 67).
These antibodies display various specificities for an-
tigens in the different parts of the nephron, in blood
vessels and in the interstitia.
Initial evidence for the presence of kidney-derived
antigens in urine was obtained by "Inhibition of im-
munofluörescence staining" assays performed with
concentrated urine of patients suffering from various
kidney diseases (68). In order to detect and quantify
antigens in native urine, more sensitive tests had to
developed. The sandwich ELISA was chosen be-
cause it allows estimation of antigens which are not
available in pure form äs is the case with these kid-
ney-derived antigens.
A number of sandwich ELISA tests have been deve-
loped by using various combinations between solid
phase adsorbed "catcher" and glucose oxidase con-
jugated "indicator" antibodies. Native urine samples
of patients suffering from various kinds of kidney
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damage were assayed with each of these test Systems,
and the percentage of urines containing antigens
were calculated. Thus the sandwich ELISA, a very
quick and easy technique, appeared to be suitable
for the detection of antigens in native, i. e. unconcen-
trated and undialysed, urine.
Each of the monoclonal antibodies used is specific
for one of the various epitopes of the kidney-derived
urinary antigens. Some of these epitopes can be situ-
ated on the same antigen. Consequently, it is possi-
ble that some of the sandwich ELISA tests measure
the same antigen(s), although each antigen was
bound to the various "catcher" antibodies by means
of a different antigenic epitope. In order to test this
hypothesis and to select those assays that allow de-
tection of different urinary antigens, correlation
analysis (Spearman) of the data were performed.
The results indicated that these assays can be divided
into groups. Thus, all tests belonging to different
groups detect:.different antigenic molecules, each
characterized by a specific combination of epitopes.
Therefore, one assay was selected from each group
for further experiments.
Although the tests are sensitive enough to allow
quantification of antigens in unconcentrated urine,
no significant amounts of antigens were detected in
human serum. To find out whether urinary excretion
is correlated with renal tissue damage, the normal
ränge (mean ± 2.5 SD) of urinary antigen was deter-
mined by assaying the urine of healthy persons.
Antigen excretion in the urine of patients suffering
from various kidiiey diseases was compäred with the
antigen excretion in the urine of healthy persons.
Within the patients' group part of the individual
values (10 to 30%) were significantly increased.
High levels of urinary antigens were observed in all
cases of clinically diagnosed acute phases of renal
diseases (acute pyelonephritis, urosepsis). Destruc-
tion of renal parenchyma in cases of hydronephrosis,
nephrolithiasis, interstitial nephritis and polycystic
disease of the kidney was always accompanied by in-
creased release of antigens in urine. In addition,
some of the patients suffering from chronic glomeru^
lonephritis or diabetic nephropathy shöwed high uri-
nary levels of antigens äs well, which is indicative of
tissue destruction.
These experiments have been described in detail re^
cently (69—72). Some of the results obtäined are
shown in figures 2 and 3.
In figure 2 the excretion of 7 urinary antigens (U A
1—7), each defined by a certain combination of mo-
noclonal antibodies, is measured in urinary samples
of patients suffering from nephrolithiasis (fig. 2a) or
pyelonephritis (fig. 2b).
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Fig. 2. Excretion of urinary antigens (UA) derived from distal (UA1, UA2, UA3) and proximal (UA4, UA5) part of the nephron or
localized in all parts of the tubular System (UA6, UA7) in patients suffering from nephrolithiasis (fig. 2ai and pyelonephritis (fig.
2b). Antigen excretion is given äs percent of upper limit of normal ränge (100% = mean + 2.5 SD).
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As expected, in such cases, in which the disease af-
flicts the distal part of the nephron primarily, excre-
tion of distal tubular antigens is strongly enhanced.
However, the proximal part of the nephron must be
involved too, since antigens from this region also oc-
cur in the urine.
Having tested, in the meantime, urinary samples
from several hundred patients with diseases related
to the kidney, using 10 ELISA test Systems based on
10 different combinations of monoclonal antibodies,
the heterogeneity of the excretion pattern observed
is confusing. Much work has still to be done to corre-
late antigen excretion with the clinically determined
state of the disease.
In a follow-up study of a patient with only one kid-
ney suffering from hydronephrosis (ureterolith), the
excretion of a distal tubular and a proximal tubular
antigen was monitored before and after removal of
the stone. As can be clearly seen (figs. 3a and 3b),
removal of the stone is immediately followed by the
release of distal and proximal tubular antigens. After
three days, antigen excretion returns to normal
values. This antigen release is most probably caused
by the washout of antigens from cells that have been
damaged by the pressure built up by the obstacle in
the ureter.
In figure 4 the immunohistochemical localization of
two of the antigenic epitopes in the kidney is shown.
The epitope recognized by monoclonal antibody PM
11 80 F5 which is part of the UA4 antigenic p rticle
is clearly localized in the luminal part of cells of the
proximal tubule (fig. 4a). In contrast, the antigenic
p rticle UA2 which carries an epitope recognized by
the monoclonal antibody PM II29 D2 is confined to
distal tubular cells (fig. 4b). This latter antigen is dis-
trib ted evenly in the tubular cells. There is no or
only very weak overlapping of the staining patterns
exhibited by the two monoclonal antibodies which
were directly labelled with fluorescein (PM II80 F5)
and rhodamine (PM II 29 D2) and applied to the
same tissue slice.
So far, the most important outcome of our studies is
that it has become possible to monitor the excretion
of antigens with clearly defined loealization in the
nephron. Correlation between antigen excretion and
localization of the primary event in the tissue there-
fore becomes possible. Whereas similar test have
been wprked out for the proximal tubular part of the
nephron, e. g. measurement of alanine aminopepti-
dase excretion (65), nothing is known about distal
tubular markers. Through our tests it has become
possible now to determine the excretion of distal
tubular markers s well. In an attempt to identify
Έ500
·**·
•=5
€300
Ι»»
S100
ι ι Π Π m"! Γ Γΐ Ι ι ι ι ι ι ι ι
' -3 ' -2 -1
^Collection,
intervols
-= 30
ί-
δ
S 10
before Operation
ι ι η ι ι ι—^-
2 ' 3 Time [d]
fter
Collection
intervals
rfo,
Operation
2 ' '" 'TJmeid)
fter
Fig. 3. Excretion of kidney-derived urinary antigens (UA) in the
urine from a case of hydronephrosis (urethrolith).
a) Proximal tubular antigen UA4 defined by monoclonal
antibodies PMII 35 Hl and PMII 80 F5 GOD.
b) Distal tubular antigen UA2 defined by monoclonal an-
tibodies PM II 29 D2 and PM II 9 C2 GOD.
Antigen excretion is given s arbitrary units per collection
interval (4 hours).
cellular breakdown products of tubular cells in the
urine of patients treated with cis-platinum, we have
used the immunogold method for ultrastructural
identification. Distal tubular antigens carrying the
PM II 9 C2 epitope were found in filament-Iike
structures recovered from the urine by ultracentrifu-
gation (72).
Monoclonal Antibodies of Other Species
Nearly all of the hybridoma work done up to date
has made use of the well defined and almost fool-
proof mouse plasmacytoma cell lines s myeloma fu-
sion partners. It was and still is difficult, however, to
immortalize lymphoid cells of species other than
mouse. Rat lymphocytes have been successfully
fused to mouse myeloma cells. This technique of "in-
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Fig. 4. Identification of localization of two antigenic epitopes in the same kidney slice by two directly labeled monoclonal antibodies.
a) Fluorescein labeled monoclonal antibody PMII 80 F5.
b) Rhodamine labeled monoclonal antibody PM II 29 D2.
Microphotographs were taken with an Olympus Fluorescence Microscope BH-2 using selection filters for each of the fluoro-
chromes. Magnification 160x.
terspecies hybridization" works in principle with
lymphocytes of all species. Whereas rat x mouse hy-
bridomas are rather stable (73), products of fusion of
mouse myeloma cells with lymphocytes from phy-
logenetically distant species such äs man are rather
labile and tend to lose mouse chromosomes and con-
sequently their immortality.
Rat Monoclonal Antibodies
Two rat myeloma lines are now available to the
scientific Community, Milstein's Y3-Agl.2.3 (74) and
Bazin's IR983F (75, 76). One of the advantages of
using rat in addition to mouse myeloma lines for cell
fusion is the expansion of the available repertoire of
monoclonal antibodies, since the rät's immune sys-
tem might recognize determinants completely differ-
ent from those recognized by the mouse's immune
System. Even more important is the observation that
monoclonal rat antibodies easily activate human
complement and, therefore, might have an advan-
tage over monoclonal mouse antibodies for thera-
peutic purposes (77, 78).
Human Monoclonal Antibodies
The fusion of human lymphqcytes with mouse plas-
macytoma cells has in some cases been suecessful
(79). Schlom et al. (80) reported the fusion of lym-
phocytes obtained from lymph node biopsy speci^-
mens from patients undergoing mastectomy for
breast cancer. These lymphocytes were fused with
mouse myeloma cells and yielded a few stable man x
mouse hybridomas secreting antibodies specific for
human breast cancer tissue componeiits. These re-
sülts süggest that the tumour elicits an autologous
immune response in the cancer bearing patient.
The availability of stimulated lymphocytes of the B
cell lineage from human doiiors is one of the precon-
ditions for fusion of human cells. Peripheral lympho-
cytes are the most common source of such fusionable
cells. They can be obtained from normal donors äs
well äs from donors immunized by naturai infection
or by vaccination. Human monoclonaj antibodies re-
sulting from such fusion experiments would yield in-
formation on the monoclonal components of the hu-
man immune response to infectious ägents. In addi-
tion, they might have advantages over polyclönäl hu-
man antisera for therapeutic purposes.
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The spectrum of human monoclonal antibodies ob-
tainable by fusion of cells from immunized donors is,
however, limited since humans cannot be immunized
Hke laboratory animals. On the other band, in vitro
immunization of human lymphocytes still is a very
complicated procedure and has only been successful
with relatively few antigens (81). The peripheral
blood of patients suffering from autoimmune dis-
eases should contain fusionable lymphocytes. The
immortalization of the monoclonal components of
the humoral autoimmune response should yield val-
uable Information on the antigens involved and on
the pathomechanism of the disease. Anti-idiotypic
antisera to such monoclonal autoimmune antibodies
might one day help to regulate autoimmune diseases
and to clear the blood of these autoantibodies
through extracorporal immunosorption.
For the preparaton of human monoclonal antibodies
to other antigens of interest, e.g. in cancer research,
one is dependent on the patient's autologous im-
mune response. If a patient has developed antibodies
to his own tumour the corresponding fusionable B
lymphocytes are available not only from the blood
but also from draining lymph nodes or from the ex-
cised tumour itself (intra-tumoural lymphocytes).
There is a considerable body of evidence for the
presence of autologous immune response to various
types of malignant diseases. These data indicate that
most tumour patients develop an autologous humor-
al immune response to their tumour. The question
whether or not such immune responses have any im-
pact on the tumour, either enhancing or inhibiting
tumour growth, inust at the moment remain unan-
swered. Irrespective of the role of the patient's im-
mune response in the immunobiology of the tumour,
the future potential of immortalization and dissec-
;tion of such autologous immune responses is a chal-
lenge äs well äs a promise for immunologists.
For the successful fusion of human lymphocytes, a
human myeloma line, comparable in its properties to
the mouse myeloma lines, is urgently needed. So far
most of the reports on successful fusions with human
myeloma lines have to be taken with great reserva-
tion and doubt (82,83). The usefulness of the availa-
ble human plasmacytoma or lymphoblastoid cells
line for fusion purposes was reviewed by Kozbor et
al. (84) and by Abrams et al. (85). In all cases, myco-
plasmal infections might cause the most severe prob-
lems in human hybridoma technology. Therefore,
availability of mycoplasma free fusion partners (both
lymphocytes and myeloma cells) seems to be the
most important precondition for successful human x
human fusions (86).
In principle the results obtained so far seem promis-
ing and should encourage other investigators to de-
velop this important field of hybridoma technology.
A patient's immune response against his own tumour
should be more specific than the immune response of
an immunized animal can be expected to be. If not
for therapeutic, then definitely for diagnostic pur-
poses, human monoclonal antibodies will have a
great future potential.
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Summary: The historical development, principle and theory of the radioimmunological lest are described,
together with the necessary test components, Separation techniques and experimental procedure. The empha-
sis on different areas of diagnosis that rely on radioimmunoassay is compared for two institutions.
Methods for the determination and presentation of reliability criteria are described, and the current Status of
quality control of radioimmunological methods is discussed.
Three high grade mechanized Systems and five fully mechanized or automated Systems for radioimmunologi-
cal assays are presented.
Future trends in the development of radioimmunoassay can be predicted with the aid of general growth crite-
ria.
Radioimmunoassay: Ein Überblick
Zusammenfassung: Historische Entwicklung, Prinzip und Theorie des radioimmunologischen Tests werden
beschrieben, Anforderungen an Testkomponenten, Trenntechniken und Durchführung werden dargestellt.
Aus dem Anwendungsbereich des RIA werden klinisch-diagnostisch wichtige Schwerpunkte anteilig für zwei
Institutionen gegenübergestellt. Methoden zur Ermittlung und Darstellung von Zuverlässigkeitskriterien so-
wie der aktuelle Status der Qualitätskontrolle radioimmunologischer Verfahren werden beschrieben.
Drei hochgradig mechanisierte Systeme zur Durchführung radioimmunologischer Tests sowie fünf vollmecha-
nisierte bzw. automatisierte Systeme werden dargestellt.
Entwicklungstendenzen des Radioimmunoassays, die anhand allgemeiner Wachstumskriterien erkennbar
sind, werden gegeben.
History
In 1952, Arthur Mirsky proposed that maturity onset
diabetes could be attributed not so much to a defect
of secretion, but rather to an accelerated degrada-
tion of insulin by "insulinase" of the liver (1). In
order to test this hypothesis, Yalow & Berson inves-
tigated the metabolism of 131I-labelled insulin, and
observed that it was eliminated more slowly by insu-
lin-sensitive diabetics than by npn-diabetics (2).
They explained this delay by the binding of labelled
insulin to an insulin-binding globulin fraction. Using
isotopic tracing and radiochromato-electrophoresis,
they showed that this globulin fraction occurred gen-
erally in the plasma of insulin-sensitive diabetics,
and suggested that it contained an acquired insulin
antibody. To the immunologists in the mid fifties,
however, this was an unacceptable concept, and the
fundamental studies of Yalow & Berson were reject-
') Presented at the Kleinkonferenz „Immunologische Diagnostik44 der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
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ed by "Science" and "Journal of Clinical Investiga-
tion" in 1955 (3). The work was accepted in 1956,
but only after a compromise has been reached with
the editors, in which the term "insulin antibody" was
removed from the title. In the same publication they
also reported that the quantity of labelled insulin
bound to a defined concentration of antibody was
related to the actual insulin concentration. This ob-
servation formed the basis for the radioimmunologi-
cal detection of plasma insulin, and for the subse-
quent development of all radioimmunological and
related methods of Saturation and displacement
analysis. Adoption of the method was, at first, ex-
traordinarily slow. Bioassays were still the preferred
methods for hormone assays. No great interest was
shown in the radioimmunological test until four
years later, when Yalow & Berson described the
measurement of plasma insulin without extraction
(4). Slowly, it became recognized that radioimmu-
noassay was a highly sensitive and comparatively
simple method, for performing assays in small sam-
ples and in large sample series.
Even up to the mid sixties, Yalow & Berson were
practically the only authors using this method. Five
years later, however, in 1970, radioimmunoassay
had already developed into the most important and
comprehensive analytical method in the endocrino-
logical laboratory. It then spread rapidly into medi-
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Fig. 1. Increase in the number of publications concerned with ra-
dioimmunoassays.
a) Yalow, R. S. & Berson, S. A. (1960) J. Clin. Invest.
39, 1157. Number of times quoted: 1100 (1961-
1975).
b) Journal of Clinical Investigation,
Diabetes,
Journal of Clinical Endocrinology,
Endocrinology
eine and veterinary medicine, and into nonmedical
areas concerned with the analysis of low concentra-
tions of organic compounds (fig. 1). In 1974, ra-
dioimmunological methods were performed in about
2000 laboratories in the USA, increasing in 1975 to
more than 4000 laboratories. Meanwhile, the funda-
,·; '
mental work of Yalow & Berson in 1960 (4) has be-
come a classic reference. The increase in the number
of radioimmunological determiriations since 1975 is
shown in figure2 (5—8).
1975
1976
1980
1985
RIA-Tests
USA
52000000
100000000
>200000000
World-wide
52000000
100000000
200000000
>400000000
1979
1985
Federal Republic of Germany
17000000
39000000
Fig. 2. Growth in the number of radioimmunological tests.
Principle and Theory
The principle and theory of the radioimmunological
test are comparatively simple and straight forward,
and therefore offer no basis for understanding the
less than satisfactory precision and accuracy of the
method that still exist today. In the radioimmunolog-
ical System (fig. 3), antigen (AG) and antibody (AB)
interact reversibly to form a soluble antigen-anti-
body complex. Labelled antigen (AG*) and unla-
belled antigen compete for binding to the limited
number of antibody binding sites. The process obeys
the law of mass action, so that the greater the quanti-
ty of unlabelled antigen present, the less labelled an-
tigen is bound. Since labelled antigen and unlabelled
antigen are in excess of the antibody (i. e. [AG*] and
[AG] in excess of [AB], where [] refers to the con-
centration of valencies, rather than the molar con-
centration), the terna, Saturation analysis, is also
used. The concentration of unlabelled antigen is de-
rived from the extent to which it competitively inhib-
its the binding of radioactive antigen tp a specific
antibody, the method being standardized with
known concentrations of unlabelled antigen. To per-
form this typical comparative in vitro analysis,
known concentrations of antibody and labelled anti-
gen are incubated at a defined teniperature with var-
ious concentrations of unlabell$d antigen (Standard
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or sample), usually until equilibrium is reached. Free
antigen is then separated from bound an t i gen, and
the radioactivity of one or both fractions is mea-
sured. If an honiogeneous antibody with equal affini-
ty for labelled and unlabelled antigen were used, and
the reaction allowed to attain Saturation, then the
Standard curve would be an hyperbola (B/Bö =
f([AG] + [AG*])), which could be transformed to a
linear, double reciprocal or double logarithmic plot
(figs. 3a and 3b). In some cases, the Standard curve
obeys a mathematical model, which suffices for the
binding kinetics and the detection limit (Scatchard
plot, quadratic equation, hyperbola, logit-log trans-
formation, etc.). This is not usually the case, howev-
er, so that purely einpirical Interpolation methods
are used for curve fitting (parabola, polynomials of
various degrees, smoothed spline approximation,
etc.) (9, 10).
AG*
(
 *
A6standard/sample
,AG*-AB
(B)
"AG - AB
9000- 0.40- 1.0-
e
l 4500
3
S
0L
-"0.20 0.5
c [nmol/l]
. f ( lA6*MA6])
Linearizotion
clnmql/U löge [nmol/l]
Fig. 3. Principle of the radioimmunological test
Test Components
Antigens and antibodies
An antigen is any sübstance that binds to an anti-
body. Large antigens are immunogens per se. If the
molecule is too small or lacks sufficient chemical dif-
ferentiation tö act äs an antigen, i t is coupled coval-
ently to a higher molecular weight carrier (serum al-
bumin possesses a large number of different reactive
groups that can be exploited for this pu ose), and
the conjugate is used for immunization. To ensure
that the assay is free froin interference, it is essential
that the Standard, the antigen used for the immuni-
zation and the labelled antigen be very pure.
The properties of an antiserum raised against an
hapten-carrier conjugate are predetermined by the
type of carrier and by the site of coupling between
hapten and carrier, whereas the properties of an an-
tiserum raised against a high molecular weight anti-
gen are rather unpredictable. Especially in the mea-
surement of pharmaceuticals and their metabolites,
it must be decided whether to use an antiserum that
recognizes a whole family of molecules (original
compound and its metabolites) or one that recog-
nizes only biologically active metabolites.
Qualitative and quantitative evaluation of an anti-
body for use in a radioimmunoassay is based on the
two criteria of specificity and affinity. Specificity is
determined from cross reaction with antigen ana-
logues (see also the section on Reliability), and affin-
ity is determined by measurement of affinity con-
stants. The stability of antigen-antibody complexes is
larger for multivalent antigens, owing to the aug-
mented formation of an intermolecular network. In
such cases the antigen-antibody reaction is more ap-
propriately characterized by the overall, average af-
finity constant, known äs the avidity constant. This
effect of antigen valency seems to be the main reason
for the greater sensitivity of immunological tests for
proteins and polypeptides, compared with those for
haptens.
To a first approximation, the sensitivity of a test, i.e.
the minimal detectable concentration, corresponds
to l/Ka or 1/Kav, where the affinity constant, Ka, for
the hapten-antibody interaction is normally in the
ränge l O6—1010 1/mol, and Kav for protein-antibody
interaction can be äs high äs 1013 1/mol (fig.4).
[AG] + [AB] ;=± [AG - AB]
Free (F) Bound (B)
Ka = ~ [ABo] = [AB] + [AG - AB]
B/F
1. [ABo] > B:
2.
Ka([AB0] - B)
/F
max (£ high sensitivity)
from 1. and 2.: [AB0] =* [Hmin]
when B/F « J : l < Ka[ABo] < Ka[Hmin]
[Hmjn] > ^~
Fig. 4. Detection limit - affinity constant.
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Labe l led an t i gen ( tracer)
The measured parameter in the radioimmunoassay is
the radiation of a nuclide, which must be introduced
into the antigen molecule. Suitable nuclides may be
isotopes of normal component atoms of the antigen,
which can be introduced by exchange or attached to
the antigen in the form of an immunologically inert
residue; or they may be foreign atoms with especially
favourable isotopic properties, and likewise intro-
duced by exchange or coupled to the antigen with an
extra residue.
To guarantee a sufficiently sensitive test for use in a
defined area of biological enquiry, the isotope must
have a certain minimal specific activity. This is illus-
trated by a survey of the factors that govern the re-
quired specific radioactivity of insulin for use äs a
marker antigen (fig. 5). Taking into consideration
the chemical feasibility of introducing the nuclide in-
to a variety of antigen structures, äs well äs the half
life of the nuclidp, only three isotopes are obviously
suitable candidates for antigen labelling; these are
the iodine isotopes, 131I and 125I, and tritium, 3H, al-
though the use of 131I is limited on account of its
short half life (fig. 6).
with Na125I involves direct iodination of tyrosine and
sometimes also histidine residues, using the iodine
monochloride method, the chloramine T method,
the electrolytic method or the lactoperoxidase meth-
od. In indirect iodination, the antigen is covalently
bound to an iodinated accessory molecule, e. g. hist-
amine, tyrosine niethyl ester, or tyramine; or it is
reacted with the iodinated N-hydroxy-succinifnide
ester of p-hydroxy^phenylpropionic acid, i.e. the
Bolton-Hunter reagent (11).
Isotope Half life Maximal specific activity
(Ci/m Atom) (Bq/m Atom)
131!
32p
I25I
MS
3H
J4C
8 days
14.3 days
60 days
87 days
12.3 years
5730 years
16000
9200
2200
1500
30
0.062
592 x 10'12
340 x 1012
81 x 1012
56 x 1012
1110 x 109
2294 x 106
Fig. 6. Nuclides used in in vitro diagnostic methods.
Plasma insulin concentration
10 mU/1 ^ 0.4 Lig/1 ^ 70 pmol/1
Detection of: 7 pmol/1
for high affinity AB: [AG*]:[AG] =10:1 ( /
 0 « 5%)
[AG*] = 70 pmol/1
70 pmol ^  3 · l O6 disintegrations per min (l -2 · l O6 counts/min)
Specific activity: 714 GBq/mmol (124 MBq/mg)
(19.3 Ci/mmol (3.35 mCi/mg))
Isotope: Insulin = 1:1
from: maximal specific activity =
3
'
56
 '
 10
 [Ci/mol] (x 37 = GBq/mol)
1172 (years)
tj/2 of isotope < 18.5 years
Fig. 5. Relationship between detection limit and the nuclide half
life.
Tritium labelling is performed by metal-catalysed
hydrogenation of unsaturated compounds, by the
metal-catalysed exchange of halogens or hydrogen
for tritium, or by the reduction of oxidized interme-
diates with tritiated metal hydrides. Iodine labelling
Separation Methods
An essential step in the radioimmunological assay is
the Separation of the free and
 fthe antibody-boimd,
labelled antigen. With the exception of the Internal
Sample Attenuator Counting method (12), all pres-
ent day radioimmunological assays are heterogene-
ous methods. The two fractions are therefore finally
separated by physical methods (centrifugation, fil-
tration, decantation, electrophoresis, chromatogra-
phy) (fig. 7). For an ideal Separation, the following
conditions must be satisfied:
1. quantitative Separation with no effect on the anti-
gen-antibody reaction (guarantee of high, preci-
sion and sensitivity),
2. simple, rapid and cheap performanee (high prac-
ticability),
3. no influence by plasma components (high repro-
ducibility and comparability) (13, 14),
4. no unspecific effects (15, 16), and
5. time-dependent stability of the antigen-antibody
complex under the Separation conditions (me-
chanized, sequential systems)Ä>(17, 18).
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Principle Method/Material
Mobility Chromatoelectrophoresis, eiectrophoresis,
gel Filtration, chromatography
Adsorption Dextran (gelatin)/active charcoal, silicales,
ion exchangers, cellulose
Fractional Organic solvente, polyhydric alcohols, salts,
precipitation acids, double antibodies (poly-
ethyleneglycol), Staphylococcal protein A
Solid phase Antibody coating: reaction vessels,
capillaries, agarose, cellulose, Sephadex,
Sepharose, polymer-encapsulated iron
Double antibody coating: Sepharose,
cellulose, etc.
Internal sample Agarose/bismuth oxide/aclive charcoal
particle
Attenuator Agarose/bismuth oxide/antibody particle
counting Cd, W, Pb, Bi, Hg?
Particle size Sedimentation?
% Absorption of radiation?
Fig. 7. Separation techniques in radioimmunoassay.
Non-Equüibrium Radioimmunoassay
Basically, it is possible to perform the test before
binding has reached equilibrium. Since the rate of
association at constant antibody concentration de-
pends on the antigen concentration, equilibrium is
reached in the flat, terminal part of the Standard
curve sooner than in the initial part. If Standards and
samples are treated identically, the test can be con-
ducted according to this principle, although the de-
tection limit is decreased äs shown by the flattening
of the initial part of the Standard curve (fig. 8).
Deiection limit
Irin
0.20
0.05
Fig. 8. Non-equilibrium radioimmunoassay (digoxin).
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If the equilibrium constant of the reverse reaction
(dissociation of the antigen-antibody complex) is
small relative to the association constant, then the
detection limit can be increased by first exposing the
antibody to unlabelled antigen until optimal binding
is attained, followed by incubation with the labelled
antigen.
Application
In principle, radioimmunoassay can be used for the
quantitative determination of any substance that is
available in pure form, and to which an antibody can
be raised. More than 400 substances of widely vary-
ing chemical types and biological importance have
now been measured by this technique, chiefly in the
fields of medical diagnosis and clinical chemical re-
search. About 100 of these are essentially important
in routine diagnosis; following a Suggestion of Rosa-
lyn Yalow, they can be divided into three classes:
peptide hormones, non-peptide hormones and non-
hormonal substances (3).
The majority of the substances shown in figure 9 can
be assigned to five crucial areas of diagnosis: thyroid,
hepatitis, cancer, Digitalis glycosides and general di-
agnosis. In figure 10, the percentage contribution of
each of these five areas is shown for Met Path, one of
the largest clinical chemical laboratories in the USA
(calculated from figures for September 1977), and
for the Medical School in Hannover (average figures
for 1982). The apportionment shown here for the
Hannover medical school is possibly not strongly
representative of other clinics in the Federal Repub-
lic of Germany, because considerable shifts of em-
phasis may be caused by local factors (a large wom-
en's hospital and a special section for diabetes cause
a disproportional increase in sector G), and by state
political or legislative measures (neonatal hypothy-
reosis screening is not included in sector T).
Reliability
It is the purpose of all clinical chemical investiga-
tions, including those performed by radioimmunoas-
say, to provide reliable analytical results äs a basis
for reliable clinical diagnosis. Reliability depends on
the type and degree of incidental and systematic er-
rors, which should be monitored, identified and clas-
sified by an internal laboratory quality control sys-
tem, the long term aim being to decrease or abolish
such errors. Since radioimmunoassay is a mulfistep
procedure, the possibilities for error are correspond-
ingly large (fig. 11).
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Peptide hormones Non-peptide hormones Non-hormones
Hypopliysis Thyroid
Human somatotropin, corticotropin, 3,5,3'-triiodothyronine, thyroxin,
-melanocyte stimulating hormone, reverse triiodothyronine
ß-melanocyte stimulating hormone,
thyrotropin, follitropin, lutropin, prolactin, Steroids
ß-lipotropin, antidiuretic hormone, Aldosterone, corticosteroids,
ocytocm oestrogens, androgens, progesterone
Placenta
Human chorionic gonadotropin,
human chorionic somatomammotropin
Pancreas
Insulin, glucagon, C-peptide, proinsulin,
pancreatic polypeptide
Calcitropic hormones
Parathyrin, calcitonin
Gastrointestinal tract
Gastrin, secretin, 'cholecystokinin,
vasoactive intestinal peptide, gastric
inhibitory peptide, motilin, neurotensin,
enteroglucagon
Vasoactive tissue hormones
Angiotensins, bradykinins
Liberins, statins
Thyroliberin, luliberin, somatostatin
Other peptides
Substance P, endorphins, enkephalins,
thyroglobulin
Prostaglandins
Leukotrienes
Biogenic amines
Serotonin, melatonin, catecholamines
Pharmaceuticals, Vitamins
Cardiac glycosides, drugs, psychoactive
agents, antibiotics, tricyclic antidepressants,
vitamin B12, folic acid
Cyclic nucleotides, enzymes
Cl -Esterase, fructose-1,6-bisphosphatase,
plasminogen, plasmin, chymotrypsin, trypsin,
carbonic anhydrase, aldose reductase,
carboxypeptidase B, pancreatic el äst äse,
creatine kinase isoenzymes,
acid phosphatase
Viruses, viral proteins, bacterial antigens,
parasite antigens, tumour antigens
Carcino-embryonic antigen, o>foetoprotein,
alkaline phosphatase,
pro-adrenocorticotropic hormone, ferritin,
coemloplasmin, tissue polypeptide antigen,
ß-microglobulin, foetal sulphoglycoprotein,
lung tumour associated antigen.
Serum proteins
Thyroxin-binding globulin, albumin, IgG,
IgE, IgA, IgM, properdin, fibrinogen,
apolipoproteins, myoglobin
Other substances
Rheumatoid factors, coagulation factors,
complement factors, neurophysins,
endotoxins
Fig. 9. List of some substances that can be determined by radioimmunoassay.
1977 1982
Fig. 10. Proportions of radioimmunological determinations in the
sectors: thyroid (T), hepatitis (H), cancer (C), Digitalis
glycosides (D) and general diagnosis (G)
1977 = Met Path, USA
1982 = Medizinische Hochschule Hannover
Reliability can be determined with the aid of the de-
fined and quantifiable reliability criteria: detection
limit, specificity, precision and accuracy. Detection
limit or sensitivity is limited essentially by the affinity
constänt of the antibody, and can be determined in
various ways (fig. 12):
1. According to Ekins (20) it is determined from the
initial slope of the Standard curve, thus represent*.
ing a special case of Ekins9 precision concept: Ac
(== precision of the measuremeiit of c) depends
on the slope and the error of the measurement of
B, i.e. ; if c = 0, the corresponding value of
Äc, i.e. Äc0, defines the detection limit.
2. Schwäres method for internal quality control.
This is based on a logit-log transformation, and
(because of heteroscedasticity i. e. irregulär distri-
bution of variance over the Standard curve) it
uses only that part of the Standard cüfve between
15 and 85% of the initial binding of urdabelled
antigen (Bö). As an operatiönal definition, test
sensitivity is therefore 0.85 x B0 (21).
3. As a general guide fof ensuring the quality of
clinical chemical results, the dection limit can be
taken äs B0 — 3sBo. ^
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Component or
step of a radio-
immunological
method
Variable factors that can cause differences
in results
1. Reagents
Standard
antigen
Labelled
antigen
Antibody
Buffer System
Standard
matrix
2. Sample matrix
3. Sample
preparation
4. Aliquotting
and dilution
Structure, purity, stability, protein binding
Type of labelling, specific radioactivity,
stability, physical-chemical properties
cornpared with those of the Standard antigen
Type of immunogcn, species, immunization
protocol, affinity constants for labclled and
unlabelled antigen
Composition, ionic strength, pH, type and
concentration of protective proteins,
addition of other reagents
(e.g. sodium azide, enzyme inhibitors)
Composition
Composition (unphysioJogical concentration
of physioiogical components, differcnt
concentrations of unphysiological
components)
Isolation, storage, transport, pretreatment
(extraction, heat treatment, anticoagulants,
etc.)
Quality of delivery System, i.e. mechanized
or manual, materials.
5. Reaction vessel Material, surface to volume ratio
6. Incubation Temperature, time
7. Separation Type of bound/free Separation, effects of
constituents of the sample matrix, unspecific
binding
8. Radioactivity Type and quality of the counter, statistical
measurement counting errors
9. Data valuation Type and quality of the fitting procedure,
individual cases of unspecific binding
Fig. 11: Sources of error in radioimmunoassay.
Specificity is a measure of the exclusive nature of the
binding between the antiserum and the antigen un-
,der investigation. The reciprocal term, cross reactivi-
ty, refers to antibody heterogene!ty (= heterogene-
ous cross reactivity) or, äs in the case of monoclonal
antibodies, it refers to a limited ability of the antigen
binding site to exclude cross reacting ligands (=
homogeneous cross reactivity).
In conventional radioimmunoassay, heterogeneous
and homogeneous cross reactivities cannot be differ-
entiated, but differentiation is possible by using the
studied antigen only in its labelled form. For t wo
cross reacting antigens, two situations can be differ-
entiated by a Scatchard plot (fig. 13):
1. saturable, high affinity binding of both labelled
antigens (AG* and AGo) with equal affinities, in
which the different binding capacity is indicative
of a fraction of low capacity anti-AGl within the
anti-AG^ population (fig. 13a) (typical of an he-
terogeneous antiserum), and
2. a different affinity of AG* and AGj with equal
binding capacities (typical of an homologous an-
tiserum).
B/F B/F
6 B
Fig. 13. Scatchard plots for the interaction of heterogeneous and
homogeneous antisera with cross reacting antigens.
a) heterogeneous antiserum
b) homogeneous antiserum
BÖ
Oeieclion
limit
Detection
limit
Detection
limit
Fig. 12. Detection limit in radioimmunoassay.
a) after R. P. Ekins, AC = factor (slope, ). .
b) according to the guide lines for internal quality control of the German Society for Chmcal Chemistry, B0 - J
c) after 5. Schwarz.
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The common influences of incidental and systematic
errors on the precision and accuracy of the radioim-
munoassay suggest that they are related. This is clear
from a comparison of two methods (fig. 14) (21):
method A with a wide scatter (= incidental errors,
poor precision, high imprecision factor) around the
true value of ä, and method B with low scatter (good
precision) about an average value, b, which differs
from the true value (= systematic error). The quality
of the analytical results from the two methods can be
compared by using Ekins* equation (fig. 14). On the
basis of its clinical value, method B would always be
preferable (21).
p*—Precision
Accurate value
Fig. 14. Relationship between precision and accuracy.
Analytical quality = Vaccuracy2 + precision2 (after
Ekins)
Fig. 15. Precision analysis of radioimmunological methods.
a) Response-error-relation
b) Standard curve
c) Precision profile
R = Replicate (mean)
In internal laboratory quality control, precision and
accuracy are monitored separatetyi Nowdays, the
normal procedure for precision analysis is to deter-.
mine a response-error relationship (RER), which is
represented by the Standard deviation of replicates
(usually duplicates), or their deviation frorn the av-
erage of the replicates. Taking into account the con-
fidence ränge for antigen concentrations determined
from the Standard curVe, a precision profile is then
constructed. For a symmetrical distribution of the
confidence limits, this profile then represents the de-
pendence of the Variation coefficient ori the antigen
concentratiön or the appropriate response parame-
ter, and it shows how the precision aiters over the
ränge of the Standard curve (fig. 15).
Precision profiles can be constructed for four differ-
ent levels of precision (fig. 16) (21):
60
50
40
30
20
10
0.5
8/Bo
4. between laboratories
% CV = g · 100
3. inter-series
% CV = -~~- - 100
2. within series
% CV = · 100
1. Standard curve and fit
% CV = in 10
B/Bö - (B/Bö)2 Bö · slope
Fig. 16. Precision profile of the radioinynunoassay.
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1. for errors that arise from the preparation of the
Standard curve and the curve fitting procedure,
2. for the level of precision within the series for re-
plicate measurements,
3. for the level of precision between series for the
measurement of an internal quality control sam-
ple, and
4. for the level of interlaboratory precision for the
measurement of external quality control samples
in interlaboratory collaborative investigations.
As a means of guaranteeing the internal quality of
results, the type 3-level of precision is important. It
comprises the total variance of "the Standard curve,
the fit and the sample, and the interseries deviation.
For radioimmunological methods it is found to be
between 7 and 20% when the optimal r nge of the
calibration curve is used for standardization.
Of the reliability criteria, accuracy contains the grea-
test element of uncertainty, s evidenced by the dif-
ference between the measured and true value of the
antigen concentration. Definitive methods, which
can be used to check the radioimmunological meth-
ods, are available for very few antigens (e.g. gas
chromatography-mass spectrometry for steroids).
For the majority of antigens, however, especially
peptide and proteo-hormones, only the "relative in-
ternal" accuracy is monitored, using recovery exper-
iments and/or the results are compared with those
from already established (possibly performed in ref-
erence laboratories) radioimmunological methods.
In addition to work at the Institute for Clinical Bio-
chemistry at the University of Bonn, contributions to
improving the cornparability of results between la-
boratories have been made in the last 10 years par-
ticularly by the group of Marschner, Scriba and
Wood, u$ing their own type of interlaboratory colla-
borative study. By identifying sources of error and
by making educative recommendations to manufac-
turers and users of kits, they have helped to bring
about a considerable increase in interlaboratory pre-
cision (fig. 17). Last year, Marschner presented the
evidence for this improvement, using the example of
thyroid stimulating hormone determination methods
in the Federal Republic of Germany (22). Also last
year, the World Health Organization presented its
experience of the previous five years with the
"matched reagents program", which involved more
than 80 laboratories in 35 countries (23). Over the
five year period, only one hormone assay (that for
luteinizing hormone) out of the seven studied
showed significantly better interlaboratory precision
when performed with WHO reagents and protocols,
than when performed with non-WHO reagents. If,
however, one assesses the changes in interlaboratory
precision over the five year period for both WHO
and non-WHO methods, s shown in figure 18, there
must be some doubt about the efficiency of the
World Health Organization programme.
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Fig. 18. Developments in precision for the determination of folli-
tropin (a) and lutropin (b), using the 'matched reagents
program' of the World Health Organization.
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Fig. 17. Improvement in the precision of the assay for thyroid stimulating hormone in the Federal Republic of Germany.
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A series of interlaboratory investigations have been
conducted in England, the Federal Republic of Ger-
many, the German Democratic Republic, Brazil and
Italy since 1979 (24-29). The results have some-
times been poor (interlaboratory coefficients of Vari-
ation of 20—70%), thus demonstrating how neces-
sary it is to seek new concepts for the improvement
of this aspect of radioimmunoassay. At present, the
quality of every single radioimmunological method is
such that it is used under regulations for exemption
from the German standardization laws (30).
Mechanization and Automation
In routine analysis, there is a critical sample frequen-
cy above which the necessity for mechanization or
automation is indicated. At the beginning of the sev-
enties, this Situation existed for certain radioimmu-
noassays.
Disregarding äiiy special stages of sample prepara-
tion, the conventional manual radioimmunoassay
consists of the following sequential Steps (fig. 19):
Radioimmunoassay — manual
1.
2.
3.
4.
5.
Dispensing of sample and reagents
Incubation
Separation of bound and free, aliquotting, filtration or
centrifugation
Radioactivity measurement, aliquotting
Data evaluation
Radioimmunoassay — mechanized
1.
2.
3A.
3B.
4.
5.
Dispensing of sample and reagents
Incubation
Separation of bound and free, aliquotting
Filtration
Gamma counting,
solid phase
Data evaluation
3B.
4.
5.
Centrifugation
Gamma flow
through counting,
liquid phase
Data evaluation
Munich, 1974 Hannover, 1974
Fig. 19. Fully mechanized radioimmunoassay Systems.
1. dispensing of sample and reagents,
2. incubation,
3. bound/free Separation, aliquotting, filtration or
centrifugation,
4. radioactivity measurement, and
5. data processing. .
 f
Amongst the developments in the early seventies,
two sequentially operating Systems should be men-
tioned. These two Systems, which were characterized
by an especially high degree of mechanization and
flexibility, were developed by the group of
Marschner & Scriba in Munich, and in the Depart-
ment of Clinical Biochemistry in Hannover (31—
36). The first three Steps (see above) were integrated
in a single programme-controlled unit for dispens-
ing, dilution, sample transport and incubation. Steps
4 and 5 were also unitized. In both Systems> howev-
er, the continuity of mechanization was broken by a
manual phase. This is advantageous, in that it makes
the process universälly adaptable to a wide ränge of
different types of radioimmunoassay. By forgoing
this advantage, sorne radioimmunological methods,
especially those with low molecular weight antigens
or haptens, can be completely automated or me-
chanized, i.e. performed with no manual Interven-
tion between sample delivery and production of the
results. For this purpose, five Systems are now avail-
able (fig. 20).
Trends in Development
Trends in the future development of radioimmu^
noassay can be discerned with the aid of various
criteria, which serve äs markers for the direction and
extent of growth (fig. 21). The publication peak was
apparently reached in 1980/81, but the number of
scientific publications is not necessarily correlated
with the prevailing market.
The introduction of new commercial tests, previous-
ly used only in research, can greatly irifluence the
market, äs exernplified by the hepatitis and carcino-
embryonic antigen tests, and the test for thyroid
stimulating hormone. Similarly, considerable growth
can be expected soon in the field of tumour markers.
An expansion of the number of measured gastroim
testinal hormones can also be predicted; this will oc-
cur slowly but inevitably, äs the ränge of the avaüa-
ble radioimmunoassays is increased. The best known
example of the application of available tests in a new
area is the use of the assay for thyroid stiinulating
hormone in neonatal hypothyreosis screening, The
assays for -foetoprotein, human ehoricmic somato^
mammotropin, ferritin, calcitonin, antidiuretic hor-
mone and coeruloplasmin are «prominent examples
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Name Manufacturer Features Tests
AR1A Becton-Dickinson Chamber with solid phase antibody,
regenerable
Automated RIA Technicon
Centria
Concept 4
Gammaflow
Kemtek 3000
Continual flow System, air bubble principle,
antibody on iron particles,
magnetic Separation
Union Carbide Batch principle (manual), centrifugal
analyser, bound/free Separation by ion
exchange
Micromedic Antibody-coated vessels, washing stage,
lOplaceracks
Squibb Continuous flow system, air bubble
principle, bound/free Separation with
regenerable ion exchanger
Bagshawe-Kemble 15 place racks, bound/free Separation by
filtration, measurement of filter
Triiodothyronine, thyroxin, oestriol, Cortisol,
digoxin, thyrotropin, Bja/folate
Triiodothyroninc, thyroxin, Cortisol, digoxin,
human placenta lactogen
Triiodothyronine, ihyroxin, thyrotropin,
insulin, digoxin, Cortisol, B i2/folate, human
placenta lactogen, lutropin, follitropin,
ferritin, prolactin
Triiodothyronine, thyroxin, thyrotropin,
insulin, Cortisol, B12
Triiodothyronine, thyroxin, digoxin, cortisol,
oestriol
Carcinoembryonic antigen, alpha-foeto-
protein, human chorionic gonadotropin,
human placenta lactogen, human somato-
tropin, triiodothyronine, thyroxin, cortisol,
oestriol
Fig. 20. Automated radioimmunoassay Systems.
of the use of existing tests for tumour markers. It can
also be anticipated that the development of tests for
newly discovered tumour antigens, such äs tissue
polypeptide antigen, colon-specific antigen p and
pro-adrenocorticotropic hormone, will lead to an in-
crease in the use of radioimmunological tests in the
field of tumour markers. An example of market reg-
ulation by legislation is seen in the Situation that ear-
lier resulted in Abbot's monopoly of the hepatitis
2000
1000
0L-
1960 1970 1980
Fig. 21. Growth in the number of publication concerned with ra-
dioimmunoassay.
Growth critena for radioimmunoassay.
New radioimmunological tests
New areas of application
Simplification of tests
Legislation
Automation
Competition
New tecihnologies
test. Infectious diseases represent a possible new
field of application for new tests, äs evidenced by the
recent development of a series of radioimmunologi-
cal tests in bacteriology, parasitology and virology
(tuberculosis, malaria, hepatitis). Over the last few
years, simplified versions of tests have increased
their share of a growing market, e.g. preprepared
reaction vessels containing appropriate quantities of
separately lyophilized antibody and/or labelled anti-
gen, or premeasured quantities of labelled antigen in
vessels coated with antibody. In this area, however,
one can expect little further impetus for expansion,
with similar low growth rates for simplified Systems
and their competitors, and little further development
of mechanized and automated Systems. It is not yet
possible to foresee whether the use of homogeneous
assays will result in a shift of emphasis in the market.
The turnover and share of radioimmunoassays in the
overall immunological analytical sector of the
market will probably stabilize in the next 3—4 years.
Deperiding on the demand for increased sensitivity,
new immunological tests, especially for small anti-
gens, will be developed äs alternatives to other
niethods. Some existing radioimmunological tests,
especially those concerned with thyroid function and
drug monitoring, have been and are being replaced
by non-radioimmunoassay methods. With the spread
of presymptomatic diagnostic screening methods,
the use of the available automated Systems will in-
crease rather than stagnate; this will perhaps lead to
an improvement in the most notable weakness of ra-
dioimmunological methods, i. e. the comparability of
results, which is so essential for positive clinical diag-
nosis (37).
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Summary: The main principles of heterogeneous and homogeneous enzyme-immunoassays are reviewed.
Furthermore, an overview is given of enzymes currently used äs labels and methods applied for conjugate
preparation. The reliability and practicability of enzyme-immunoassays are discussed. Special consideration is
given to possible interferences, the detection limits and the mechanization of these assays. A ränge of curve-
fitting methods for evaluation of the results is listed. Future prospects for the further development of enzyme-
immunoassay and application of this technique are discussed.
Enzym-Immunoassay: Eine Übersicht
Zusammenfassung: Es wird eine Übersicht über die wichtigsten Prinzipien des heterogenen und homogenen
Enzymimmunotests gegeben. Ferner wird über die gegenwärtig zur Markierung verwendeten Enzyme und
Methoden zur Herstellung von Konjugaten berichtet. Erfahrungen hinsichtlich der Zuverlässigkeit und Prak-
tikabilität von Enzymimmunotests werden mitgeteilt. Besondere Berücksichtigung finden die möglichen In-
terferenzen, die Nachweisgrenzen und Verfahren zur Mechanisierung dieser Tests. Eine Anzahl von mathe-
matischen Methoden zur Ermittlung der Ergebniswerte ist aufgeführt. Zukünftige Aspekte der Weiterent-
wicklung des Enzymimmunotests und der Anwendung dieser Technik werden diskutiert.
Introduction Principles of Heterogeneous Enzyme-Immunoas-
In recent years numerous non-isotopic immunoas- saYs
says have been developed, and many different labels Assay Systems, in which the enzymic activity of the
have been evaluated for their practicability (tab. 1). conjugate is not influenced by the antigen-antibody-
Among these new techniques the enzyme immu- reaction require a Separation Step and are called he-
noassay in particulaf has proved to be an especially terogeneous enzyme-immunoassays.
suitable alternative to radioinununoassay. In these ^
 tQ ^  ^ ^  other es rf ^
assays, enzymes, coenzymes, fluongemc Substrates
 & ^  ^ .^  ^  ^  n Qr ^  ^
and enzyme Inhibitors are used äs markers. There
 $ use<J for ^  tion of free and bound
are several reviews dealing with enzyme-unmunoas- ^^
 molecyles are most,y solid.phase. For ex_
say (1^8). Enzyme-immunoassays can be catego- , antibody-coated polystyrene tubes, cellulose
rized äs either "heterogeneous» or 'homogeneous .
 and a,SQ magnetic polyacrylamide agarose particles
have been used for the Separation of bound and free
Tab. 1. Labels used inDon-isotopicimmuDoassays(frornl.c.(l)).
 enzyme conjugate (3j ^  9_n) A separation can al-
Enzymes Bacteriophage so be effected by precipitation of the immune com-
Coenzymes Latexes plex formed with polyethylene glycol (12) or a se-
Ruoirigenic Substrates Liposomes
 con(j antibody (13) and by using a preprecipitated
Enzyme inhibitors ^ ' complex of first and second antibodies (14).Fluorescent dyes Metalatoms *" ^ '
Fluorescence quenchers Metal sols jf Äe $econd antibody used for the separation Step is
Chemiluminescence precursors Stabie free radicals • • j u / r v ^ i ^ x L j ·
_ __  _ _ _
 s _ bound to a solid phase (Fig. 1.1.2), the procedure is
]) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
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called a double antibody solid phase (DASP) tech-
nique.
The compet i t ive enzyme- immunoassay (fig.
1.1.1) is analogous to the well known classical ra-
dioimmunoassay of Yalow & Berson (15). Labelled
(E-L) and unlabelled antigens (L) compete for the
binding sites of a limited amount of antibody (AB).
The Saturation of the antibody occurs simultaneous-
ly, providing all reactants are incubated together.
The principle of "sequential Saturation" is preferred
under certain conditions, e.g. if antigens with very
low serum concentrations are to be determined (16).
However, according to Pratt et al. this technique
leads to reduced specificity (17).
Recently a new approach to heterogerieous enzyme-
immunoassays has been described (18), in whieh the
enzyme label is not only covalently linked to a ligand
of the type to be determined, but also to a "tag"
molecule (fig. 1.1.3). Free ligand and enzyme conju-
gate compete for an antibody. If
 fthe enzyme conju-
gate is bound to the antibody its tag is masked so that
it can no longer bind to the insolubilized receptor
(RI). The amount of enzyme cpnjugäte boüiid to this
receptor is proportional to that of the free ligand to
be assayed. This procedure is called "antibody
masking enzyme tag immunoassay (AME-
TI A). In a model System biotin has been used äs the
tag and avidin äs the insoluble receptor (18).
Competitive enzyme immunoassay Competitjve sandwigh assay
1.1.1
1.1.2
1.1.3
l mmuno-enzy mometric_ assay
1.2
Sandwich artigen assay
1.4.1
1.4.2
Sandwich antibody assay
Fig. 1. Principles of heterogeneous enzyme-immunoassays (ELISA).
L ligand; E-L enzyme labelled ligand; L-E-T tagged enzyme-ligand conjugate; E-AB, E-AB2 enzyme labelled äntibodies;
AB, ABi äntibodies against ligand under test (1.H.4) or antibody to be determined (1.5); AB2 antibody directed against the
immunoglobulin of the species, which was immunized with the antigen to be determined (1.1—1.4) or against the antibody to be
detected (1.5); RI insolubilized receptor (from I.e. (1)). ,;
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Procedures in which the sample antigen (L) is bound
to an enzyme-labelled antibody (E-AB) added in ex-
cess, are classified s immuno-enzymometr ic
assays (fig. 1.2). The remaining, free labelled anti-
body is separated in a subsequent step by binding
with antigen (L) coupled to a solid phase, which is
added in excess.
In a rapid one step procedure called inh ib i t ionen-
zyme-immunoassay the antigen-antibody inter-
action between solid phase-coupled antigen and an
enzyme-labelled antibody is inhibited by free anti-
gen of the sample. The enzymic activity detected on
the solid phase is inversely proportional to the
amount of antigen present in the sample.
"S a n d w i c h " a s s a y s have been described in numer-
ous modifications (19). In a Variation of the sand-
wich antigen assay (fig. 1.4.1), the bound antibody
(ABi) is indirectly labelled by a second enzyme-la-
belled antibody (E-ABa), which is directed against
the first (ABi) and should not react with the anti-
body (AB) attached to the solid phase (fig. 1.4.2).
The antibodies ABi and AB should be be obtained
from different species. Such an indirect labelling can
also be applied to immuno-enzymometric tests (5)
and Inhibition enzyme-immunoassays (20). The
method of indirect labelling has the advantage that
the same enzyme-antibody conjugate can be used in
assays for various different antigens. Thus the often
difficult direct labelling of the antibody may be cir-
cumvented. In the Sandwich antibody assay (fig.
1.5), the antibody to be determined (ABi) reacts
'with an antigen (L) bound to the solid phase, and is
detected by a second enzyme-labelled antibody (E-
AB2).
Enzyme-Labels Used in Heterogeneous Enzyme-
immunoassays
The quality of an enzyme-immunoassay depends
very much on the purity of the antigen or hapten
used for immunization, calibration and conjugation,
the specificity of the antibody and the choice of a
suitable enzyme label. Sensitive assays require a
highly purified enzyme with a high turnover number,
and a low detection limit for the reaction product
(4).
The enzymes listed in table 2 have proved generally
useful. The enzymes most frequently used so far for
heterogeneous enzyme-immunoassays are horse-
radish peroxidase, alkaline phosphatase and -D-ga-
lactosidase.
The determination of the enzyme activity is chiefly
performed by photometry. In order to increase the
detectability of the assays, however, fluorigenic, ra-
dioactive and chemiluminescence-producing sub-
strates are also used. In a further procedure, the ac-
tivity of peroxidase bound to an antibody-coated
membrane is determined by an iodide-sensitive elec-
Tab. 2. Enzyme labels used in heterogeneous enzyme-immunoassays (from I.e. (l, 21)).
Enzyme Source Indicator Analytical principle
Peroxidase
(EC 1.11.1.7)
Horse-radish
H2O2/pyrogallol or luminol,
photon
Η2Ο2/ΚΙ/ΔΕ [mV]
Photometry
Luminometry
Potentiometry
Alkaline phosphatase
(EC 3.1.3.1)
-D-Galactosidase
(EC 3.2.1.23)
Glucoamylase
(EC 3.2. 1.3)
Glucose oxidase
(EC 1.1.3.4)
Acetylcholinesterase
(EC 3.1.1.7)
Glutamate decarboxylase
(EC4.1.1.15)
Catalase
(EC 1.1 1.1.6)
Urease
(EC 3.5.15)
Calfintestine
E. coli
E. coli
Rhizopus niveus
Aspergillus niger
Electrophorus electricus
E. coli
Beef liver
Jack bean
Baci us pasteurii
4-Nitrophenol
4-Methylumbelliferone
2-Nitrophenol
4-Methylumbelliferone
Glucose/NADPH
H2O2/chromogen
[3H]Acetyicholine
14C02
H2Q2/enthalPy
NHs/bromocrcsol purple
Photometry
Fluorimetry
Photometry
Fluorimetry
Fluorimetry
Photometry
Scintillation spectrometry
Scintillation spectrometry
Calorimetry
Photometry
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trode (tab. 2). A thermometric enzyme-immunoas-
say with adequate sensitivity has been described, in
which the enthalpy of the enzymic reaction is mea-
sured (22). In this assay, a continuous flow System
with immobilized antibodies is used.
Coupling procedures
Enzymes can be coupled to antibodies and protein
antigens by various procedures, using e.g. glutaral-
dehyde, periodate or N,N'-o-phenylenedimaleim-
ide. Hapten-enzyme conjugates can be formed by
the carbodiimide and mixed anhydride methods. The
more important of these procedures have recently
been reviewed (6).
Suitable coupling reactions should allow a high de-
gree of incorporation of enzyme into the conjugate
with minimal changes in immunoreactivity and in the
properties of the coupled enzyme. Furthermore the
degree of Substitution of the enzyme by the hapten
must be adequate and conjugates should be stable.
The immunoreactivity of a compound can be altered
by cross-linking reactions. If, for instance, the en-
zyme is coupled to important antigenic sites on the
hapten, a reduced avidity of the antibody for the la-
belled compound may result (6). On the other hand,
the affinity of the labelled antigen for the antibody
may be higher than that of the free antigen, if an
antigen derivative similar to the immunogen is used
to form the labelled antigen (23). In these cases an-
tibodies may recognize the bridge between antigen
and carrier molecule in addition to the antigen itself.
Furthermore, multivalent labelled antigens may be
able to compete very effectively with unlabelled an-
tigen for antibody binding sites. The combination of
bivalent antibody with multivalent antigen, especial-
ly, may yield extremely high overall affinities (23). If
the affinity of the antibody for labelled antigen is
much lower or higher than that for unlabelled anti-
gen, a loss in sensitivity of the assay may result (6,
23).
The problem of the degree of Substitution of the en-
zyme by the hapten requires further systematic in-
vestigation. At present, a convenient approach is to
take conjugates with varying degrees of hapten Sub-
stitution, and select that which provides the best
Standard curve (6).
Principles of Homogeneous Enzyme-Immunoassays
In homogeneous enzyme-immunoassays a Separa-
tion step is avoided. The enzymatic activity is influ-
enced by the antigen-antibody reaction in these
tests.
• r
In the two variations of the EMIT (fig. 2.1.1, 2.1.2)
the activity of the marker enzyme is inhibited or in-
creased, if the conjugate is bound to the antibody
(24, 25).
The "enzyme channeling immunoassay"
(ECIA) represents a rather complex assay System
(fig. 2.2). In this procedure (8) the ligand (L) is co-
valently labelled with an enzyme (Ei). This conju-
gate competes with the ligand of the sample for the
binding sites of a limited amount of antibody which
is co-immobilized with the second enzyme (£2) on
beads (B). The overall enhäncement in the rate of
formation of the reaction product (?2) from the sub-
strate (S) depends on the ligand (L) concentration.
In the presence of a high ligand (L) concentration
there would be less ligand-enzyme conjugate (Ei-L)
bound to the antibody and consequently less Sub-
strate (S) converted to the product (P2). In order to
reduce background reactions, the prodüct PI gener-
ated by the unbound conjugate is converted to the
product Q by a further soluble, scavenger enzyme
(£3). Recently an enzyme channeling immunoassay
for determination of IgG has been described in
which hexokinase-labelled antibody and glucose-6-
phosphate dehydrogenase-labelled antigen were
used (26).
A further homogeneous enzyme-immunoassay (eri-
zyme-enhancement immunoassay, BEI A)
for proteins has been described (27), which avoids
the need for a labelled antigen (fig. 2.3). The en-
zyme-labelled antibody (E-ABi) and the succinylat-
ed antibody (AB2) form an immune complex with a
polyvalent antigenic analyte (L) present in the sam-
ple. An enzyme within this negatively charged mi-
cro-environment converts a Substrate (S) to a pro-
duct (P2) which forms a second light-scattering
phase. The pfodüct (Pj) formed by the free enzyme-
conjugate remains soluble. The concentration of the
second-phase product (P2) is proportional to the
amount of sample antigen (L) and can be deter-
mined by turbidimetry.
Fig. 2. Principles of homogeneous enzyme-immunoassays. All reactants are present in one reaction medium: L ligand; E-L, Ej-L
enzyme labelled ligands; M-L ligand-substituted enzyme modulator; FAD-L ligand covalently linked to flavin adenine dinu-
cleotide; S-L ligand labelled Substrate; P-L ligand labelled product; AB limited amount of antibody; ABi antibody to be
detected; AB2 succinylated antibody; ABi-E, AB2-E enzyme labelled antibodies; E2-B-AB antibody co-immobilized with
an enzyme (E2) on fine beads (B); E, EI, E2, E3 enzymes; Apo-E apoenzyme; Holo-E holoenzyme; S Substrate; RBC
erythrocyte; P, P,, P2, Q Products of enzymic reactions, i Inhibition of the "marker enzyme" (frofrn I.e. (1)).
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2ΛΛ 2.4
EMIT (enzyme multlplled immunoassay technique) EMMIA(enzyme modulator mediated immunoassay)
L·"
E
2.1.2
EMIT (enzyme multiplied immunoassay technique) 2.5 PQLIA (prosthetic-groupHabel immunoassay)
2.2 ECIA (enzyme channeling immunoassay)
2.3 EEIA (enzyme-enhancement immunoassay)
2.6
SLFIA(substrateHabeled fluorescent immunoassay)
2.7 EIIA (enzyme Inhibition immunoassay)
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Theenzyme modula to r media ted immunoas-
say (EMMIA) described by Ngo et al. (28) is
based on the ability of a ligand-coupled enzyme
modulator (L-M) to influence the activity of the in-
dicator enzyme (fig. 2.4). Ligand-substituted en-
zyme modulator (L-M) and ligand from the sample
compete for a limited amount of antibody (AB). If
the enzyme modulator (L-M) is bound to the anti-
body, it cannot affect the activity of the indicator en-
zyme. Modulators which increase or decrease the en-
zyme activity can be used. In assays with an inhibit-
ing modulator the enzyme activity is inversely pro-
portional to the concentration of the analyte. This
technique has been used for determination of thyr-
oxine (29).
A further homogeneous enzyme-immunoassay is
based on a l igand- label led enzyme prosthetic
group (30). In the scheme of figure 2.5, ligand-flav-
in-adenine-dinucleotide conjugate (L-FAD) and li-
gand (L) from the sample compete for a limited
amount of antibody (AB). If the ligand-FAD conju-
gate is bound by the antibody, it can no longer com-
bine with the apoenzyme (Apo-E) to form an en-
zymatically active holoenzyme (Holo-E). Thus the
observed enzyme activity is directly related to the
concentration of the analyte (L). This principle can
be used for the determination of haptens and anti-
gens (8, 30, 31).
The principle of the substrate-labelled fluores-
cent immunoassay is schematically presented in
figure 2.6. In this assay a ligand (L) labelled with a
fluorigenic Substrate (S) is used. This conjugate is
non-fluorescent and competes with the analyte (L)
for a limited amount of antibody (AB). When the
substrate-ligand conjugate (S-L) is bound by the
antibody, it cannot be converted by an enzyme to a
fluorescent product (P-L). The amount of conjugate
available for reaction with the enzyme and the re-
sulting fluorescence intensity are proportional to the
concentration of the analyte. Since in assays of this
type the enzyme does not produce an amplification
effect and the amount of unbound substrate-labelled
ligand available for the enzyme depends on the ana-
lyte concentration, it is necessary to use a fluorigenic
Substrate to label the ligand. Substrate-labelled fluo-
rescent immunoassays have been described for the
determination of haptens and antigens (32, 33).
A further homogeneous immunoassay has been de-
scribed by Wei et al. (34). A hypothetical scheme of
this System is shown in figure 2.7. Rabbit antihüman
IgG (AB2) was labelled with phospholipase C (E).
The enzymatic activity of the conjugate was inhibited
by human IgG (ABt). The Substrates (S) used were
phospholipids, which are coiiiponents of the erythro-
cyte membranes and therefore may be viewed äs be-
ing immobilized. When IgG (ABi) forms a complex
with the enzyme-anti-IgG conjugate, it sterically
prevents an interaction between the enzyme label
(E) and the Substrate (S).
Other competitive procedures, in which coenzymes
are used to label the ligand (35, 36), may also be
classified äs homogeneous enzyme^immunoassays. If
the ligand-coenzyme conjugate is bound to an anti-
body, its cycling in a suitable enzymic cycle is pro-
portionally reduced. This Inhibition is reversed by
unconjugated ligands in competitive binding reac-
tions. So far, however, this assay principle has gained
no significance in clinical diagnosis.
Enzyme-Labels Used in Homogeneous Enzyme Im-
munoassays
The enzymes listed in table 3 have proved generally
useful äs labels in homogeneous enzyme-iiiimunoas-
says.
In the EMIT, an NAD-dependent glucose-6-phos-
phate dehydrogenase is mainly used. The activity of
this enzyme can be easily determined photometrical-
ly or fluorimetrically. In an antigemlabelled homo-
geneous enzyme-inhibition immunoassay for serum
proteins and an enzyme-enhancement immunoassay,
ß-galactosidase was used äs label and a synthetic ma-
cromolecular dextran-linked ö-nitrophenyl-ß-galac-
toside äs Substrate (27, 37). Litman et al. (26) em-
ployed the enzyme pair, hexokinase and glucose-6^
phosphate dehydrogenase, in an enzyme channeling
immunoassay. Scavenging was achieved in this assay
by phosphoglucose isomerase (EC 5.3.1.9) and
phosphofructokinase (EC 2.7.1.11).
In various other homogeneous enzyme-immunoas-
says the indicator enzyme is coupled neither to the
antigen nor to antibody (fig. 2). Horseradish peroxi-
dase (EC 1.11.1.7) or acetylcholinesterase (acetyl-
choline hydrolase; EC 3.1.1.7) have been used in en-
zyme modulator immunoassays (28, 29). In pros-
thetic-group-label homogeneous immunoassays
flavin adenine dinucleotide has been used äs the
prosthetic group and ghicose oxidase (EC 1.1.3.4)
from Aspergillus niger äs the holoenzyme (30, 31).
For homogeneous substrate-labelled fluorescent im^
munoassays ß-galactosidase (ß-D-galactosidase ga-
lactohydrolase, EC 3.2.1.23) from Escherichia coli
and a fluorigenic Substrate (e.g. ß-galactosyl-umbel-
liferone) was employed (32, 3$)·
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Tab. 3. Enzyme labeis used in homogeneous enzyme-immunoassays (from I.e. (1)).
Enzyme Source Indicator Analytical
principle
Lysozyme
(EC3.2.1.17)
Malate dehydrogenase
(EC 1.1.1.37)
Glucose-6-phosphate dehydrogenase
(EC 1.1.1.49)
Chicken egg-whtte
Pig-heart mitochondria
Leuconostoc mesenleroides
Cell wall fragments of
Micrococcus luleus
NADH
NADH
* Antibody-hexokinase conjugates were used in combination with glucose-6-phosphate dehydrogenase (26).
** "Second-phase product" not further described by the authors (27).
Turbidimetry
Photometry
Photometry
Fluorimetry
Hexokinase
(EC2.7.1.1)
ß-0-Galactosidase
(EC 3.2.1.23)
ß-Amylase
(EC 3.2.1. 2)
Phospholipase C
(EC 3. 1.4.3)
Yeast
E. coli
Potato
Clostridium welchü
*
Dextran-linked 2-nitrophenol
**
Starch/reducing groups
Haemoglobin release
*
Photometry
Turbidimetry
Photometry
Photometry
Enzyme-hapten conjugates have been prepared, for
example, by rnixed anhydride reactions or by acetim-
idate-linking (38, 39), and enzyme-antibody conju-
gates (26, 27) by the m-maleimidobenzoyl-N-hy-
droxy-süccinimide ester (MBS) method (4).
Application of Enzyme-Immunoassays
The field of application of the enzyme-immu-
noassay corresponds largely to that of radioimmu-
noassay. Assays fpr the determination of plasma
proteins, tumour antigens, drugs, horrnones, anti-
gens of pathogenic organisms and antibodies have
been developed (4, 6, 19).
The imprecision of enzyme-immunoassays is of
the sarne order of magnitude äs that of correspond-
ing radioimmunoassays. With^partially or fully me-
chänized enzyme-immunoassays for quantitative de-
terminätions, between-days coefläcients of Variation
of about 2-10% were achieved in the medium
working ränge of these tests (2).
The inaccuracy of enzyme-immunoassays has
been examined in many comparative studies. Mainly
comparable results were observed with enzyme-im-
munoassays and other immunological and non-im-
rnunological procedures (2).
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Interference
Enzyme-immunoassays may be subject to interfer-
ence due to disturbances of the enzymic or immuno-
logical reaction. Endogenous enzymes with biologi-
cal effects, similar to those of the enzyme used äs
label, or other factors which directly influence the
enzymic reaction, may lead to wrong results. Fur-
thermore, interference can be caused by an unspecif-
ic binding of the conjugate to the solid phase, or by
certain plasma proteins or transport proteins which
compete with the antibody. In the substrate-labeled
fluorescent immunoassäy, interference occurred in a
few cases, presumably due to the presence of fluo-
rescing compounds in the sample (42).
With the ELISA-technique, interference by light ab-
sorbing substances such äs haemoglobin or bilirubin
or by turbidity, or by endogenous enzymes or en-
zyme inhibitors, is reduced if the activity of the
bound enzyme conjugate is measured. However, the
washing Steps required with this technique may theo-
retically influence the imprecision of these assays
considerably.
In homogeneous enzyme-immunoassays for quan-
titative determinations, interference is only rarely
observed. An essential reason for this appears to be
the high dilution of the serum sample in the reaction
medium. To avoid interference from certain serum
proteins in some assays the serum must be pretreat-
ed (2).
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Cross-reactions with other compounds occur if the
antibody lacks specificity. The antibodies of various
commercial assays for quantitative determinations
show a relatively high specificity (2). However, con-
siderable differences in specificity have been ob-
served, for example, among various commercial im-
munoassays for determination of theophylline (42).
Detec t ion L imi t s
In a number of heterogeneous enzyme immunoas-
says the detection limits are the same äs those of ra-
dioimmunoassay (2). In general, the detection limits
of radioimmunoassays ränge from 1—500 pmol/1 or
0.2—50 fmol/tube (4). Moreover heterogeneous en-
zyme immunoassays with an extraordinarily high de-
tectability have been described. Such assays were
capable of detecting even l amol/tube (10~"18 mol) of
ornithine-6-aminotransferase (43) or 24000 mole-
cules of purified mouse myeloma IgG (44).
The detectability of homogeneous enzyme-immu-
noassays is lower than that of heterogeneous tests
(2). The detection limits and the lower limits of the
working ränge with EMIT for various drugs and
thyroxine were 2—107 pmol/1 (2), with substrate-
labelled fluorescent immunoassays for several drugs
and immunoglobulins the corresponding ränge was
105-106 pmol/1 (l, 32-33), and with the enzyme
modulator mediated immunoassay for thyroxine, 6.4
x l O3 pmol/1 (29). However, the detectability of
these assays is sufficient for the determination of
many diagnostically relevant compounds (2).
Evalua t ion of the results
For the evaluation of the results from enzyme-im-
munoassays Computers are increasingly used. Manu-
al procedures are lengthy and sometimes less depen-
dable.
A ränge of available curve-fitting methods is shown
in table 4. Some of these procedures are based on
Tab. 4. Curve fitting methods for enzyme-immunoassay (from
I.e. (2)).
l. Model-based methods
1. l Parabolic regression
l .2 Linear regression after logit-log transformation
1.3 Weighted linear regression after logit-log transformation
l .4 Weighted non-linear regression after logit-log transformation
2. Data-based methods
2.1 Manual curve-fit
2.2 Polygonal Interpolation
2.3 Empirie spline-interpolation
2.4 Cubic spline-interpolation
2.5 Spline approximation
certain models, whereas "data-based" methods can
be applied without knowledge of the type of function
underlying the calibration curve. The niost suitable
methods must first be ascertained for each enzyme-
immunoassay.
• r
Future Aspects
In the past few years enzyme-immunoassays have
been increasingly used, especially for the determina-
tion of substances like drugs, hormones, antigens of
pathogenic organisms and antibodies.
The development of enzyme-immunoassay is cur-
rently still in a state of flux. Further possible sources
of improvement lie in a better standardization of the
reagents and methods, in the search of more effec-
tive marker enzymes and better cross-linking rea-
gents. Systematic investigations are needed concern-
ing the influence of the degree of labellirig, the site of
cross linking and the natuf e of the bridge on the per-
formance of an assay. Alternative procedufes for the
determination of enzyme activities, such äs fluorime-
try and calorimetry should be evaluäted.
The use of suitable monoclonal antibodies
could contribute to an improvement of the specificity
of enzyme-immunoassays. Although it is stijl quite
difficult to obtain suitable high-affinity monoclonal
antibodies, the application of such antibodies ap-
pears to be promising in the immunodiagnostic field.
For example, in a newly developed enzyme immu-
noassay for determination of thyrotropin, which is
based on the "sandwich" prineiple, monoclonal anti-
ß-thyrotropin antibodies and peroxidase labeled
Fab' fragments of sheep antibody have been used
(41). The results obtained by this method were in
relatively good agreement with those determined by
radioimmunoassay (tab. 5). The use of selected pairs
of monoclonal antibodies could allow the develop-
ment of new heterogeneous and homogeneous assay
principles.
Mechanization
A far-reaching mechanization of enzyme-immu-
noassays appears to be essential. According to exist-
ing experience, the improvement of the reliability
and practicability of these assays by mechanization is
likely to be far greater than the beneficial effects of
mechanization on the commonly used clinicäl chemi-
cal routine procedures. As enzyme^immußoassays
show non-linear calibration curves, the accuracy of
these tests depends very much on the precision,
wfiich can be cönsiderably increased by mechaniza-
tion. . jr
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Tab. 5. Comparison of the results obtaincd by enzyme-immunoassay (ELISA, Enzymun-Tcst® TSH) and radioimmunoassay (TSH-
Henning) for determination of thyrotropin (TSH) in serum samplcs from paticnts.
Methods
(y) vs
ELISA vs
n1) Standardized principal sy.x2)
component
(x)
RIA
Slope
40 0.90
Intercept
-0.30 1.81
y(s)3) x(s) t4) Corrcla-
tion
coefficicnt
11.5(12.1) 13.0(13.4) 3.22* 0.97
1) number of contributing values
2) Standard error of the residuals
3) mean value (mU/l) with Standard deviation in parenthesis
4) t-value (paircd t-test)
* significance of the bias — y(p < 0.05). Three samples wcre excluded from statistical evaluation of the results:
1. ELISA: <0.5 mll/i, RIA: 1.5 mU/l;
2. ELISA: <0.5 mU/l, RIA: 1.7 rnU/l;
3. ELISA: <0.5 mU/l, RIA: 1.1 mU/l. (I.e. (40))
Furthermore, the costs of reagents and technician
time can be considerably reduced if suitable mechan-
ization is chosen (2). A large reduction in reagent
costs may be achieved by adaptation of EMIT to
centrifugal analysers, and of the substrate-labelled
fluorescent immunoassay to the Micro-ERMA (Mi-
cro Enzyme Reaction, Multiple Assay) System (45).
Because of the incubation periods, and the washing-
and Separation Steps, it is difficult to fully to mechan-
ize the ELISA-technique. Certain Steps, such äs the
washing procedure, the dispensation of the reagents
and the photometric measurement have already
been mechanized (tab. 6).
The performance of helerogeneous enzyme-immu-
noassays generally takes several hours at least. In
our experience 200—300 patient samples can be as-
sayed for thyroxine or hepatitis B surface antigen by
one technical assistant per day using partially me-
chanized Systems. Up to 4000 samples have been an-
alysed per day with an enzyme-immunoassay for de-
termination of antibödies against Trichinella spiralis
(46).
Tab. 6. Värious anaiytical Systems used for enzyme immunoas-
says.
Homogeneous
enzyme=immunoassays
Heterogeneous
enzyme-immunoassays
Centrifugal analysers
(i.e. CobasBio)
AutoLab 5000
ACA Du Pont
Eppendorf ACP 5040
ABA-100
Fluorostat
Optimale
ELIS A-Meßplatz Eppendorf
Abbott Quantum I
Riele PMC Automatik
GilfordEIA-PRSO
LKB 2074
Titertek-Multiskan
Enzymun-Test® System ES 22
The mechanization of heterogeneous enzyme-immu-
noassays may perphaps be facilitated in the future by
the use of aqueous two-phase Systems for Separation
of bound and free ligand. The principle is that free
and bound antigen are distributed unevenly between
two immiscible water-soluble phases and can subse-
quently be recovered from separate phases (47).
Homogeneous enzyme immunoassays have been
partially and fully mechanized by use of many differ-
ent anaiytical Systems (2). Several examples are giv-
en in tableo. Single emergency determinations of
drugs such äs theophylline, can be performed by
EMIT within 10-20 minutes. By using quantitative
EMIT drug assays adapted to an Eppendorf System
ACP 5040, for example, about 250 patient samples
can easily be analysed by one technical assistant per
day (2). With the ACA from Du Pont, calibration
curves for EMIT were stable for many weeks, pro-
vided that the same lot of reagents was used (48).
The development of dry chemistry Systems could
greatly simplify the performance of enzyme-immu-
noassays. In the EMIT®-st™ drug detection System
all the reactive components such äs enzyme conju-
gate, Substrate, antibody and buffer are already pres-
ent in one vial in the dry form. The assay is carried
out merely by adding patient sample plus water and
taking a reading at a fixed time. Recently, reagent
strip Systems for theophylline and phenytoin have
been described which are based on the prosthetic-
group-label homogeneous immunoassay (31). Such
reagent strip Systems may allow rapid determina-
tions and evaluation of the results either with the un-
aided eye or by use of reflectance spectrophotome-
try. Further developments in this field might include
dry, solid-phase reagent Systems such äs multilayer
film elements (49).
J. Clin. Chem. Clin. Biochem. / Vol. 22,1984 / No. 12
904 Oellerich: Enzyme-immunoassay: A rcview
Fu tu re f i e lds of app l ica t ion
The demand for existing and new immunoassays is
expected to grow considerably in future. The deter-
mination of numerous clinically relevant proteins
and drugs in serum or plasma will gain increasing im-
portance (1). Furthermore, enzyme-immunoassays
will have a wide application äs screening tests for an-
tigens from pathogenic organisms and antibodies di-
rected towards them. Moreover such assays will be
frequently used in diagnostic strategies, which are
concerned with presymptomatic diagnosis. It is to be
%expected that the use of monocloncal antibodies in
particular will lead to the discovery of many new dia-
gnostically important antigens, which for technical
reasons have so far been inaccessible. Furthermore
immunoassays could also be applied in non-medical
disciplines dealing with food pro$uction or environ-
mental pollution.
It can be predicted that the further development of
immunological techniques will contribute to a con-
siderable improvement of clinical diagnosis and ther-
apy.
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Summary: This article reviews the field of bioluminescence and chemiluminescence immunoassays, and gives
examples from past and present work in these areas. The problems of luminescence immunoassays are dis-
cussed, and include the choice of label, solid phase, immunogen/hapten-protein conjugates for immobilisation
and the stability of bio- and chemiluminescent reagents.
Examples have been given to show the stages in the development of luminescence immunoassays up to their
acceptance for routine clinical in-vitro diagnostic use.
Luminometers and commercial kits have been discussed, with regard to the present Situation in these fields
and the personal experience with two semi-mechanized luminescence analysers in routine use.
Lumineszenz-Immunoassays: Probleme und Anwendung
Zusammenfassung: Die vorliegende Arbeit gibt einen kurzen Überblick über das Gebiet der Lumineszenz,
hauptsächlich über Lumifteszenzimmunassays. Ausgehend von den ersten Untersuchungen bis hin zum ak-
Abbreviations used in the text.
Diazoluminol Diazotised 5-amino-2,3-dihydrophthalazine-l ,4-dione
Diazoisoluminol Diazotised 6-amino-2,3-dihydrophthalazine-l,4-dione
Pyruvate kinase ATP: pyruvate phosphotransferase - EC 2.7.1.40
SPALT Solid phase antigen luminescence technique
ILMA Immunöluminometric assay
IRMA Immunoradiometric assay
ILSA Immunöluminometric labelled second-antibody assay
CELIA Chemiluminescent immunoassay
RIA Radioimmunoassay
EIA Enzymeimmurtoassay
B(j Bindung of the zero Standard under assay conditions
Bx Binding of a given Standard under assay conditions
ÜB Unspecific (non-specific) binding
EOB Enzyme oxidant (reagent) blank
T Signal of the tracer given to each tube (total counts)
Buffer 4L 0;<Ö5 mol/1 Tris-HCl containing 0.02 mol/1 KC1 and 2.5 g/l bovine serum albumin, pH 7.4
Buffer 4N As buffer 4L, but with 0.1 g/l NaN3
PBS 0.05 mol/1 phosphate buffer containing 0.15 mol/1 NaCl, pH 7.4
PBS-Tween As PBS, with 0.5 ml/l Tween 20
Tween 20 Polyoxyethylene sorbitan monolaurate
LKB 1250 Single channel manual luminometer - LKB-Wallac, Turku, SF.
LKB 1251 25-sample serni-automatic luminometer - LKB-Wallac
Lß 950 · 250/300 sample semiautomatic luminometer - Laboratorium Prof. Dr. Berthold, Wildbad, D.
') Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
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tuellen Stand der Lumineszenzimmunassays wird die Entwicklung der Bio- und Chemilumineszenz aufge-
zeigt. Auf die praktischen Probleme bei der Entwicklung von Lumineszenzimmunassays wie Wahl des Lumi-
nogens, Herstellung und Stabilität von bio- und chemilumineszierenden Markersubstanzen, die Bedeutung
der Verwendung des geeignetsten Immunogens sowie die Festphasen-Problematik wird umfassend eingegan^
gen. Beispiele von Lumineszenzimmunassays und deren Entwicklung und Optimierung bis hin zur routinemä-
ßigen Anwendung sind beschrieben. ,
 f
Luminometer und kommerzielle Testbestecke werden kurz angesprochen, insbesondere die persönlichen Er-
fahrungen mit zwei teilmechanisierten Luminometern in der Routine.
Introduction
Many scientists and philosophers have dedicated
part of their studies to luminescent phenomena over
the past two millenia. Gaius Plinius Secundus de-
scribed marine phosphorescence in the second Cen-
tury A.D. Other well-known figures who showed in-
terest in luminescence include Francis Bacon, Gali-
leo Galilei, Leonardo da Vinci and Theophrastus
Bombastus von Hohenheim (Paracelsus)\ büt it was
Robert Boyle in the 17th Century who made the first
scientific observations which defined the properties
of bioluminescence in his studies on rotten wood,
shining flesh and stinking fish (l, 2).
The terms luciferin and luciferase were first intro-
duced by Dubois in a series of articles written in the
last quarter of the 19th Century (3, 4).
Präctical application of bio- and chemiluminescence
are a phenomenon of the 20th Century and have
been dependent upon the progress in the electronic
industry associated with photon detection devices.
Chemiluminescent compounds include lucigenin (5)
acridinium derivatives (6), luminol and isoluminol
(7, 8) and pyrogallol (9) and it has become possible
to synthesize derivatives of these compounds for use
in chemiluminescent detection Systems both in-vivo
and in-vitro. An in-vivo application is the study of
phagocytosis (10), whereas an in-vitro application,
luminescence immunoassays (11—15) forms the
main part of this article, with an accent upon the
Problems and pitfalls encountered, especially in the
laboratory of the author.
Principles of Luminescence
Chemiluminescence
Chemiluminescence occurs when excited molecules
return to a stable state with the emission of energy äs
light quanta. The efficiency of chemiluminescent Sys-
tems is usually very low (under 5%), the majority of
energy being dissipated in "dark" reäctiöns. It has
been reported that specially synthesised oxamides
have an efficiency of above 30% (16), and it is to be
awaited that when the need arises, chemiluminescent
compounds with a highly efficient light Output will be
synthesised.
The reäctiöns which occur during the light-genera-
tion process appear to be of two main types, namely
a one-electron transfer process resulting in radical
ion-pairs, and secondly energy transfer from singlet
oxygen (16, 17).
As the name chemiluminescence implies, one does
not necessarily need biological agents äs interme-
diates in the light-generation reäctiöns, although
very often a pseudoperoxidase, e.g. haemin or mi-
croperoxidase from cytochrome-c, is used in con-
junction with a peroxide or persülphate or perborate
(18).
Chemiluminescence can be regarded äs a "one-off"
reaction, i. e. when the reaction has taken place there
is no second chance of measurement, äs in the case
of radioactivity. This is an important and practical
point to note when considering assays using a chemi-
luminescent label!
The main groups of compounds at present used in
chemiluminescent studies are, äs stated above, deriv-
atives of luminol, isoluminol and acridine. Figure l
shows a few chemiluminescent compounds in use,
whereas table l shows the main characteristics of
chemiluminescence äs well äs both its advantages
and disadvantages.
Bioluminescenee
As the name implies, this type of luminescence is as-
sociated with biological Systems, either in-toto or in
isolated form. The components involved in the light-
generäting reactions include a luciferin in redueed
form äs Substrate, together with a luciferase äs spe-
cific enzyme. An energy-supplying Substrate or co-
factor is preserit, often in the form of NAD(P)H or
ATP.
Figure 2 shows the structures of a. few luciferins and
table 2 lists ä few luminescent organisms. The basic
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Luminol derivatives
R * NH2 - Luminol
R = N « N4X- - Diazoluminol
R2-N
Isoluminol derivatives
R i and
Rj
RJ
RI
ol
Rj
= H - Isoluminol
R2 = (CHz)2NH2 - 2-aminoethyI-N-ethyl isoluminol
Rz = (CH2)4NH2 - 4-aminobutyl-N-ethyl isoluminol
R2 = (CFhJsNHi - 5-aminopentyl-N-ethyl isolumin-
R2 - 6-aminohexyl-N-ethyl isoluminol
(see I.e. (22))
Acridine derivatives
RI absent, Rz = H - Acridine
RI = CHs R2 = COORa where R3 is an alcohol
e.g. a sterol - Acridinium ester
R i == CHa R2 = N-methyl acridine — Lucigenin
(9,9'-bis-(N-methylacridinium nitrate))
Fig. l. Some of the most commonly used chemiluminescent com-
pounds.
tenets of bioluminescence äs stated by Robert Boyle
(1,2) are listed in table 3.
The most commonly used luciferin-luciferase System
is that derived from the American firefly (Photinus
sp.). The purified reagents can be purchased either
separately or äs a "ready-to-use" mixture, sold äs
ATP-monitoring reagent or a similar name by sever-
al cheinical producers.
In the bioluminescent immunoassays developed in
this laboratory (14) pyruvate kinase was chosen äs
label, using ADP and phosphoenolpyruvate äs sub-
strates, the ATP being produced being monitored ki-
netically in a luminometer attached to an integrator/
plotter (LKB 1250).
Tab. l, Characteristics, advantages and disadvantagcs of chemi-
luminescencc.
Character is t ics
a. Chcmiluminesccnce is commonly associated with "non-bio-
logical' 'systems.
b. It often involvcs compounds related to luminol, isoluminol and
acridine.
c. An enzyme is not ncccssary for light production, although a
pseudoperoxidase is oftcn used to generate nasccnt oxygcn.
d. Active oxygen is needed (Oj or O2H-) lo initiatc chemiiumi-
nesccnce.
Advantages
a. All molecules can be labelled (in contrast to radiolabelling) in
a given substance.
b. the chemiluminescent rcaction velocity can bc controlled (in
contrast to radioactivity where onc is dependent upon the half-
Hfc of the radionuclide).
c. Chemiluminescent labels arc usually vcry stable and can be
storcd in Solutions containing azidc or mcrthiolatc.
Disadvantagcs
a. The efficiency of the chemiluminescent reaction is usually very
Iow (undcr 5% of the total energy released), although ncw
compounds with efficiencies above 30% have bcen reported
(see I.e. (16)).
b. Chemiluminescence suffcrs from the same disadvantages äs ß-
scintillation counting, i.e. signal "quench" effects.
Tab. 2. Examples of somc organisms exhibiting bioluminescence.
Noctiluca mlllarls
Renilla reniformis
Diplocardia longa
Octochaetus tnultiporus
Latia neretoides
Arachnocampa luminosa
Chaetopterus variopedatiis
Hoplophorus graälorostris
Parapriacanthus ransonneti
Watasenia sdntillans
Mycena cltricolor
Photobacterium phosphoreum
Photinus pyralis
a marine dinoflagellate rc-
sponsible for marine phospho-
rescence,
the sea pansy.
luminescent earthworms.
a freshwater limpct.
the New Zcaland glow-worm.
a marine polychaete annclid.
a deep-sea shrimp.
a luminescent fish.
a luminous squid.
a luminous fungus.
a luminescenl bacterium.
the American firefly.
Tab. 3. Basic tenets of bioluminescent observed by Robert Boyle
(see I.e. (1), (2)) in the 17th Century.
a. Light without hcat.
b. Very littlc oxygcn is needed for the maximal light Output.
c. The oxygcn-dependent lighl-rcaction is reversible.
d. The light can bc extinguishcd with chemical rcagents, c.g. tur-
pentine oil, strong spirit of sah, weak spirit of sal ammoniak.
J. Gin. Chem, Clin. Biochem. / Vol. 22,1984 / No. 12
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CH=CH-N
"NH,
CH
Figure 3 shows the measurement of both biolumi-
nescent and chemiluminescent reactions äs practiced
in this laboratory and table 4 shows the advantages
and disadvantages of bioluminescent measurements.
Cypridina Sp. an ostracod crustacean
srvd:COOHi^A HH
Phoiinus Sp. (only the D-form is biologically active)
OH
OK
Renilla reniformis
CH,-(CH2)n-CHO
Photobacterium Sp.
(n = 8-12)
Tab. 4. Characteristics, advantages and disadvantages of bio-
luminescence.
Characteristics
a. Associated with living organisms.
b. Consists of two main components, a luciferin (substrate) and a
luciferase (enzyme).
c. Often, but not always, linked with ATP or NAD(P)H depend-
ent enzymes.
d. Components usually sensitive to conventional anti-microbial
agents such äs azide or merthiolate.
Advantages
a. Light Output highly efficient (up to 90% of theoretical values)
b. Kinetic measurements are possible.
c. Amplification effects of ATP or NAD(P)H-producing en-
zymes can be utilised. This can lead to more sensitive immu-
noassays.
Disadvantages
a. Reagents are more expensive than for chemiluminescence.
b. The enzymes are often unstable and cannot be stored in liquid
state for long periods of time.
c. Preparation of "labels" usually complicated (for luminescence
immünoassay purposes).
CH3CH3
Latia Sp.
CH3
>CH-CH2-C —NH-CH2-CH2-CHOCH3
Diplocardia longa
Fig. 2. The chemical structures of several luciferins. The Cypridi-
na luciferin represents the indole group, whereas the luci-
ferin from Photinus is a member of the thiazole group.
The Renilla luciferin works only in the presence of calcium
ions, that from Photobacterium requires NAD. The Latia
luciferin is an enol formale and Diplocardia luciferin re-
quires oxygen for its activity.
Solid Phase Luminescence Immunoassays
In contrast with other laboratories carrying out
"conventional" liquid-phase luminescence immu-
noassays, (13, 18) the assays here described üse one
reaction compoüent convalently coupled to a solid-
phase, in this case, to a polystyrene ball with a diam-
eter of 6.4 mm/0.25 inch (23> 24), (Sphefotech
Kugeln, Fuldä, D, or Precision Plaistic Ball Co. Chi-
cago, Illinois, USA). The SPALT method published
from this laboratory (14) has the antigen, or a deriv-
ative of the antigen to be measured coupled to the
solid-phase whereas the ILMA and ILSA methods
have the substance specific antibody (purified IgG-
fraction thereof) coupled, analogous to the IRMA
technique (25, 26). Other solid-phases used in lumi-
nescence immunoassays have been microcrystalline
cellulose (14) and polystyrene tubes (11, 27).
The advantages of SPALT, ILMA and ILSA tech-
niques are that they both use a "tracerless" incuba-
tiori Step ^  i. e. there is no dilution of the antigen in
the sample with labelled antigen in the first iiicuba-
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Luminescence measurement
Substance
or
species-specific antibody
labelled with
Bioluminescence
Pyruvate-kinase
+ ATP-monitoring reagcnt
+ Tris-HCl 0.05 mol/1 with EDTA-K 10 g/l
+ ADP-phosphoenolpyruvate (0.33 g/l ADP +
+ 0.67 g/l phosphoenolpyruvate) in 0.1 mol/1 KC1 + MgCI2
Chemiluminescence
Luminol derivative
4- NaOH (0.8 mol/1)
+ H202 (3 g/I)
+ microperoxidase (5 /1)
dl
Rate
measurement
background
In tegra l
m e a s u r e m e n t
dt t
Fig. 3. The two forms of luminescent measurement used in the luminescent immunoassay sytems described in this article. The reagents,
together with the concentrations used in the light-generation Step have also been included.
tion Step äs in conventional CELIA and RIA meth-
ods. This partly explains the lower detection limits of
SPALT, ILMA and ILSA for a given antigen, when
compared with conventional CELIA methods. A se-
cond advantage of SPALT and ILSA is the ability to
use a "universal label", in this case labelled species-
IgG-specific antibody, e.g. donkey anti-rabbit IgG,
which is the only tracer needed for all antibodies
raised in rabbits. The label can either be chemilumi-
nescent, e.g. diazolümiiiol or bioluminescent, e.g.
pyruvate kinase. The disadvantage of the ILSA
methqd is that in order to use a "universal label", the
two substance^specific antibodies must come from
non-related species, e.g. mouse and rabbit. Figures
4a-4d summarise the CELIA, SPALT and ILSA
techniques. The choice of label for luminescence im-
munoassay depend to a large extent upon the chemi-
cal expertise available. The choice of diazoluminol
and pyruvate kinase äs Jabels was made because of
the ease of synthesis of the antibody-luminogen de-
rivatives (23, 28, 29). Füll details of synthesis and
practical application are just published (24, 25, 29).
The question bioluminescence or chemilumines-
cence can be answered äs follows: As the biolumi-
nescent System is more sensitive, it should be used
where the chemiluminescent label is not yet sensitive
enough. Bioluminescent components are more ex-
pensive and less stable in solution, than are their
chemiluminescent counterparts. The cost ratio is at
least 20:1 more expensive in favour of biolumines-
cence. The progression from bioluminescent to
chemilummescent assays can be given using this la-
boratory äs an example. The first luminescent immu-
noassay for serum transferrin used a pyruvate kinase
labelled antigen (28) and was used äs the sole rou-
tine assay for over 12 months. As the expertise with
chemiluminescent Systems was improved, the assay
was substituted by a bioluminescent SPALT and
than a chemiluminescent SPALT, the latter being
the current routine serum transferrin method, (see
gg.4c). The only bioluminescent immunoassay
which has not yet been replaced by a chemilumines-
cent one in the author's laboratory is for serum thy-
rotropin levels. The reason here is that the assay,
J. Clin. Chern. Clin. Biochem. / Vol. 22,1984 / No. 12
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•v
t — — — hv
--- .
 hv
Macro-solid-phase coupled "first" antibody
Antigen labelled with luminogen
Antigen in sample to be measured
•
>-
-r Macro-solid-phase coupled antigen
— Antigen
- Antigen specific '*first" antibody
- Luminescence-labelled species-specific "second"
antibody
.r =* 4.
•
>-
—· —- -*. hv
- Macro-solid-phase coupled antigen
— Antigen
— Antigen specific "first" antibody
— Luminescence-labelled species-specific "second"
antibody
©-< -
··**· -* -»- hv
Macro-solid-phase (polymer-ball) coupled "first"
antigen-specific antibody
Antigen
"Second" antigen-specific antibody
Luminescence-labelled species-specific antibody
Fig. 4. Reaction schemes.
a. "Conventional" solid-phase chemiluminescence immunoassay, CELIA.
b. Sequential SPALT assay äs already described (23, 26).
c. A modification of b, where the first two incubation steps have been combiried. This assay can be used where the required
sensitivity is easily obtained, e.g. in serum protein or drug assays.
d. ILSA principle. It is used for proteins and peptides with at least two determinants or epitopes, and where a low detection liihit
is needed, e.g. in proteohormone assays.
Assay a. uses a labelled antigen, assays b—d a labelled species-specific (second) antibody. Separation of unbound material is
effected by washing.
which uses the ILSA technique, has two substance-
specific antibodies which are not optimally mätched.
To^ive an idea of the use of luminescent immunoas-
say in routine in-vitro diagnosis, table 5 gives ä list of
such assays either in routine use, or undergoing clini-
cal evaluation in the author's laboratory. Table 6
shows both the advantages and disadvantages of sol-
id-phase immunoassays.
Evaluation of Luminescent Immunoassays
The proof of the püdding is in the eating — so runs
an old English proverb; and so it is with newly deve-
loped methods that they can only be accepted after
they have been "standardised" against existiiig
methods. In the case of the luminescent assay,, it
must be cömpared with RIA and other established
immunologicäl procedüres. As there are only a few
J. Clin. Chem. Clin. Biochem. / Vol. 22,1984 / No. 12
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Tab. 5. List of luminescence immunoassays undergoing clinical trials or already in routine use in the laboratory of the author (June
1983).
Component Label Assay type Stage of development
Transferrin
Transferrin
Transferrin
Transferrin
Coeruloplasmin
Orosomucoid
Transthyretin (TBPA)
Ferritin
Thyroxine binding globulin (TBG)
Thyroxine binding globulin (TBG)
Thyrotropin (TSH)
Thyroglobulin
Thyroglobulin antibody
Insulin
Thyroxine (T4)
Triiodothyronine (Ta)
Gentamicin
ai-Foetoprotein
Cortisol
Cortisol
Pyruvate kinase
Pyruvate kinase
Diazoluminol
Diazoluminol
Diazoluminol
Diazoluminol
Diazoluminol
Diazoluminol
Diazoluminol
Diazoluminol
Pyruvate kinase
Diazoluminol
Diazoluminol
Pyruvate kinase
Diazoluminol
Diazoluminol
Diazoluminol
Diazoluminol
4-Aminobutyl-N-ethyl isoluminol
Diazoluminol
CELIA (28)
SPALT
SPALT
SPALT (comp)++)
SPALT (comp)
SPALT (comp)
SPALT (comp)
ILSA
CELIA
ILSA
ILSA
SPALT
SPALT
SPALT-MCC")
SPALT
CELIA
SPALT (23)
ILSA
CELIA
SPALT
R+) - disctd.·)
R - disctd.
R - disctd.
R
R
CE
CE
CE
CE - disctd.
R
D
CE
CE
CE - disctd.
CE
CE
R
R
R - disctd.
R
+) R — routine, CE — clinicaJ evaluation, D - development stage
*) disctd. — assay discontinued or superseded.
++) competitive assay — see figure 4c
**) MCC - microcrystalline cellulose äs solid-phase.
Tab. 6. .Advantages and disadvantages of solid-phase immu-
noassays.
Advantages - coated tubes
a. Ease of mechanization.
b. Reduction in the number of pipetting Steps.
c. No need for centrifugation for "bound/free" Separation.
d. Possibility of "sandwich-type" assays, e.g. IRMA, ILMA and
ILSA.
Additional advantages ·=· coated balls
e. Additional flexibility due to free choice of reaction/measure-
ment vessel.
f. Possibility of "tube-change" before measurement to remove
unspecific label binding to reaction vessel wall.
g. Reduction iii bülk of the immobilised reactant (storage space
saving!).
h. Ease of handling, and ppssibility of simultaneoüs dispensing of
balls.
Disadvantages — coated tubes
a. Difficujties in mechanization of tube-activation and compo-
nent coating.
b. Difficulties in obtaining accepiable precision using adsorptive
techniques.
c. Limitation in the choice of measuring equipment (especially
true for luminescence and enzyme immunoassays).
d. Relatively large waste of coating-solutions (high volume/sur-
face area coated relatiohship).
e. Not suited for small laboratories without considerable expe-
rience in coating procedures (only for experimental and assay
development purposes).
Disadvantages — coated balls
Only (b) for coated tubes applies also to coated balls.
compounds for which definitive methods are availa-
ble (30), i. e. where the true value can be measured,
comparisons must be made with established interna-
tional reference preparations from the World Health
Organisation (WHO) or the National Institute for
Biological Standards and Controls (NIBSC) (for-
merly the Medical Research Council (MRC)) in
London, GB, for peptide hormones. For comparison
of hapten immunoassays, the "pure" substance can
be weighed in, preferably using a human serum ma-
trix.
As one can see, the accent must be on precision rath-
er than accuracy. Three assays have been chosen to
show the stages in assay comparison. All three have
been developed by students working for their thesis
in the author's laboratory.
An ILSA for -foetoprotein was chosen äs it was
possible to compare the assay with established radio-
and enzyme immunoassays äs well äs with the inter-
national reference preparätion, WHO 72/225. An
orosomucoid (oti-acid glycoprotein) SPALT assay
was chosen äs a protein for which no such reference
preparation was obtainable and for which the only
comparison was a radial immunodiffusion method.
As a hapten assay where weighed-in Standards were
used, äs well äs a commercial RIA, gentamicin was
chosen äs a SPALT assay.
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Table 7 shows the assay schemes for oti-foetoprotein
in short and long versions, the former for pregnancy
control the latter for post-operative tumour control.
Table 8 shows results from radio- enzyme- and lumi-
nescence immunoassays for selected patient samples.
The correlation between all three assays was excel-
lent when the kit Standards were us'ed for the com-
mercial test packs and the WHO 72/225 Standard
for the luminescent assay. The correlation between
RIA and ILSA on 40 samples for the regression y =
a + bx gave the following values: r = 0.986, a =
2.80, b = 0.934. The corresponding values for EIA
and ILSA were: r = 0.996, a = -1.50, b = 0.992.
The radioimmunoassay kit was from Amersham
(Amersham-Buchler, Brunswick, FRG) and the en-
zyme immunoassay kit from Abbott (Abbott GmbH,
Wiesbaden-Delkenheim, FRG).
Tab. 7. Assay scheme for the αι-foetoprotein ILSA.
Component/Step Assay A+ Assay B
Serum/sample voJume (μΐ)
Buffer 4L + PBS/Tween (mixed in
equal proportions) (μΐ)
Anti-ai-foetoprotein (sheep) ball
Incubate time (h)/temp. (°C)
Aspirate off buffer and wash with
PBS/Tween (l ml). Aspirate and
wash with 0.15 mpl/1 NaCl (l ml).
Aspirate.
Anti-ai-foetoprotein (rabbit) (μΐ)
Incubate time (h)/temp. °C
Wash s above
Diazoluminol-donkey
anti-rabbit-IgG (μΐ)
Incubate time (h)/temp. (°C)
Wash s above, transfer ball to
measuring cuvette, add 250 μΐ
0.15 mol/1 NaCl, measure in
Luminometer.
20
300
50
250
l
2/20-24 14-20/20-24
300
2/20-24
300
6/20-24
300 300
2/20-24 2/20-24
+
 Assay A was designed for pregnancy monitoring and Assay B
for post-operative follow-up of hepatoma patients, or patients
with pre-operatively elevated αι-foetoprotein levels.
The sheep anti-ai-foetoprotein was obtained from Seward Anti-
bodies (Proma, Augsburg, FRG).
The rabbit anti-cti-foetoprotein was purchased from DAKO
(Boehringer Ingelheim, Ingelheim, FRG) and was diluted 1:500
befpre use.
The donkey anti-rabbit-IgG (Wellcome RD-17, Wellcome, Burg-
wedel, FRG) was first purified over DEAE-Cellulose, labelled
with diazoluminol and passed over an Ultrogel A4 column (LKB,
Munich FRG) before use. The working dilution was estimated at
approximately 1:700 when compared with the starting material.
The concentration of Tween 20 in the buffers was l ml/l.
Figure 5 shows Standard curves for the short and
long arfoetoprotein ILSA using identical reagents
and set up at the same time.
Table 9 shows the orosomueoid assay procedure, us-
ing commercially obtained human material (Sigma,
Munich, catalogue riumber G-9885) for the Standard
curve. The r nge of values found in a mixed patient
group including outpatients and patients in the in-
tensive care unit was 0.24-^1.90 g/l, which agrees
with values to be expected ("normal r nge" from
Behringwerke, Marburg a.d. Lahn, FRG, 0.55—
1.40 g/l, mean 0.90 g/l). The number of serum sam-
ples measured was 45. The next stage is the compari-
son with radial immunodiffusion in a study where 50
Tab. 8. Selected sefa to demoiistrate performance of the ai-foe-
toprotein ILSA.
1. Test for "High dose hook" effect.
Sera from patients with hepatomas, concentration measured
by dilution with normal human serum foll wed by radioimmu-
noassay (Amersham RIA-kit).
Patient l - concentration in serum by RIA 112.5 Χ 106 U/l
Light Signal of 400 x 103 U/l Standard in ILSA - 6200 mV · s
Light signal of undiluted patient sample — 8340 mV · s
Patient 2 - serum concentration by RIA 2560 x l O3 U/l
Light signal of undiluted patient sample — 7355 mV · s
2. Dilution of a patient with a hepatoma to demoiistrate linearity.
Concentration measured by EIA (Abbott AFP-EIA kit) at a
1:10 dilution (corrected) 856 x 103 U/1.
Dilution factor
1:1 (undiluted)
1:2
1:4
1:8
1:16
1:32
1:64
1:128
Concentration
in ILSA
103 U/I
>200
>200
199
112
55.6
27.4
14.0
7.11
Concentration
corrected for dilution,
103 U/I
__.
—
796
896
890
877
896
910
Samples diluted with human serum with an αι-foetoprotein con-
tent under 103 U/L Samples assayed in Assay B in tafele 7.
3. Serum from pregnant women (15—20th week of pregnancy).
Patient No.
1
2
3
4 .
5
RIA
(103 U/l)
79
70
75
177
59
EIA
(103 /l)
71
77
69
192
55 .
ILSA(io3y/i)
69
67
78
184
52
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Sample Assay
volume time(μ\] [h]
50 24
24 ^
500 *103
Fig. 5. The effect of serum sample volume and assay time in an
ILSA for m-foetoprotein.
routine sera are exchanged, each party only knowing
bis obtained values. This somewhat shaky compari-
son must unfortunately suffice for the moment, al-
though it is far from an acceptable solution. Figure 6
shows an orosomucoid Standard curve.
Table 10 shows the optimised gentamicin SPALT
which has replaeed its fprerunners (14,23). Figure 7
shows a Standard curve and table 11 quality control
data. This assay is in routine use and has fulfilled the
requireinents of an independent external quality
control programme, (INSTAND, D sseldorf, FRG).
0.1 0.5 1 5'
Orosomucoid [g/l]
Fig. 6. Typical Standard curve for a SPALT assay for orosomu-
coid (αι-acid glycoprotein) in which Standards and sample
are pre-diluted 1:25 before assay. The dotted line shows
the unspecific binding, i.e. where the substance-specific
antibody has been omitted from the System. It represents
the adsorption of label to the balls and is under 0.1% in an
optimised system.
The gentamicin assay has been chosen to show the
precision and accuracy (against weighed-in Stan-
dards) of solid-phase luminescence immunoassays
using the equipment at present available for mea-
surement. All data used here was obtained from an
LKB-1251 luminometer.
Tab. 9. Assay scheine for the orosomucoid (aj-acid glycoprotein)
SPALT.
Tab. 10. Assay scheine for the Gentamicin SPALT in routine
use.
Component/Step Volume/Time Component/Step Volume/Time
Sample/Standard 50
(prediluted 1:25 with buffer 4N) (μϊ)
Rabbit anti-human orosomucoid 250
(1:500 in buffer 4N) (ul)
Incubate at ambieht temperature (min) 10
Add l orosomucoid-coated polystyrene ball
and gently agitate.
Incubate at ambient temperature (min) 120
Wash s in the cti^fpetoprotein assay (see tab. 7)
Donkey antj-rabbit-IgO^diazoluminol (μϊ) 300
Incubate at ambient temperature (min) 120
Wash s above, transfer ball to clean measuring
cuvette and insert in luminometer after adding
250 ul 0:9 mol/1 NaCl to keep ball wet.
The donkey anti-rabbit-IgG-diazoluminol was identical with that
used in the cti-foetoprotein assay described in tab. 7.
The addition of the NaCl to keep the ball wet improved assay pre-
cision.
Sample/Standard 50
(1:450 dilution in 0.15 mol/1 NaCl) (μϊ)
Buffer 4L + PBS-Tween (see tab. 7) (μϊ) 200
Anti-gentamicin (rabbit) l: 125 dilution 50
in buffer 4Ν(μΙ)
Incubate at ambient temperature for 15 min
Add a gentamicin-coated polystyrene ball
Incubate at ambient temperature for 35 min
Wash s in αι-foetoprotein ILSA (see tab. 7)
Donkey anti-rabbit-IgG-diazoluminol (ul) 300
Incubate at ambient temperature for 60 min
Wash s above, transfer ball to cuvette,
add 250 μΐ 0.15 mol/1 NaCl
and measure in luminometer.
The donkey anti-rabbit-IgG-diazoluminol used was identical to
that in the αι-foetoprotein assay in table 7.
The "gentamicin-coated ball" was coated with a gentamicin-bo-
vine serum albumin complex to complement the gentamicin-
transferrin cpnjugate used for immunising the rabbits.
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Tab. 11. Seiected quality-controi parameters for the gentamicin
SPALT.
1. Standard curve data
a. Intercept stability, data from 20 assays
80% intercept - 0.893
 Mg/l ± 0.103 ng/1 (CV 11.5%)
65% intercept - 1.58 ng/1 ± 0.130 ^ig/l (CV 8.19%)
50% intercept - 2.62 §/1 ± 0.137 §/1 (CV 5.24%)
35% intercept - 5.29 fig/1 ± 0.389 Mg/1 (CV 7.35%)
20% intercept — outside the Standard curve
(above 16 g/I)
b. Unspecific binding data from 20 assays —
ratio to Bö and B15.
Ratio Bo/UB - 22.6 ± 2.07 (CV 9.16%)
Ratio B,6/UB - 5.43 ± 0.716 (CV 13.2%)
These figures are related to the sensitivity of the luminometer and
represent the signal to noise ratios at the zero and 16 g/l Stan-
dard curve points (see tab. 12 for corresponding data for the LB
950).
2. Intra- and inter-assay coefficients of Variation for three control
sera. Data from 20 samples (intra-) from mean of duplicates
(inter-assay).
Intra-assay Serum IV Serum V Serum VI
Mean (Mg/l)
Standard deviation (ng/l)
Coefficient of Variation (%)
2.21
0.042
1.93
7.04
0.371
5.27
0.55
0.027
4.91
Inter-assay
Mean(ng/l) 2.26 7.14 0.59
Standard deviation ^ig/l) 0.078 0.659 0.045
Coefficient of Variation (%) 3.46 9.23 7.62
-
-600
§400
i, 200
0.1 1 2
Gentamicin img/l)
Fig. 7. Gentamicin SPALT assay which has been designed to
measure "trough" values (values directly prior to drug ad-
ministration). The area of interest covers the ränge up to
4 mg/1, trough values above 2 mg/1 being regarded äs too
high.
Problems with Luminescence Immunoassays
The problem with bioluminescent labels have been
dealt with inasmuch äs they are relatively unstable
and cannot be conserved with the usual anti-micro-
bial agents such äs azide or merthiolate. Chemilumi-
nescent compounds, when used in liquid-phase im-
munoassays suffer from the same drawbacks äs ß-
emitting radioisotopes such äs 3H or 14C, namely
quench effects due to serum components which ab-
sorb light of the same wavelengths äs that emitted by
the luminescent compound. These effects ean be
minimised by using solid-phase immunoassays (26,
27) or by extracting the components to be measüfed
prior to assay (27).
The main problems encoüntered in assay develop-
ment in this laboratory have been of a chemical ria-
ture, especially when working with hapten SPALT
assays. Here the structure of the immunogen is of
utmost importance äs is the structure of the hapten-
protein complex coupled to the solid-phase, espe-
cially where carbodiimides are used äs coupling rea-
gents. The effect of the "bridge" between hapten
and protein in tracef-binding in RIA is well known
(31), and figures 8 and 9 show the reactions occur-
ring with carbodiimides and the effects of immuno-
gen and immobilised hapten-proteiii on the Standard
curve produced (26).
Practical problems which can arise in luminescence
immunoassays can be demonstrated using the genti-
micin SPALT described earlier. The precision of the
assay was not only influenced by the incubation
times and wash Solutions used, but also by the state
of the solid-phase before measurement of the lumi-
nescent signal. The Coefficient of Variation obtained
using dry balls was more than double that obtained
when the bells were kept covered with physiological
saline (dry balls coefficient of Variation (CV) 8.7%,
moist balls CV = 6.9%, balls in saline CV = 4.0% -
all values being those at a concentration of 6.0 mg/1
gentamicin).
Problems in using coated tubes, especially for steröid
assays, have already been published (32) with regard
to unspecific binding of tracer and with regard to the
efficiency of adsorption of antibody depending upon
the ionic strength and pH of the coating solution
(33).
When using the ILSA technique, the substänce spe-
cific antibodies must come from two uarelated spe-
cies in order to be able to use a labelled antibody
directed against the "outwards-pointing" antibody.
An alternative to this is to use a modified ILMA in
whieh the "outwards-pointing" antibody has been
labelled with N-hydroxysuccinimidyl-biotin. In this
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.C-OH
R—N«=C=N-R'
R'
U
0 NH , -
.c-o-c ^
NH
,C-NH-m
A
T 14+l
r
-o-c
R-NH-C-NH-R'
l Infernal rearrangement
fa& 9 ?·
«V^IK^HÄ
Warer-soluble carbodümides
/ V-N=C=
l-Cyclohexyl-3-(2-mo holinyl·4-ethyl)ca bodiimide
CH3
* 0
CH3-CH2-N= C=N-(CH2 \~ NH*Q-
l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
Fig. 8. Reaction scheme showing the two possibilities which can occur when using carbodümides for coupling haptens to proteins. In one
case (shown here äs intcrnal rearrangement) ihe carbodiimidc becomes attached to the protein and can act äs a potent antigcn. In
such cases, antibodies are raised to the hapten äs well äs to the rearranged carbodiimide.
·= 200-
10 20 40 ' 80
Thyroxine l/ig/U
160 320
Fig. 9. The importance in the choice of immunogen and protein-
hapten conjugate for coating balls for a hapten-SPALT in
practical terms. In case I, identical conjugates were used äs
immunogen and for ball-coating. In case II a transferrin T4
conjugate was used to coat the balls, the conjugate being
formed with the same carbodiimide äs the immunogen. In
case III the hapten-protein conjugate for ball-coating was
identical to case II with the exception that another carbo-
diimide had been used for coupling. Figure 9 shows the
practical consequences of figure 8! Measured with LKB
1250.
case, the species-specific antibody label is replaced
by diazoavidin, avidin N-(4-aminobutyl-N-ethyl)iso-
luminol hemisuccinamide or avidin pyruvate kinase.
A biotin-avidin coupled System can be used in CE-
LIA Systems where the ligand to be measured (e. g.
insulin) can be biotin labelled. The amplification ef-
fect necessary is obtained from the avidin-luminogen
complex. The latter has the advantage that the serum
sample and luminogen can be kept separate, thus re-
ducing potential interference from serum compo-
nents.
Another labelling possibility is to label peptides di-
rectly with N-(4-aminobutyl-N-ethyl)isoluminol he-
misuccinamide or diazoluminol, although this is of
minor interest when SPALT or ILMA assays are
possible. Newer results have shown that all ILSA as-
says using diazoluminol äs label can be replaced with
ILMA assays in which the antibody is labelled with
N-(4-aminobutyl-N-ethyl)isoluminol hemisuccin-
amide (26, 29). The advantage gained here is that
the antibodies at both sides of the sandwich can
come from the same species, äs is the case in the thy-
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roglobulin ILMA. The use of N-(4-aminobutyl-N-
ethyl)isoluminol hemisuccinamide via an active ester
(N-(4-aminobutyl-N-ethyl)isoluminol hemisuccin-
amide N-hydroxysuccinimide ester) allows a high
incorporation of luminogenic groups without loss of
solubility and immunological activity. This results in
assays with lower detection limits thän for assays us-
ing diazoluminol äs label.
Instrumentation
The Instrumentation for luminometry is still in the
early stages of development, especially where immu-
noassays are concerned. At present only semi-me-
chanized luminometers are available, mainly with a
limited sample capacity (under 50 samples) which
precludes their use for long routine series.
The author's laboratory has experience with two
semi-mechanized luminometers, the main features
of which are shown in table 12. Neither machine is
able to process the raw data fully so that a manual
entry of "counts" must be made into a desk-top
Computer with modified RIA-dat^ processing pro-
gramme. One canriot expect a laboratory with auto-
matic RIA equipment to charige över to a semi-me-
chanized luminömeter, even when the assay proce-
dure is äs easy or easier than the original RIA. In the
case of the LB 950, extensive experimenting and
modification was needed üiitil the accepted reliabili-
ty and precision was attained so that routine assays
were possible without the assistant having to stand
over the machine to make sure that nothing went
wrong!
The LKB-1251 is built to such fine tolerances that
small deviations in the cuvette diameter lead to
Tab. 12. Major features of the LKB 1251 and LB 950 luminometers.
LKB 1251 LB950
1 . General
Capacity — no. of samples
Cuvette size (mm)
Special cuvettes
No. of injectors (maximum)
Pump-type
Pump-speed variable
Pump-volume variable
Mixing possible during injection/measurement
Pump volume maximum ( )
Repeat-dispensing possible
2. Measurement and Electronics
Dialogue with luminometer possible directly
Software for automatic data processing for luminescence immunoassays included
Reaction kinetics displayable
Data/Programme storage
Computer/Microprocessor delivered with luminometer
Selected intention times possible
Kinetic (rate) measurements possible
25
51 X 12
Yes
3
Peristaltic
No
Yes
Yes
ca50
Yes
Yes
No
via plotter
EEPRÖM
Built-in Microprocessor
andRS232-Coutlet
Yes
Yes
300
37 x 12 - 55 x
No
3
Syringe
Yes
Yes
No+)
350 (700++))
No
12
Only via Computer
No
onVDU
Diskette
Apple II
or Basis 108
Yes
Yes
3. Performance (in terms of gentamicin SPALT run with identical reagents
at the same time by the same technician
CV of reagent blank (enzyme oxidant blank) (%)
CV of sample with 2.2 g/l (n = 20) (intra-assay Variation) (%)
Ratio of Signals (see also tab. 1 1)
BO/UB
BJ6/UBBO/EOB
UB/EOB
1.39
1.93
22.6
5.43
62.4
2.93
2.04
2.39
9.49
2.87
62*6
6.59
) There is the possibility of blowing compressed air into the measurement chamber to effect mixing of tjie reagents.
) The LB 950 in use has been modified äs follows: All syringes have been replaced by syringes with Teflon plüngers (Hamilton,
Bonaduz, CH), the volume of the syringe for injecting into the measurement chamber being increased ifrom 0.5 ml to 1.0 ml.
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blockage of the transport System. This means that
only high-quality cuvettes (LKB or Sarstedt No.
68.750) can be used. The advantage of the LB 950 is
that high quality test tubes of diameters 11—12 mm
and length 37—55 mm can be used. Here again, the
emphasis is on the quality, äs many test tubes tried
had unacceptable tolerances so that only tubes from
Sarstedt (55 x 12mm No. 55.484) were used.
Over 4000 samples were run in parallel on both
LKB-1251 and LB 950 to test for precision and dy-
namic ränge. After optimisation of both luminome-
ters, no difference in performance could be seen.
The LKB 1251 was used for short experimental se-
ries, the LB 950 for longer routine luminescence im-
munoassays. In order to make luminescence immu-
noassays an interesting alternative to RIA the Instru-
mentation may have to be presented in the form of
"Black Boxes" with high reliability and throughout
äs the main criteria.
Commercial Kits
Although there are no commercial luminescence im-
munoassay kits on the market at the time of writing,
it is to be expected that they will soon make their
debut. Important points to be considered are, for ex-
ample, if coated tube assays are to be produced, will
the tubes fit into all luminometers? The answer is at
present definitely no, and it is easy to see, that if co-
ated ball assays were developed, that this problem is
automatically bypassed. Similarly, liquid phase as-
says of the CELIA-type also circumvent the need for
,special cuvettes.
Commercial kit producers do not seem to have rea-
lised the füll potential of luminescence immunoas-
says, and are no doubt waiting for the first firm to
launch itself into this field, where the "patent-densi-
ty" is still relatively thin!
Conclusions
This article has been intended go give a brief over-
view äs to what is happening in the field of lumines-
cence immunoassay, and is intended to stimulate the
reader into action in this field! Although is is now
evident that luminescence immunoassays can replace
other immunoassays in all sectors (26) the impact of
such assays will depend on their commercialisation.
Parallel to the development of robust kits, the lumi-
nometer producer must present an Instrument which
has all the comforts of the present-day RIA-and
EIA-automatic assay and data-reduction Systems.
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Summary: The antigen-antibody reaction itself acts äs the "marker System" in the marker-free immunological
methods. This group of analytical techniques includes radial immunodiffusion, nephelometry, turbidimetry
and nephelometric Inhibition. The Particle Counting-Immunoassay (PACIA) technique also belongs to this
group, although it employs latex particles äs markers for the intensification of the indicator reaction.
The principles of the above methods are described, and their applications in diagnosis, their detection limits
and important interfering factors are discussed. For all methods, the precision in series and from day to day is
in the ränge of 5—10%. The detection limits are l ng/1 for the PACIA technique, 10 g/l for nephelometric
Inhibition, l mg/1 for nephelometry äs an end point technique, ancJ 10 mg/1 for nephelometry äs a kinetic tech-
nique.
Commercial sources of reagents and apparatus are given in an appendix.
Markerfreie immunologische Analysenverfahren
Zusammenfassung: Die Antigen-Antikörperreaktion stellt für die markerfreien immunologischen Analysen-
verfahren das „Markersystem" dar. Zu dieser Gruppe von Analysenverfahren werden die radiale Immunodif-
fusion, die Nephelometrie, die Turbidimetrie, die nephelometrische Inhibierungstechnik und die Particle
Counting Immunoassay (PACIA)-Technik gezählt. Letztere verwendet allerdings zur Verstärkung der Indi-
katprreaktion Latexpartikel als Marker.
Die Prinzipien der genannten Verfahren werden dargestellt, die diagnostische Bedeutung, Nachweisgrenzen
sowie die wesentlichen Störfaktoren werden diskutiert. Die Präzision in der Serie und von Tag zu Tag liegt für
alle Verfahren im Bereich von 5 bis 10%. Die Nachweisgrenzen für die PACIA-Technik liegt bei l ng/1, für
die nephelometrische Inhibierung bei 10 g/l, für die Nephelometrie als Endpunkttechnik bei l mg/1 und für
das kinetische Verfahren der Nephelometrie bei 10 mg/1.
In einem Anhang werden die Bezugsquellen für Reagenzien und Geräte aufgeführt.
Introdüction
 In the present contribution only those methods are
Marker-free immunological methods use the prim- presented that are normally found in the routine la-
ary reaction between antigen (Ag) and antibody boratory.
(Ab) äs an mdicatorreaction.Thefollowing reaction In radial immunodiffusion, electroimmunodiffusion
scheme forms the basis of the method: and counter current electrophoresis, precipitate for-
mation (the 3rd step of the above reaction scheme) is
.,
 A used for the detection of the reaction. For optimalAb -l· Aß > AbAß5 &
 precipitate formation, all reactants must be present
nAbAg —» (AbAg)n in mutually compatible concentrations. this accord-
ingly places a restriction on the lower detection limit
x(AbAg)n -^ precipitate
 for these anaiyses.
l) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hiimburg, Juni
1983.
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Radial Immunodiffusion
In this procedure, the formation of precipitation
lines in a suitable medium of agar or agarose serves
äs the marker. Precipitate formation depends on the
following factors:
1. molecular weight,
2. protein concentration,
3. agar concentration in the gel,
4. ionic strength,
5. incubation temperature.
Anitibody is present in the agar in a defined concen-
tration. Antigen diffuses radially from a punched cir-
cular well into the agar medium. A stable ratio of
antigen and antibody is attained, and a ring shaped
region of precipitation becomes visible. At the end
of the reaction, the logarithm of antigen concentra-
tion is proportional to the diameter of the precipita-
tion ring. The diameters of the sample and Standard
precipitate rings^are measured, and the antigen con-
centrations of the samples are determined from a
Standard curve.
Two evaluation procedures are commonly used:
1. the technique of Mancini (1), based on measure-
ments after diffusion is complete, and
2. the kinetic procedure of Fahey & McKelvey (2).
Different diffusion times are observed for the var-
ious plasma proteins, e.g. 24—50 hours for IgG, and
50—80 hours for IgM and aa-macroglobulin. These
differences in diffusion time depend essentially on
molecular size or molecular weight. Under certain
conditions, for example in the presence of 7S IgM
which has a lower molecular weight than normal
IgM, the accelerated diffusion gives the false impres-
sion of increased protein concentration. Conversely,
the presence of high molecular weight secretory IgA
or immune complexes results in the recording of er-
roneously low antigen concentrations. The lower de-
tection limit of radial immunodiffusion is about 20
mg/1; the procedure is capable of an in series preci-
sion of 2—5%, while precision day to day is in the
order of 3-7% (3).
In the Fahey method, the diffusion time is short, so
that the strict control of reaction time and tempera-
ture, and the exact measurement of the sample are
very important. This procedure has the same detec-
tion sensitivity äs the Mancini technique. Precision
from day to day is in the ränge of 3—7%. In practice,
both methods have advantages and disadvantages.
The presence of rather high antigen concentrations
may lead to premature reading of the results, with
consequent inaccuracies.
For the determination of especially low concentra-
tion ranges in cerebrospinal fluid, ürine, venous um-
bilical blood and venous punctates, so-cälled LC-
plates (low-concentration-plates) are used.
The quality of the Standard is critically important for
the quantitative evaluation, and it'should be based
on the recominendations of the WHO. To obtain the
highest possible precision, the diameter of the pre-
cipitation ring should be determined with the aid of a
measuring microscope, or at least with a measuring
lens, to an accuracy of ±0.1 mm.
Since the plates must be evaluated visüälly, the qual-
ity of the results caii also be judged by inspection,
and any possible sources of error will be apparent.
Asymmetrie precipitate rings can be caused by the
following faults:
1. protuberances or indentations in the agar,
2. inadvertant application of sample outside the
starting well,
3. damage by freezing of the plates,
4. Separation of the agar layer from the base, and
diffusion of the sample underneath the agar.
Elliptical rings are caused by:
1. overfilling of the starting well,
2. non-horizontal positioning of plates during the
diffusion process,
3. partial drying out of the plates, e.g. by exposure
to the sun.
' r ·
Weak precipitate rings are found under the following
circumstances:
1. antigen excess (M-protein),
2. antibodies of the patient against other proteins of
the antiserum.
Double or triple precipitation rings are caused by:
1. multiple filling of the starting well,
2. proteolytic cleavage products of proteins,
3. unspecific (inappropriate) antisera,
4. cryoglobulin precipitation,
5. protein precipitation at the Start
6. reaction with rheumatoid factors (IgM antibo-
dies),
7. presence of circulating immune complexes.
Table l lists the analyses that are at present per-
formed by immunological methods, based on RID
and nephelometry, and to some extent turbidimetry.
The appendix lists the commerqal sources of rea-
gents and apparatus.
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Tab. l. List of proteins that can at present be determined by RID
and nephelometry.
Albumin
Antithrombin III
cti-Antitrypsin
Apolipoprotein A-I
Apolipoprotein B
Cj-Inactivator
C3c
C4
(FactorVIII)
(associatcd protcin)
Coeruloplasmin
C3-Activator
C-reactive protein (CRP)
a-Foetoprotein
Fibronectin
Fibrinogen
Acidic-a i -glycoprotein
a:-HS-glycoprotein
ß2-Glycoprotein I
ß-SP-1-glycoprotein
a-PA-glycoprotein
Gc-Globulin
Haemopexin
Haptoglobin
Human-placental lactogen
IgA
IgD
IgE
IgG
IgM
Lactoferrin
ß-Lipoprotein
Lysozyme
a-Macroglobulin
Plasminogen
Prealbumin
Proth rombin
Retinol binding protein (RBP)
Thyroxin binding globulin (TBG)
Transferrin
Applicat ion
Radial immunodiffusion is used for the determina-
tion of specific proteins from various sources. More
recent diagnostic procedures, e. g. the determination
of apolipoproteins, are also possible with the aid of
this technique. The fnethod is simple to apply and
requires little space. As mentioned above, the plates
also provide more Information about the guality of
the results than can be obtained with other methods.
Several operational procedures are involved in one
analysis, which means that the method is costly in
operational time. A further disadvantage is that the
method does not lend itself to mechanization.
Developmental trends
As an alternative to RID, nephelometry requires an
Investment in apparatus of between 30000 and
90000 DM Partly mechanized clinical chemical ap-
paratus, which operates on an exact time cycle, en-
ables the turbidimetric determination of the most
important specific proteins, without additional in-
vestment, Within a reasonable space of time, it will
therefore be possible to perform all immunological
analytical methods by RID or nephelometry. The
ränge of reagents for these procedures will also be
extended by the introductiön of new tests.
In the routine clinical chemical laboratory, elec-
troimmunodiffusion (rocket electrophoresis) (4)
does not play a naajor role. The preparation of the
plates is work intensive, and high quality results are
difficult to obtain. This very demanding procedure is
firmly established in laboratories of scientific protein
research, where multidimensional techniques are fa-
voured for the characterization of proteins and for
testing the homogeneity of protein preparations.
Nephelometry
Principle
In a "clear solution", particles of a certain size cause
a scattering of incident light. Usually, the wavelength
of the scattered and incident light is the same. To a
small extent, light of longer wavelength, i. e. of lower
energy, is also emitted (Raman effect).
Condensed monochromatic light of a certain wave-
length causes polarization of the molecules of parti-
cles in a solution. Oscillations then result in the emis-
sion of light of the same wavelength äs the excitation
light. .
If the particle size is in the order of 0.1 of the inci-
dent wavelength, all particles are excited in the same
way, and Rayleigh scattering (5) occurs.
Equation
10 = Io 2 4
COS
"
Providing the excitation is performed with non-po-
larized light, the intensity of scattered light is pro-
portional (l/ 4) to the incident wavelength. The in-
tensity increases with decreasing wavelength. The
scattering diagram (fig. 1) shows that the distribution
of scattered light is symmetrical, and the same quan-
tities of light are scattered forwards and backwards.
With increasing particle size, the nature of the light
scattering changes with respect to the wavelength of
the incident light. The symmetry around the 90 de-
gree axis is retained, but the ratio of backwards to
forwards scattering is changed. For this reason the
photomultiplier is placed at an angle of 15 to 30 de-
grees to the axis of the incident light. Figure 2 shows
the type of light scattering that exists in the nephelo-
metric measurements in immunological tests.
If the particles are larger than the wavelength of the
incident light, äs in the determination of suspended
bacteria or blood cells, then Mie scattering (6) oc-
curs. The diagram for Mie scattering is shown in fig-
ure3.
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source Condensor Blind Filier Cuvette
Backword Forword
270e
Fig. 1. Light scattering by a particle (P) of size less than 0.1 .
Fig. 2. Light scattering by a particle when the particle size is the
same äs, or only slightly less than .
Light
source
X-
180°
Fig. 3. Light scattering by a particle (P) when the particle size is
greater than the incident wavelength.
Light scattering by ant igen-ant ibody com-
plexes
The antigen-antibody reaetion proceeds in several
stages. The rate of formation of antigen-antibody
complexes depends on temperature, pH, ionic
strength and the relative quantities of reactants. An-
tigen-antibody complexes are always lager than
0.1 .
Addition of 4% polyethyleneglycol (PEG 6000) ac-
celerates and intensifies the reaction (7).
Apparatus
Nephelometric determination of the complexes may
be performed kinetically (8), or by the end point
method after incubation for 30 to 60 müiutes (9);
much less sample is required for the kinetic method.
The layout of a nephelometer is shown schematically
in figure4.
Filter
Photo-detector
- Amplifier
Display
Fig. 4. Schematic representatiqn of a nephelometer.
The light source is either a halogen lämp ör an heli-
um-neon laser. Practically all nephelometers can be
converted to partly or fully mechänized Systems,
which perform all Steps from sampling, reagent se-
lection and dispensation to the calcülation of the re-
sults.
Reagent packs are available for all specific proteins,
and the ränge is continually being extended.
For all apparatuses and procedures, the precision in
series shows a Standard deviation of 3—5%, while
day to day precision is 4—7% (3). Nephelometry in-
volves the same problems of standardization äs al-
ready encountered in radial immunqdiffusion. The
accuracy of the nephelometric determination is sim-
ilar to that of RID.
The lower detection limits are 10 mgA for the kinetic
method and l mgA for the end point method.
Nephelometry has the following advantages over ra-
dial immunodiffusion:
1. rapid availability of results,
2. simple mechanization,
3. short incubation times.
These advantages müst be set against certain notable
disadvantages. In the first place, capital Investment
costs are in the order of 30000 to 90000 DM, which
can be justified oiily for large analytical loads and a
demand for the rapid production of analytical re-
sults.
In the presence of an excess of antigen, the immune
complex redissolves and erroneously low results are
obtained. Excess antigen is tested for by a further
reaction Step, involving the addition of extra anti-
body.
Each commercially available apparatus has its own
specially designed reagents, so that it 'is very incon-
venient to adapt to a new test, and for reasons of cost
or comparability of analytical results, it is difficult to
use the tests süpplied by other manufacturers, or to
prepare reagents in the laboratqry.
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Since RID naturally involves visual inspection of the
plate, it permits the detection of atypical precipitate
rings and other errors. Nephelometry, on the other
hand, provides no control over the presence of un-
specific reactions.
Turbidimetry
In contrast to nephelometry, turbidimetric methods
measure the decrease in intensity of incident light.
Accordingly, a turbidimeter has a similar construc-
tion to that of a photometer. By the preparation of
highly pure antisera, and especially by the produc-
tion of clinical chemical equipment with precise tim-
ing facilities, turbidimetric procedures have found a
very wide application.
The decrease of light intensity corresponds to an ap-
parent absorbance
I = I0 · e-1*
where I0 is the intensity of incident light, I corre-
sponds to the transmitted light, and S is the light path
of the cuvette. T is the turbidity coefficient, and it
depends on the wavelength, the concentration and
the type of particles.
Test packs are available for the most important spe-
cific proteins that are present in sufficiently high
concentrations for turbidimetric assay. If the tests
are performed with mechanized apparatus, similar
precision and accuracy are obtained with nephe-
lometry and RID. Turbidimetry has a shorter linear
measurement ränge than nephelometry. Nephe-
lometry and türbidimetry require high affinity anti-
sera, which are prepared by adsorption, affinity
chromatography and ultrafiltration. All reagents of
nephelometric quality are also suitable for türbi-
dimetry.
Turbidimetry also has the same limitations äs nephe-
lometry with respect to the ocqufrence of undetected
interference. Attentioa shpuld also be drawn to the
unspecific pfecipitatioti of proteins (e.g. fibrinogen)
by PG 6000, which is added to accelerate the reac-
tion; or the fluorescence of pharmaceuticals, which
can be caused especially by the UV light favoured
for turbidimetric ineasurements.
Turbidimetric analyses can be performed with "fast
analysers" and automated analysers, e.g. the ACP
5040:
Nephelometry and türbidimetry require about 5
times more antiserum than does radial immunodiffu-
sion.
Nephelometric Inhibition Method
The methods described so far are used for the quan-
titative determination of macromolecular substances
on the basis of their antigenic properties. Low mo-
lecular weight compounds, e.g. pharmaceuticals,
have not antigenic properties. These haptens be-
come antigenic when they are coupled to bovine al-
bumin, and they can be used in this way for the prep-
aration of antibodies. Thus, the immunological de-
termination of pharmaceuticals is possible, and it is
performed chiefly by radioimmunological or enzy-
meimmunological methods. If relatively high con-
centrations of pharmaceuticals are present in blood,
they can be determined by the nephelometric Inhibi-
tion technique. The nephelometric Inhibition immu-
noassay was developed at about the same time by
two independent research groups (10, 11).
Principle
Hapten and corresponding antibody are present in
the reaction mixture. Depending on the antigen con-
centration, antigen-antibody complexes are formed,
but no signal is produced, because the antigen is of
low molecular weight. A response is not obtained
until a complex of the hapten with another macro-
molecule (e.g. ferritin) is added. The added macro-
molecule-linked antigen forms a nephelometrically
detectable complex with the remaining free anti-
body. The quantity of free antigen in the initial reac-
tion mixture determines the quantity of macromole-
cule-linked antigen (starter antigen) that can be-
come bound and thereby give rise to a signal. Figure
5 shows the reaction principle and a calibration
curve.
By using this technique the sensitivity is increased by
a factor of 1000; the detection limit is 10 §/1. An in
series precision of 5% is possible, and day to day
precision is 8—10%. For technical reasons, the sensi-
tivity is not in the same order äs that of the radioim-
munological test. Variable protein binding by some
pharmaceuticals is a source of error; the resulting
complexes may act äs Starter antigens and contribute
to signal generation, thereby leading to falsely high
results. This source of error can be excluded by prior
extraction of pharmaceuticals from the sample; in
addition, the resulting enrichment of the analyte
leads to an increase in the sensitivity of the assay.
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Cojugate Antibody
~ l l Antibody
Conjugate
assay mixture causes the agglutination of several ia-
tex particles. After the reaction, a wide ränge of par-
ticle sizes is present. Quantitation is performed with
a particle counter with dark field Illumination. Un-
specific reactions are suppressed by the reaction con-
ditions (pH, ionic strength and suijface treatment of
the latex particles). Macromoleculaf reactants be-
come bound directly to the surface-treated latex par-
ticles. Haptens are linked to the latex particles with
the aid of ferritin molecules. In both cases, the im-
munological reactivity is not affected by linkage to
the latex. The method has the same sensitivity ränge
äs radio- or enzymeimmunological procedures.
The latex aggregates or reaction prqducts are deter-
mined in a Technicon continuous flow System, linked
to a dark field illuminated cell counter. The thre^
shold is set at about 1.2 . After the reaction is
complete, the signal decreases, because the number
of free particles decreases. Figure 6 shows the princi-
ple of the PACIA technique. Compared with the ca-
pacitive technique, the optical measurement has the
Free hopten
Latex-Antigen
Serum «· Antibody (Abj ·
(Lx-Ag)
fTTx-Ag.Ab), ~|
UJ Agglutination * Latex-Antigen I-
[37 °C Z9min _j l
**·
•
\ «
Only single particles counted
• · Maximum unagglutinated
Latex-Antigen
= Minimum antibody
Fig. 5. Principle of the nephelometric Inhibition technique. Fig. 6. Schematic representation of the PACIA apparatus from
TECHNICON from (13).
Nephelometric Determination of Antigens with La-
tex Particles (PACIA Method)
Principle
The PACIA method (particle counting immunoas-
say) was developed (12) to increase the sensitivity of
the antigen-antibody reaction. It is suitable for the
determination of both antibodies and antigens, and
is based on a similar principle to the latex test. Carb-
oxylated latex particles are loaded with antigen or
antibody. The corresponding reaction partner in the
advantage of interference^free counting. Automa-
tion of the procedure güarantees the most reliable
results.
The detection limit is l ng/1. Precision in series and
from day to day for alpha-foetöprotein are 2—
12.9% and 5.8-12.8%, respectively.. If very low
concentrations are present, the possibility of a prp-
zone effect must be borne in mind. Other interfering
factors, e. g. agglutination of the latex particles, reac-
tion with the complement system of IgM rheumatoid
factors are largely avöided by cöupling the IgG-F
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(ab')2-fragment to the latex particles and by chang-
ing the ionic strength.
This method promises well for future developments.
A number of tests have so far been introduced, rang-
ing from kits for the determination of circulating im-
mune complexes to methods for the determination
of insulin or pharmaceuticals, e.g. digoxin.
The equipment first developed by Technicon was
discontinued, and it has only recently become availa-
ble again from the firm of Acade in Brüssels, under
the name of IMPACT. Technicon now uses the PA-
CIA reagents on the Random Access Analyser RA
1000 with the customary photometric technique. In
the same way, it may be possible to use this sensitive
method with other conventional analytical Instru-
ments. It is to be expected that this new method will
be subject to fax fewer problems than the other im-
munological analytical methods, whose inadequacies
with respect to reagent storage and availability, and
mechanization of analysis are well known.
Future Perspectives
At present, acceptable Solutions exist to all problems
concerning the available tests, the detection princi-
ple and the mechanization of the individual analyti-
cal Steps. For certain levels of analytical throughput,
however, mechanization of the overall process is still
not entirely satisfactory. Just äs the scientific re-
quirements for the analytical adaptation of the anti-
gen-antibody reaction have now been met, it re-
mains to be hoped these problems of mechanization
will also be rapidly solved. Depending on the con-
centration of analytes in the test material, simple
methods such äs radial immunodiffusion, or mechan-
ized methods such äs nephelometry (kinetic or end
point methods), or turbidity can be used. For trace
concentrations, the PACIA method represents an al-
ternative to known and proved, but not problem-
free techniques (RIA and EI A). For obvious rea-
sons, a reduction in the number of radioimmunoas-
says is desirable.
Appendix
Suppliers of reagents and apparatus
Radial immunodif fus ion
1. Behringwerke AG Postfach 1130, D-3550 Mar-
burg/L.
2. Cooper Biomedical Rebstöcker Str. 33—39,
D-6000 Frankfurt M.
3. Kallestad Diagnostica GmbH, Colombistr. 27,
D-7800 Freiburg.
4. Miles GmbH, Lyoner Str. 32, D-6000 Frankfurt/
M.
Nephelometry and türbidimetry
A = apparatus; R = reagents
1. Atlantic Antibodies, Vertrieb durch AHS-
Deutschland GmbH. Lefchenstr. 5, D-8000
München 50 ' R
2. Baker Instruments, Vertrieb durch Fa. Vogel
GmbH, Maiburger Str. D-6300 Gießen A, R
3. BecKnaan Instruments GmbH, Frankfurter Ring
115, D-8000 München 40 A, R
4. Behringwerke GmbH, Postfach 1130, D-3500
Marburg/L. A, R
5. Boehringer Mannheim GmbH. Sandhofer Str.
116, D-6800 Mannheim 31 A, R
6. Cooper Biomedical, Rebstöcker Str. 33-39,
D-6000 Frankfurt/M. ehem. Travenol GmbH,
Sparte Hyland Diagnostica. A, R
7. DAKO, Vertrieb d. Fa. Boehringer Ingelheim
Diagnostica GmbH Gutenbergstr. 3, D-8046
Garching/München R
8. Immuno GmbH. Postfach 103080, D-6900 Hei-
delberg A, R
9. Kallestad Diagnostica GmbH, Colombistr. 27,
D-7800 Freiburg i.Br. R
Nephelometric Inhibi t ion technique
1. Beckman Instruments GmbH, Frankfurter Ring
115, D-8000 München 40 A, R
PACIA technique
1. ACADE S. A. 17, Passage de la Vecquee, Box
4100, B-1200 Brüssels
2. TECHNICON GmbH, Im Rosengarten 11,
D-6368 Bad Vilbel A, R
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Summary: The practicability, Operation time and cost of ligand binding assays are clearly more favourable
than those of the possible and sometimes highly spedfic alternatives. At the same time, however, they have
distinct weaknesses with respect to the criteria of analytical performance. For the routine determination of
individual clinical chemical parameters, which are otherwise difficult to quantify, ligand binding assays (espe-
cially in those versions that do not use radioisotopes) are markedly superior to other methods. Chromato-
graphie methods, however, offer greater advantages for the determination of profiles.
Wertigkeit immunologischer Methoden aus der Sicht des Klinischen Chemikers
Zusammenfassung: Der Vergleich von Ligandenassays mit ihren möglichen, teilweise hochspezifischen Alter-
nativen zeigt ihre klare Überlegenheit bezüglich der Praktikabilität, Arbeitszeit und Kosten. Gleichzeitig wer-
den aber auch ihre Schwächen hinsichtlich der analytischen Methodenkriterien deutlich. Zur routinemäßigen
Bestimmung von sonst schwierig quantifizierbaren klinisch-chemischen Einzelkenngrößen sind Liganden-
assays, vor allem in ihrer Variante als Nicht-radioisotopenassays den anderen Verfahren eindeutig überlegen,
zur Bestimmung von Profilen allerdings den chromatographischen Methoden eindeutig unterlegen.
Introduction
When ligand binding assays were introduced in 1960
by Yalow & Berson and by Ekins (l, 2) the epoch-
making importance of this technique and its subse-
quent far reaching application were not foreseen.
Owing to the esoteric nature of the procedure, it was
used only by a few initiates. With the advent of its
commercialization in 1975 the method became
widely available, albeit chiefly in the form of the ra-
dioimmunoassay. Npwdays the technique has wide-
spread application, it is no longer considered to be
special ör exceptional, and it can now be evaluated
dispassionately·
For the laboratory clinician and the clinical chemist,
ligand binding assays represent only one of several
groups of methods. They müst therefore address
themselves directly to the problem of comparing li-
gand binding with alternative methodology. Such a
comparison is attempted in the present paper, and
the subject is viewed from the standpoint of those
who must use these methods daily.
c , . , , . , , , ,Several problems have already been touched upon
or discussed in previous papers, but in the interests
of a balanced presentation repetition cannot be en-
tirely avoided. Since limitations of space make it
necessary to be selective, the following discussion
will deal largely with the areas of endocrinological
diagnosis and drug monitoring.
decision fof or ^ introduction of an
^
 dure fa dictated fundamentally by the
tQ thfee tions.
1. Does the measured parameter provide an answer
to the clinical enquiry?
2. Which method gives optimally useful clinical in-
formation?
3 Does the chosen method fulfil the stated require-
ments with respect to quality of analysis, time re-
sponse, practicability and cost?
Since questions 1. and 2. are outside the remit of the
present discussion, they will not be discussed further.
Presented at the Kleinkonferenz „Immunologische 'Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg» Juni
1983.
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General
As alternatives to the immunoassay (radio-, enzyme-,
fluorescence- and bioluminescence-immunoassays)
one can consider methods based on electrophoresis
(e.g. isoelectric focussing), spectrophotometry, fluo-
rimetry, radioenzymic assays and chromatography,
e. g. gas chromatography (GC) or high performance
liquid chromatography (HPLC). All these alterna-
tive methods are applicable completely or in part to
the determination of steroids, iodoamino acids and
biogenic amines, but they are not suitable or have
only doubtful value for the measurement of peptide-
or proteohormones (tab. 1). Pharmaceuticals can be
determined with the above methods.
Tab. 1. The suitability of various methods for the determination
of hormones, pharmaceuticals, proteins and peptides.
Tab. 2. Fundamental analytical Steps in ligand binding assays and
"chemical" methods.
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Gas chromatography and gas chromatography-mass
spectrometry (GC-MS) have the following limita-
tions. Since the material to be measured must be vol-
atile, these methods are normally suitable only for
substances of molecular weight less than 1000. Polar
and unstable compounds must be derivatized to de-
crease adsorption or increase stability.
Comparison of immunological methods with the al-
ternatives on the basis of the fundamental analytical
Steps (tab. 2) shows that the reaction step, the Sepa-
ration step after the reaction (with the exception of
the homogeneous techniques) and the detection are
all absolutely necessary in the immunological proce-
dure. In the chemical methods only the detection is
indispensable, the Separation and reaction Steps be-
ing optional.
Analytical step Ligand binding assays
homo- hetero-
geneous geneous
"Chemica
methods
Separation step(s)
Reaction
Separation step(s)
Detection
(+)
+
During the reaction stage of ligand binding assays,
comparatively weak intermolecular iriteractions are
involved, such äs the formation of hydrophobic or
hydrogen bonds. In contrast, derivatization involves
the formation of covalent bonds, which are naturally
more stable, and resistant to interference.
Quality
Since the value of immunological methods from the
standpoint of the clinician has been presented separ-
ately (3), I can limit myself here to a discussion of
the quälity of the analysis, and omit the diagnostic
aspects.
A cornparison of the analytical performance of the
immunoassay, gas chromatography, gas chromato-
graphy-mass spectrometry and the bioässay (tab. 3)
shows that gas chromatography-mass spectrometry
is superior on all counts, providing the analyte is
amenable to this procedure.
Tab. 3. Comparison of the analytical performance of immunoas^
say, gas chromatography-mass spectrometry and bioäs-
say.
Accuracy
Precision
Specificity
Detection limit
Assay ränge
Linearity
Immuno-
assay
(+)
5-15%
(+)icr12
1:50
·—
Gas-
chromato-
graphy-mass
spectrometry
-h
1-5%
+
10-14
1:104
+
Bioässay
(+)
10-30%
(+)
10-io
1:20
—
Specificity and accüracy
In the absence of a signal, it can be assumed with a
high degree of ceftainty that the analyte is not pres-
ent. It is less certain that a positive signal is due to
the substance in question. ^
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As shown in figure l, reputedly highly specific im-
munological methods may sometimes be subject to a
certain lack of specificity. Voelkel & Tashjian inves-
tigated calcitonin in urine (4) and found differences,
which were sometimes very pronounced, between
the biologically and immunologically determined
concentrations. Such deviations frequently show no
definite relationship to each other, so they cannot be
predicted or corrected by calculation. A further ex-
ample is the determination of ocytocin after incuba-
tion with pregnancy serum (fig. 2) (5). In this case,
the values determined radioimmunologically were
much higher than those from the bioassay. A similar
Situation exists for angiotensin II and insulin.
100000-
Bioossay Immurioassay Bioassay Immunoassay
Fig. 1. Calcitonin concentration in urine and urine concentrate
measured by bio- or radioimmuno-assay in patients with
medullary cärdnpma of the thyroid (4).
Hormone Standards from different species may pos-
sess the same biological activity, but different immu-
' noreactivity. Conversely, chemically different sub-
stances of different biological activity may have sim-
ilar immunochemical reactivity. Likewise, äs already
mentioned, fragmentation products, metabolites or
prohormones of the compound in question can lead
to erroneously high values. The extent of loss by
degradation of an analysed substance in the sample
solution (frequently serum, which contains enzymes)
can be very different from that in the Standard solu-
tion.
These phenomena can be explained by the presence
of either hormone precursors or hormone cleavage
products, which have no biological activity, but pos-
sess immunological reactivity. It is known that the
binding site of an antibody recognizes antigenic de-
terminants equivalent in size to only 4 amino acid
residues or 6 hexose residues (6).
Precision
Under routine conditions, the interassay precision of
immunological methods usually lies between 5 and
15%. It should be mentioned, however, that this im-
precision can be decreased by a factor of 1.5—2 un-
der favourable circumstances, e.g. in a laboratory
test study, with equivalent charges, continuity of per-
sonel and low pressure of work (7).
Series to series precision is essentially similar for me-
chanized EIA (thyroxin), mechanized RIA (cortisol)
and manual RIA (thyrotropin). Only the determina-
tion of oestradiol, which involves a solvent extrac-
tion, shows a distinctly higher Variation coefficient
(tab. 4).
Bipassoy
60 90
t (min)
150
Fig. 2. Decrease in ocytocin concentration by incubation with
plasma from womcn during late pregnancy, measured by
bio- (·—·) and radioimmuno-assay (O—O) (5).
Tab. 4. Inter-assay precision for mechanized EIA (thyroxin),
mechanized RIA (cortisol), manual RIA (thyrotropin)
and manual RIA with solvent extraction (oestradiol).
CV(%)
Thyroxin ( §/1)
«
Cortisol ^g/l)
Thyrotropin (mU/1)
Oestradiol (ng/1)
33
92
167
114
233
310
2.4
12.0
120
260
479
13.9
4.3
4.0
8.6
7.3.
5.2
9.2
4.5
14,6
12.4
10.8
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In contrast to the immunological methods, the preci-
sion of the gas chromatography-mass fragmento-
graphic methods with internal standardization lies
between l and 5%.
Three examples serve to demonstrate the precision
and accuracy of interlaboratory investigations: al-
dosterone, which can be standardized with a highly
accurate reference method; total T.*, for which there
is a defined Standard material, but no reference
method; and follitropin, äs an Illustration of a meth-
od of unknown accuracy, calibrated against a Stan-
dard preparation (e.g. MRC 68/40). Surprisingly,
the medians of the results obtained with varioüs
commercial or self-prepared reagent kits showed
about the same maximal scatter (factor of 1.4 to 2.5)
(tab. 5) for all three parameters. This was considera-
bly increased, however, for the 16th. percentile (8).
In t e r f e rence
Patients with paraproteinaemia often show a clini-
cally meaningless total T4 profile. Patient serum may
even contain antibodies against the investigated anti-
gen or against the antibody of the assay, thus render-
ing the analytical results useless.
Owing to the weak nature of the intermolecular for-
ces in the immune reaction, alterations of pH, ionic
strength, temperature and matrix exert a large influ-
ence on the results.
Detection limit
The maximal detection limits of different analytical
procedures are shown in figure 3, and compared with
the normally encountered serum concentrations of
varioüs parameters. Haemoglobin is included äs the
blood analyte with the highest concentration, while
substances such äs triiodothyronine (T3), parathyrin,
aldosterone, corticotropin and oestradiol are present
in especially low concentrations. Most pharmaceuti-
cals are found in the concentration ränge 10~2 to
10"1 g/l. To give a mental picture of the detection
limits that can be achieved nowdays, let us consider
l g äs equivalent to the distance between the earth
and the moon (about 400000 km); l pg than corre-
sponds to the dot of a letter i (0.4 mm). Such quanti-
ties can be measured by GC-MS with a precision de-
cidedly better than 10%.
Linear i ty
Reference curves for immunological assays are non-
linear. This means that the distribution of errors in
c
ig/ml]
S l i *
<_> CJ
Haemoglobin
-Glucose
| Antiepileptics
§> Theophylline
u Aminoglycosides"
Cortisol ^^
Ferritin
Thyroxine
a- Foetoprotein
Prostate aeid
phosphatase
Carcino embryonic
antigen
"p-Microglobulin
Digoxin
Triiodothyronine
Parathyrin
Aldosterone
o* Oestradiol
•2!
-1CT
-10r6
-10' 15
Fig. 3. Comparison of detection limits attainable for analytical
methods and typical concentration of various clinical
chemical analytes. Diverging from the rules of the Sys-
teme International d'Unites g/ml was chosen äs the unit of
substance concentration, äs only this allows for a meaning-
ful synopsis. For procedures marked with a star, the sub-
stance amounts detectable absolutely are given.
the assay ränge is not homogeneous. Usually only
the first quarter of the reference curve has a steep
slope. At higher concentrations the curve becomes
increasingly flat. The assay ränge of 1:60 for thyro-
tropin is relatively high for a radioimmunological
method. The ränge of 1:6 for valproic acid is more
tyrjical. In contrast, the linearity and assay ränge for
gas chromatographic-fnass spectrophotometric
methods are frequently more than 1:1000.
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Duration
Comparison of the pre-analysis and analysis times
for a simple and an involved procedure shows that in
each case immunological methods are distinctly su-
perior to gas chromatography (fig. 4). The total anal-
ysis time for the determination of the steroid profile
of a urine sample is nearly 90 hours, ineluding 22
hours of pre-analysis operations. By cpmp rison, the
27 hours needed for the total analysis of thyrotropin
by RIA is short, despite the faet that this particular
procedure is known to be rather time consuming
compared with other radioimmunoassays. A similar
relationship is evident from the oomp risoii of the
two simpler analyses.
Steroid profile Fatty qcid profile Thyrotropin Antiepileptics
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Fig. 4. Bench work (—m) and analysis ( ) times for two gas Chromatographie methods (steroid and fatty acid profiles) and two iigand
binding assays (thyrotropin by manual radioimmunoassay, and antiepileptic agents by a fu y mechanized, homogeneous enzyme-
immunoassay).
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Practicability
Table 6 shows the number of ligand binding assays
against the actual number of requested analyses.
This ratio is always greater than two, because dupli-
cate determinations are normally performed. It de-
pends strongly on the number of points required on
the reference curve, and the number of control sam-
ples used. In addition, a series may be repeated if the
initial data are of poor quality. Thus, for thyrotropin,
a ratio of determinations to requested analyses of 4
indicates that an average of four determinations
must be performed to obtain one result. Short series,
e.g. valproic acid assays, show an even less favoura-
ble ratio.
Tab. 6. Ratio of the number of analyses to the number of re-
quested investigations.
U U/P Method
Diphenylhydantoin
Valproic acid
Digoxin
Thyroxin
Triiodothyronine
Thyrotropin
3018
1950
18240
27642
25800
14916
744
282
5658
9894
9917
3696
4.1
6.9
3.2
2.8
2.6
4.0
EIA-Cobas
EIA-Cobas
EIA-LKB
EIA-LKB
RIA-C4
RIA-man
U = number of analyses
P = number of requested investigations (figures for 1983)
Cobas = CobasBio, Hoffmann-La Röche
LKB = Ultralab System 2074
C 4 = Concept-4, Micromedic
man = manual, Henning
At this point we cannot ignore the fact that the care
and disposal of radioactive materials has become an
increasingly diffictilt problern in recent years. Reas-
suring Statements that the disposal of radioactive
waste presents no problems are either euphemistic,
or they are based on the non-observance of the stat-
utary regulations. Our institute alone produces each
year 18 drums of solid and 8 x 60 litre cannisters of
liquid waste, which must be stored for several years
in a separately appointed room of the clinic for ra-
dioactive decay. In comparison, the management of
non-radioactive immunoassays is naturally free from
such problems, which is why we fundamentally pre-
fer them.
The requirements for apparatus and space, äs well äs
the qualification of the operaior, are exorbitantly
higher for gas chromatography-mass spectrometry
than for immunoassays.
J. Clin. Chem. Clin. Biochem, / Vol. 22,1984 / No. 12
Costs
In view of present day financial stringencies, the
question of costs is especially important. Calculation
of the real cost in public Services is, of course, ex-
traordinarily difficult The figures quoted here can
only be taken äs a guide.
There are various reasons for this. The cost of a BAT
(Bundes-Angestellten-Tarif, Federal Employee Ta-
riff) post is calculated simply äs the sum of the salary
and the social taxes. Figures for overheads (e.g. total
administrative Services) are not included and are not
available. Furthermore, Information is lacking on
operational costs, building depreciation and the in-
terest on capital.
The net working time, based on a 40 hour week, al-
lowing for holidays, illness, etc., is 100320 minutes
per year. This is about the same äs quoted in the
guidelines for the reagent producing industry. The
cost of a BAT Vc appointment (1983 scale) is 47 050
German marks, which represents 0.469 mark/work-
ing minute. For a BAT Vb appointment, this figure
becomeS 0.514 mark/working minute.
The provision of apparatus and its depreciation con-
tribute markedly to the total costs.
Assuming a linear depreciation to zero over ten
years, the equipment costs per analysis ränge from
0.2 mark for the manual RIA to 106.25 marks for
the computerized combined gas chromatography-
mass spectrometry.
The total costs per analysis have been calculated
from our figures, and they are presented äs four se-
parate examples in tables 7—10. Thus, the average
cost of a mechanized enzyme-immunological deter-
mination is 5.47 marks, without taking account of
building costs and electricity, etc. For a manual RIA,
the corresponding figure is 7.34 marks. If the calcu-
lation is based on the guidelines for industry, the re-
sult is similar, although the figure then includes all
costs. Comparison with the corresponding figures for
gas chromatography (94.15 marks per analysis) or
gas chromatography-mass spectrometry (214.95
marks per analysis) clearly demonstrates that these
latter methods cannot be considered äs alternatives
for routine purposes.
This Overall assessment shows that at present there is
no reasonable alternative to the ligand binding assay
for the measurement of individual compounds that
are otherwise difficult to analyse. Of the different
types of ligand binding assay, those that do not em-
ploy radioisotopes are decidedly preferable. On the
other hand, for the determination of several differ-
ent substances simultaneously, Chromatographie
techniques are clearly superior to ligand binding as-
says.
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Tab. 7. The cost of one determination by mechanized enzyme-
immunoassay. One technical assistant performs 32540
assays per year.
3.1 min/investigation
l .45 DM technical assistant/investigation
+ 0.41 DM academicsupervision/investigation
l .86 DM personel costs/investigation
0.21 DM apparatus costs/investigation
3.40 DM reagent costs/investigation
5.47 DM total cost/investigation
Tab. 9. Average costs of a gas Chromatographie determination.
One technical assistant performs 1100 assays per year.
91.2
46.50 DM
+ 39.00 DM
85.50 DM
3.90 DM
5.75 DM
94.15 DM
min/investigation
technical assistant/investigation
academicsupervision/investigation
personel costs/investigation
apparatus costs/investigation
reagent costs/investigation
total cost/investigation
Tab. 8. The cost of one determination by manual radioimmu-
noassay. One technical assistant performs 12330 assays
per year.
8.1 min/investigation
3.82 DM technical assistant/investigation
H- 0.41 DM academicsupervision/investigation
4.23 DM personel costs/investigation
0.20 DM apparatus costs/investigation
3.00 DM reagent costs/investigation
7.43 DM total cost/investigation
Tab. 10. Average cost of a gas chromatographic-mass spectro-
photometric determination.
One technical assistant performs 800 assays per year.
125.4 min/investigation
63.95 DM technical assistant/investigation
+ 39.00 DM academic supervision/investigation
102.95 DM personel costs/investigation
106.25 DM apparatus costs/investigation
5.75 DM reagent costs/investigation
214.95 DM total cost/investigation
(figures for 1983)
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Automated Flow-Cytometric Identification of Colo-Rectal Tumour Cells
by Simultaneous DNA, CEA-Antibody and Cell Volume Measurements1)
By C. Valet, L. Rüssmann
Max-Planck-Institut ßr Biochemie, Martinsried, FRG and
R. Wirsching
Chirurgische Klinik Großhadern der Universität München, München, FRG
(Received April 25/September 25, 1984)
Summary: A new method for the automated flow-cytometric identification of colo-rectal tumour cells was
developed. Fresh tissue is cut mechanically to obtain single cell suspensions. The cells are then incubated with
antibodies in an indirect immunofluorescence assay for CEA (carcino-embryonic antigen) on the cell surface,
and counterstained with the DNA stain propidium iodide. Monosized latex particles are added äs internal
Standard, then cell volume, antibody fluorescence and DNA are measured simultaneously in a FLUVO-
METRICELL flow cytometer. A FORTRAN IV Computer program was used to determine whether aneu-
ploid cells or cells with high density of CEA on their surface were present in the sample. All relevant data
were stored automatically in a seif updating data base, which is important for quality control and automated
thresholding. The samples were taken from 120 different patients. A tumour sample and a sample of healthy
adjacent mucosa of the same patient were available in 88 patients. 97.5% of all tumours and 88.6% of the
normal mucosa samples were correctly identified. This shows for the first time that the majority of colo-rectal
tumour samples can be identified by a flow cytometric measurement with automated data evaluation. The
identification of tumour samples was substantially better when based on the measurement of the three pa-
rameters, compared with identification by aneuploidy (59%) or by the CEA antibody alone (91%). It will be
possible to automate the measurement of the samples.
Automatische Identifizierung colo-rektaler Tumorzellen mit Hilfe simultaner durchflußcytometrischer Messung
von DNA, CEA-Antikörpern und Zellvolumen
Zusammenfassung: Es wurde eine neue Methode für die automatisierte durchflußcytometrische Identifizie-
rung colp-rektaler Tumoren entwickelt. Sie besteht aus der mechanischen Zerkleinerung frischen Gewebes
zur Eiiizelzellsuspension, Inkubation der Zellen mit Antikörpern in einem indirekten Immunfluoreszenzan-
satz für ZelloberflächemCEA (carcino-embryonales Antigen), Gegenfärbung mit dem DNA-Farbstoff Pro-
pidium-Iodid, Zusatz rnoriodisperser Latex-Partikel als internem Standard und simultaner Messung von Zell-
volumen^ Antikörper Fluoreszenz und DNA-Fluoreszenz jeder Zelle in einem FLUVO-METRICELL
Durchflußcytometer. Mit einem FORTRAN IV Computer-Programm wurde bestimmt, ob in der Probe
aneuploide Zellen oder Zellen mit hoher CEA Packungsdichte auf der Zellmembran vorhanden waren. Alle
relevanten Daten der Auswertung wurden automatisch in einer selbstergänzenden Datei abgelegt, was für die
Qualitätskontrolle und die automatische Schwellensetzung von Wichtigkeit ist. Es wurden Proben von 120
verschiedenen Patienten untersucht. Von 88 Patienten waren sowohl eine Tumorprobe als auch eine Probe
der umgebenden, gesunden Darmschleimhaut verfügbar. 97,5% der Tumoren und 88,6% der normalen Mu-
cosa-Proben wurden richtig identifiziert. Dieses Ergebnis zeigt erstmals, daß die Mehrheit colo-rektaler Tu-
moren mit durchflußcytometrischer Messung und automatischer Datenauswertung identifiziert werden kön-
!) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
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nen. Die Identifizierung der Tumorproben durch die Dreiparametermessung war wesentlich besser als durch
Aneuploidie (59%) oder CEA-Antikörper (91%) allein. Die Probenmessung kann in der Zukunft ebenfalls
automatisiert werden.
Introduction
The correct identification and characterization of
malignant and premalignant cells in smears, effu-
sions or biopsy material is of great importance for
tumour diagnosis, therapy and prognosis. The recent
advances in flow cytometric Instrumentation, the use
of microprocessor technology (1), development of
flow chambers for automated Instruments (2), new
staining techniques for the measurement of function-
al cell parameters in living cells (3—5) and the in-
creasing number of monoclonal and conventional
antisera produced against tumour-associated cell
surface antigens open new possibilities for an auto-
mated identification of tumour cells by flow cytome-
try. The reexpression of onco-developmental anti-
gens on tumour cells e. g. carcino-embryonic antigen
(CEA) (6, 7) or ct-foetoprotein (AFP) is of particu-
lar interest, because these antigens are biochemically
well characterized. The determination of serum
CEA-levels for the recognition of tumour relapses is
an established clinical procedure (8), and potent an-
tisera are available for this purpose. CEA is secreted
by tumour cells and its cellular location can be dem-
onstrated by immune histology using fluorescein-iso-
thiocyanate (FITC) or peroxidase coupled antibo-
dies (9,10). Although serum CEA is often increased
in gastrointestinal tumours, an increase is not seen
for all tumours (8). Furthermore, elevated CEA lev-
els may occur in e.g. smokers or during inflammato-
ry disease without the presence of a tumour. CEA is,
therefore, not an absolute tumour marker (7, 8). Hi-
therto, the measurement of FITC-antibody-labeled
cells in flow cytometers and cell sorters has been per-
formed mainly in connection with immunological
studies for the identification of cellular subpopula-
tions of the immune System. There has been little
work on the determination of CEA-antigen in single
cell suspensions of solid tumours, due to difficulties
of tissue desintegration and preservation of the anti-
genic determinants on the cell surface.
In addition to changes of the cell surface antigen
pattern, malignant transformation is often associated
with chromosomal aberrations resulting in measura-
ble cellular aneuploidy. The flow-cytometric mea-
surement of DNA distribution curves has become a
routine procedure during the last decade (11—14).
Although cellular DNA-aneuploidy is a good indica-
tor of malignancy, it is not very useful on its own for
cancer prescreening purposes, because not all tum-
ours are aneuploid.
Few reports are available on combined DNA-immu-
nofluorescence measurements for tufmour cell recog-
nition. We have shown in an earlier investigation
(15) that the simultaneous flow cytometric measure-
ment of DNA, CEA-immunofhiorescence and cell
volume is a fast and sensitive method for identifyiftg
cervix uteri cancer cells in suspensions. The purpose
of this study was to extend this work to gastro-intes-
tinal tumours. The study was also undertaken to ex-
plore the conditions for the automation of sample
measurement and data evaluation.
Material and Methods
Cells
Between 0.05 to 0.5 g tumpur tissue was removed from malignant
colo-rectal tumours immediately after surgery. Tumours from 120
sequentially operated patients,
Dukes stage (16) A: 20.1%,
B: 34.1%,
C: 34.1%,
D: 11.7%;
histological grading (17):
2.5% well differentiated adenocarcinoma (I);
72.5% moderately differentiated (II);
13.3% moderately to poorly differentiated (II-III);
11.7% poorly differentiated (III).
A second tissue sample of similar size was taken from the healthy
adjacent intestinal mucosa of the same patient. Both samples were
immersed in a 0.15 mol/1 NaCl solution, buffered with 10 mmol/1
Tris/HCl to pH 7.35 (Tris buffered saline), cooled to 0 °C in an ice
bath and kept at 0—4 °C during the foliowing procedure until cell
fixation. The samples were separately minced once with a Mcll*
wain electric tissue chopper (The Mickle Comp., Gomshall, Eng-
land). The chopper was modified so that five parallel razor blades
with 0.8 mm spacing were used äs the cutting knife instead of the
one blade provided by the manufacturer. The chopped tissue was
taken up in 10 ml Tris buffered saline containing 10 mmol/1 ED-
TA in a 50 ml plastic Falcon tube with cohical bottom (Becton
Dickinson, Heidelberg, FRG). The Suspension with the sinall
tissue pieces was quickly sucked 30 to 50 times back and forth in a
l ml Eppendorf pipette (Eppendorf, Hamburg, FRG) without
producing aif bubbles. The disposable plastic tip of the pipette
was cut for this purpose at the bottom to obtain an opening of 0.5
or l mm in diameter in order to let the tissue pieces just freely
pass. The cell Suspension was filtered through a V2A-steel sieve
of 60 mesh width, washed twice by centrifugation in 50 ml Tris
buffered saline at 300 g and resuspended in Tris buffered saline at
a cell concentration of 5 x lOVml. The majority of the cell sus-
pension was fixed at 0 °C for 12 h by addition of an equal amount
of a freshly prepared formaldehyde solution (35 g/l Tris buffered
saline adjusted to pH 7.35). For immunofluorescence staining, the
fixed cells were washed twice with 50 ml Tris buffered saline to
eliminate the formaldehyde and resuspended at a cell concentra-
tion of 5 x 107/ml in Tris buffered saline containing 15 g/l bovine
serum albumin and 40 mg/1 of propodium iodide (Sigma Cheml·
cals, Munich, FRG) to stain the cellular DNA. The remaining all·
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quot of fresh cells was centrifuged for 5 min at 300 g, resuspended
to the original cell concentration in albumin/Tris buffered saline
and stained according to the same protocol s fixed cells. 85% of
the samples were stained s fixed cells and the remainder s fresh,
unfixed cell preparation.
Jmmunof luo re sccnce
Aliquots (50 μ!) of fixed or vital cell Suspension were incubated
for 12 h at 0°C in 96 well microtiter plates (250 μΐ welis), either
with 10 μΐ of an antibody dilution in albumin/Tris buffered saline
or with albumin/Tris buffered saline alone s a control. Diluted
(1/100) mouse monoclonal anti-CEA antibody (Hybritech, Pae-
sel, Frankfurt, FRG. l g/l IgG), or diluted (1/100) rabbit-anti-
CEA monospecific antiserum (DAKO, Hamburg, FRG) ren-
dered free of anti-NCA (non specific cross reacting antigen) an-
tibodies by absorption with human spieen and Jung tissue (serum
kindly provided by Dr. Lamerz, Klinikum Gro hadern, Munich,
FRG, 5.3 g/l IgG) were used to detect cell surface CEA. The
assays were washed twice by centrifugation (10 min, 300g) with
200 μΐ albumin/Tris buffered saline and reincubated with either a
fluoresceine isothiocyanate (FITC)-labelled rabbit-anti-mouse or
a FITC-labelled goat-antirabbit IgG (bolh antisera: Paesel,
Frankfurt, FRG, 10 g/l IgG, fluoresceine/protein ratio 3.71
(mg/g) and 12.0 g/1 IgG, fluoresceine/protein ratio 3.95 (mg/g))
for another 12h at 0°C. Both antisera were 1/40 diluted with
albumin/Tris buffered saline. The cells were washed twice with
albumin/Tris buffered saline and finally resuspended in 200 μΐ
Tris buffered saline containing 40 mg/1 propidium iodide. Resus-
pension of the cells after each wash was effected by a Titertek
Vibration mixer (Flow-Laboratories, Gro meckenheim, FRG). A
sample (5 μΐ) of porous, NHa group-containing, monosized (6 μπι
diam.) latex particles (kindly provided by Prof. J. Ugelstad, SIN-
TEF and University of Trondheim, Norway) were prestained with
FITC and added at a final concentration of 2.5 x 105/ml to each
assay s internal Standard.
Flow-cytometr ic measurement
The cell volume and the green FITC and the red propidium iodide
fluorescence of the double stained cells were determined in a
FLUVO-METRICELL flow cytometer (18). The volume of each
cell was measured electrically at a current of 0.47 mA in a Tris
buffered saline-filled measuring chamber at 22 °C after hydrody^
namic focusing of the sample beam through the center of a cylin-
drical orifice of 85 μιη diameter and 100 μϊη length. The fluores-
cence was excited by epi-Illumination with UV light between 418
and 500 nm from a HBO-100 high pressure mercury arc lamp,
after the cell had left the sizing orifice. The red and green fluores-
cences were separated by a 530 nm dichroic mirror. The green
FITC-fluorescence was collected between 500 and 530 nm and
the red propidium iodide fluorescence between 550 and 650 nm.
The maximum height of each Signal was amplified by a 2.5 decade
logarithmic amplifier for the cell volume signal and by linear am-
plifiers for the FITC and propidium iodide Signals. The amplified
signals of each cell were stored in list mode on magnetic tape and
subsequently analysed by FORTRAN IV Computer programs de-
scribed in part earlier (19). The analysis consisted of the calcula-
tion and plot f three one parameter distribution curves (cell vo-
lume, FITC-antibody and propidium iodide-DNA distribution)
(figs. l, 2), a two parameter FITC-antibody versus propidium io-
dide-DNA histogram (fig. 4) and a three dimensional cube for vis-
ual inspection (fig. 3). The total data evaluation was recently au-
tomated. After completion of the measurements, the user only
types the word "ANTIGEN" in the Computer (INTERDATA 7/
32, Perkin Eimer, Oceanport, NJ, USA, 768 kbyte core memory,
200 Mbyte disc, magnetic tape, electfostatic plotter, graphic dis-
play) which Starts a command-file where all calculation proce-
dures are defined. The user obtains the above mentioned graphs
and a data list for each sample. The data list contains the number
of antigen positive cells, the mean antigen surface density per cell
and the aneuploidy index. The antigen positive cells are the cells
beyond a threshold in the FITC-antibody versus propidium io-
dide-DNA histogram (fig. 4a, b). The antigen surface density of
the antigen positive cells was calculated for each cell from the cell
volume and the intensity of the FITC-antibody fluorescence, as-
suming a spheroid shape of the cell. To determine the aneuploidy
index l (AN1), the product of % cells in S+G2/M phase times
their mean DNA-fluorescence was divided by the product of %
cells in Go/Gi phase times their mean DNA-fluorcscence. The
aneuploidy index 2 (AN2) was calculated, when a sample of nor-
mal mucosa from the same patient was also available. AN2 is the
ratio of AN1 of the tumour divided by AN1 of the mucosa. AN2
was a very sensitive indicator of abnormalities because it indicated
minor differences between tumour and mucosa. A sample was
judged aneuploid above an AN l or AN2 of 1.2. All calculated
data were automatically stored in a seif updating data base which
was installed for long time quality control and automated optima-
tion of the decision thresholds. A cell sample was automatically
judged malignant by the Computer classifier program either when
it was aneuploid or when the surface density of CEA-positive cells
exceded the normal r nge.
Results
The identification of samples containing tumour cells
was easily possible when aneuploid cells were pres-
ent. They were visible s a separate peak (fig. l a)
which did not occur in cell samples from the healthy
adjacent mucosa (fig. Ib). 71 out of 120 malignant
tumour samples (59%) were aneuploid with DNA-
indices mostly in the hyperdiploid region (1.15—
1.90).
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Fig. 1. DNA distribution curve.
a) of an aneuploid human rectuin cancer cell sample.
Number of particles measured: 3401.
Maximal frequency: 394.
b) of the adjacent healthy mucosa.
Number of particles measured: 8870.
Maximal frequency: 2243.
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The Identification of euploid tumour cells was not
possible with one-parameter measurements alone.
This is apparent from figure 2 where the DNA distri-
bution (fig. 2a, b), the antibody distribution (fig. 2c,
d) and the volume distribution curves (fig. 2d, e) of
cells of the tumour (fig. 2a, c, d) and the normal mu-
cosa (fig. 2b, d, e) of a patient with a euploid tumour
are shown. All curves begin with an exponentially
decreasing background in the left part. The respec-
tive curves of tumour sample and normal mucosa
were quite similar. The shape of the diploid peak of
the DNA distributions (fig. 2a, b) was broad with
coefficients of Variation (CV = 100 · Standard devia-
tion/mean value) in the order of 8 to 10%. The CV
of the DNA distribution curves was lower (6 to 8%)
for fresh cells. The high CV's were due to the intesti-
nal cells and to formaldehyde fixation, but not to in-
strumental Variation because CV's of 1.5 to 1.9%
were obtained for ethanol-fixed rat thymocytes.
Ethanol fixation caused, however, celi clumping.
The diploid peaks of the DNA distribution curves
were often left skewed after formaldehyde fixation
because the large epithelial cells stained slightly
higher with propidium iodide s compared to the
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Fig. 2. DNA, FITC-antibody and cell volume distribution of an euploid colon cancer (left) and of the adjacent healthy mucosa (right).
All three curves begin with an exponentially decreasing experimental background on the left side of the plot. It is most pro-
nounced in the antibody (c, d) and cell volume distribution (fig. 3e, f).
Between 10600 and 18700 cells per curve were measured.
a) DNA, euploid colon cancer; maximal frequency 1906.
b) DNA, adjacent healthy mucosa; maximal frequency 1547.
c) FITC-antibody, euploid colon cancer; maximal frequency 6286.
d) FITC-antibody, adjacent healthy mucosa; maximal frequency, 9496.
e) Cell volume, euploid colon cancer; maximal frequency 2969. One class on the logarithmic volume scale corresponds to 30 fl.
f) Cell volume, adjacent healthy mucosa; maximal frequency 3120.
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small inflammatory leukocytes. The left skew is vis-
ible in figure 2a, b. Since the identification of euploid
tumour cells by the one parameter measurements of
figure 2 was not possible one could conclude that
flow cytometry is not a suitable method for this pur-
pose.
This was, however, not true, when a simultaneous
measurement of the same three parameters was per-
formed. The measurement resolved additional fea-
tures of the different cell populations (fig. 3a, b).
The three parameter measurement distinguishes be-
tween cell debris and morphologically intact cells.
Only particles with DNA and volume are morpho-
logically intact cells. Cell debris i.e. enucleated celis
or broken cells give rise to volume Signals but not to
DNA signals, and bare nuclei show DNA Signals but
only very small volume Signals which do not appear
on the volume scale. Cell debris is significantly pres-
ent in the tumour sample (fig. 3a) and also in the
normal mucosa sample (fig. 3b). Intact, antigen posi-
tive cells are visible amongst the cells with large vo-
lume in the tumour sample (fig. 3a). This is reasona-
ble because tumour cells occur amongst the large
epithelial cells. Some CEA-antigen positive cells
were also present in the normal mucosa sample of
the same patient (fig. 3b). The intact inflammatory
cells at the lower edge of the volume scale are not
antigen positive, indicating that the antiserum is free
of granulocytes that react with NCA-antibodies. The
cluster of calibration particles is also visible. It is sit-
uated where no interference with stained cells oc-
curs. The particles serve äs internal Standard for the
calculation of the cell concentration. They are also
useful for checking Instrument function with regard
to cell volume and fluorescence. They allow a precise
recalibration of the Instrument from day to day,
which is important in automated Operation for main-
taining Standard thresholds over a long period of
time. The cube display is useful for a quick visual
judgment of the three parameter measurement, but
not suitable for quantitative evaluation. The quantit-
ative evaluation is performed on two parameter his-
tograms obtained by projecting the content of the
cube onto the antibody versus DNA plane (fig. 4a,
b). The calibration particles were not projected to
simplify the distributions. The solid lines of the
graph separate the area of antigen negative and anti-
gen positive cells used by the Computer program for
the calculation of cell parameters. The substantial
amount of cell debris which is strongly positive for
the CEA-antibody is again visible. The quantitation
would be significantly influenced if the debris were
not distinguished from the intact cells by the DNA
stain of the cell nuclei. The evaluation of the tumour
samples and of the normal mucosa cells of two pa-
tients (figs. l and 2, 3) is given in table 1. The aneu-
ploidy of the tumour sample of the first patient is
31 26 21 16 11 6
Antibody [arb.UJ
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Fig, 3. Three dimensional representation of a simultaneous cell volume, DNA and CEA-antibody measurement of colon cancer ceils (a)
and cells of the adjacent healthy mucosa (b). The cells are derived from the same samples äs those represcntcd in the one
parameter distribution curves of figure 2. The increased number of morphologically intact CEA-positive cells in the tumour cell
sample (a) is visible. The contour lines surround the areas where particles and cells are located. The channcl contenis are
standardized to the maximum logarithmic channel content and plotted for the 10% levcl. Channels with 2 and 3 cells are already
contoured which means that the location of most of the measured cells is indicated. The calibration particles are uscd äs internal
concentration Standard and also for day to day standardisation of the fluorescence measurement. One class on the logarithmic
volume scale corresponds to 30 fl. 19419 (a) and 11948 particles (b) were measured. The maximum channel Contents are 256 and
245 particles respectively. GO/G1, S and G2/M represent the cell cyclc phases.
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Fig. 4. CEA-antibody versus DNA histogram of colon cancer cells (a) and cells of the adjacent healthy mucosa (b). The graphs were
obtained by projecting the respective cube diagrams of figure 3 onto the antibody/DNA plane. The solid lines represent the areas
used for the Computer evaluation. To the left is the antibody negative and to the right the antibody positive compartment. 16.1%
CEA positive cells were found in the tumour sample and 7.9% in the normal mucosa. The graphs were standardized to the
maximum logarithmic channel content and contour lines are plotted in 10% linear increments. To simplify the calculation of
antibody positive cells the calibration particles of figure 3 were not projected onto the antibody/DNA plane. 18574 (a) and 10665
particles (b) were measured. The maximum channel Contents are 523 and 395 particles respectively.
Tab. 1. Calculated parameters from simultaneous CEA-anti-
body, DNA and cell volume measurement of samples
from an aneuploid (fig. 1) and an euploid colo-rectal
tumour (fig. 2 to fig. 4).
Aneuploid
Rectum carcinoma
Normal mucosa
Euploid
Colon carcinoma
Normal mucosa
CEA-
positive
cells (%)
15.13
4.24
16.12
7.89
Relative
antigen
density
0.653
0.406
0.759
0.389
Aneu-
ploidy
index 1
1.35
0.36
0.842
0.840
Aneu-
ploidy
index 2
3.75
1.00
correctly recognized by the AN2 (>1.2). The
number of antigen positive cells is abnormally high
in both patients and the mean antigen density/cell is
substantially increased in the tumour samples. A to-
tal of 120 patients with colo-rectal tumours and 88
normal mucosa samples from the same patients have
been screened so far by this method. All samples
were measurable. The lower number of mucosa sam-
ples is due to the fact that some of the tumours were
taken from patients prior to cryotherapy without a
normal mucosa sample. Also included in the tumour
cases are 11 patients from which only metastatie
lymph-node material was obtained by abdominal
surgery. The mean antigen density on the antigen
positive cells of most tumour samples was higher
than on the antigen positive cells of the adjacent nor-
mal mucosa. 109 (91%) of the tumors were recog-
nized by the CEA-antibody alone. Of the remaining
11 tumours, 8 were aneuploid and thus could be ad-
ditionally identified. 3 tumours i.e. 2.5% of all tum-
ours were not recognized. The metastatie cells be-
haved similarly to the tumours. Table 2 contäiiis the
quantitative vaiues. The conventional anti-CEA
Tab. 2. Flow-cytometric classification of colorectal tumour and
mucosa cells by CEA-antibodies and DNA-aneuploidy.
Aneuploidy +
% CEA-positive
cells
Aneuploidy +
rel. CEA-äntigen
surf ace density
Monospecific
DAKO-antibody
Tumour Mucosa
FN(%) FP(%)
8.3 13.7
2.5 11.4
Monoclonal
Hybritech
antibody *
Tumour Mucosa
FN(%) FP(%)
6.1 27.5
4.9 18.3
FN = false negative (n = 120 tumour samples)
FP = false positive (n = 88 mucosa säniples)
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Fig. 5. Mean CEA density on colorectal tumour, mucosa and
metastatic cells. The closed Symbols represent euploid
samples, the open Symbols aneuploid tumours. With a
fixed borderline at a relative density of 0.45, a fraction of
0.025 of the tumours are false negative and a fraction of
0.114 of the mucosa samples are false positive. For the
metastases similar results äs for the tumours are obtained.
antibody recognized the cells better than the mono-
clonal antibody. It is important to note that the re-
cognition of the tumour cell-containing samples was
substantially better if the antigen density on the anti-
gen positive cells was compared instead of the
number of antigen positive cells alone. Altogether
the flow-cytometric method identified correctly
97.5% of the tumours and 88.6% of the mucosa
samples in a fully automated way.
Discussion
The most important fesult of this study is that more
than 95% pf tumour samples were correctly recog-
nized by an automated flow-cytometric evaluation
method. TO oür knowledge it is the. first time that
this has been possible. Most flow-cytometric work
has been döne, so far, on the aneuploidy of tumours.
The search for aneuploidy alone is, however, not suf-
ficient for patient screening, since not all tumours
are detectably aneuploid (11-14). 59% of the tuni-
ours in the present study were aneuploid. This result
compares well with values between 50% and 78%
given by other investigators (20-22). The measure-
ment of additional cell parameters, such äs light scat-
ter and cellular protein (23, 24, 25) do not improve
the results very much, because these parameters are
not tumour-specific enough.
In the present approach, the first two parameters
(cell volume and DNA) were used to identify aneu-
ploid cells, to distinguish the morphologically intact
cells from cell debris, and to separate the large
epithelial cell compartment with the carcinoma cells
(fig. 3a, b) from the small inflammatory cells (lymr
phocytes, granulocytes). The third parameter, the
CEA-antigen of the morphologically intact cells, is
important for the recognition of euploid tumour
cells. CEA is expressed to a certain extent on normal
mucosa cells, mainly on the brush borders, äs re-
vealed by light microscopic examination. Although
not strictly tumour-specific, the fluorescence Signals
of the CEA-antibodies shift a significant number of
tumour cells into an area of the three parameter
cube (fig. 3a, b), where not many cells are located in
cases of normal mucosa samples. The cell volume
served for calculation of the mean antibody packing
density on the cell surface. This is an important as-
pect of the volume measurement since the cell is
used äs a minicuvette to obtain standardized data.
The validity of such calculations was shown earlier
when the electrical Charge density on the cell surface
of erythrocytes could be correctly predicted by a
flow-cytometric measurement (26). It is evident that
the simultaneous three parameter measurement of-
fers substantial advantages over one or two parame-
ter measurement.
It can be argued that this method, although superior
to other flow cytometric methods is still worse than
the normal histo-pathological examination of colo-
rectal tissue sections. This is true at the present time
but there are possibilities of improvement. As in the
case of the CEA and epithelial membrane antigen
(EMA), which are independently expressed on cer-
vix tumour cells (15), it is possible to test antibodies
against other tumour associated antigens on colo-
rectal tumour cells (27) for the detection of the re-
maining 2.5% false negative tumour samples. The
automation of a diagnostic flow cytometric proce-
dure is substantially easier than the automated re-
cognition of cancer cells from histological or cytolog-
ical specimens by Computer image analysis. It seems,
therefore, of particular interest to further pursue the
flow cytometric approach.
There is the practical question of whether automated
analytical flow cytometers with automated evalua-
tion can be developed for routine clinical and re-
search application. The Operation of a flow cytome-
ter at the present time is comparatively complicated
and slow, and typically between 5 and 10 min are
required to measure and change a cell sample. The
purpose of recent microprocessor (1) and measur-
ing-chamber (2) development was to increase the
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speed (30 to 60 s/sample) and simplify the Operation
of flow cytometers. An important requirement for
automation are monosized calibration particles of
suitable size, which became available only recently
(28). They can be used äs internal Standard for cell
concentration but also for the continuous monitoring
of the correct sample flow by the microprocessor da-
ta analysis System. The Software was adapted for au-
tomated Operation. The relevant pararneters of each
measurement are automatically stored in a data bank
file which assures the long term stability of the mea-
surements. It will be possible to use automated flow
cytometers in the same way äs äs photometers, thus
greatly extending the possibilities for cellular work.
In addition to the identification of tumour cells it is,
for example, of interest to count blood cells and to
determine simultaneously their functional state (29),
to measure cellular assays for cytostatic drug testing
on patient tumour cells (30), to partially differen-
tiate bone marrow aspirates (31) and to measüre ra-
diation damage in bone marrow and blood samples
for biological radiation dosimetry (32). Fully mi-
croprocessor-controlled flow cytometers are com-
paratively cheap and will also be accessible to small-
er hospitals and to specialized private praetice.
Although the prospects for a broatjier application of
flow-cytometry in diagnostic medicine are substan-
tially increasing at the present time^ it is obvious that
one is still at the beginning of a development, Much
further work is needed to elaborate a spectrum of
diagnostic methods for cells, comparable to the large
number of common clinical chemistry assays. Des-
pite the improvements one has to see the lirnitations
of the method. The tissue architecture has to be de-
stroyed for the preparation of single cell süspensions.
Flow cytometry can, therefore, not replace the histo-
pathological examination. Nevertheless, the possibil-
ity of performing fast and quantitative biochemistry
in singie cells is of great interest for the characteriza-
tion of the alterations of cell metabolism in disease.
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Summary: The paper presented deals with the general potentialities of the immunological determination of
enzymes, using selected examples to describe the most important variants of the immunoassay for clinical
chemical enzyme diagnostics. The principle of each test and the respective possibilities of interference are
described. The analytical efficiency and applicabilities of these immunoassays are assessed critically.
Immunologische Verfahren in der klinischen Enzymdiagnostik,
Zusammenfassung: Die vorliegende Arbeit geht auf die grundsätzlichen Möglichkeiten der immunologischen
Bestimmung von Enzymen ein und stellt an ausgewählten Beispielen die für die klinisch-chemische Enzym-
diagnostik wichtigsten Varianten des Immunoassays dar. Neben einer Beschreibung des jeweiligen Testprin-
zips und seiner Störmöglichkeiten werden die analytische Leistungsfähigkeit und die Anwendungsmöglichkei-
ten dieser Immunoassays kritisch beurteilt.
Introduciion
Up to now the immunoassay has played only a sub-
ordinate role in enzyme diagnostics in the clinical
chemical laboratory; here the "classical" photomet-
ric test, which determines an enzyme purely by
virtue of its functipn, i.e. its catalytic activity, still
dominates.
The immunological determination of enzymes,
isoenzymes, proenzymes and enzyme complexes2) is
however growing increasingly attractive, particularly
for the clinical läboratory, due to methodical and
technical advances in the field of the immunoassay
(e.g. non-radioactive labels, monoclonal antibo-
dies). It is most likely that in the future it will not
only replace some of the traditional methods, but al-
so lead to a considerable broadening of the diagnos-
tic spectrum.
Enzymes äs Antigens
Due to their protein structure, enzymes represent
the prototype of a multivalent antigen. As specific
anti-enzyme antibodies react with exactly defined
antigenic determinants (epitopes) on the surface of
the enzyme molecules, any change in the enzyme
conformation, which includes these epitopes, can
lead to a change in the antigenicity of the enzyme.
Structurally modified enzymes do not only provoke a
qualitatively different immune response in the test
animal, but they also react differently in the immu-
noassay.
Frequently, antisera which have been obtained by
means of immunization with a particular enzyme al-
so react with Structurally similar or related enzyme
forms. Such cross reactions are known to occur with
proenzymes (1), aged enzymes (2) and enzymatically
!) Presented at the Kleinkonferenz „Immunologische Diagnostik** der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
?) Detailed specialized literature is available on request dir;ectly from the authors.
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silent products of mutated structure genes ("silent
genes") (3, 4).
Polyclonal and Monoclonal Anti-Enzyme Antibo-
dies
Even if a highly purified enzyme or isoenzyme is
available äs an antigen, immunization leads to the
formation of anti-enzyme antibodies of varying spe-
cificity and affinity. The quality of these convention-
al i. e. polyclonal antisera can however be improved
either by enriching the specific antibodies through
affinity chromatography or by removing the unspe-
cific antibodies by means of immune absorption, äs
shown in the example of a polyclonal antiserum di-
rected against the intestinal isoenzyme of alkaline
phosphatase (5).
Monoclonal antisera (6) were introduced for the
decisive improvement of the specificity of immuno-
logical enzyme assay. It was shown that monoclonal
antibodies are even able to differentiate clearly be-
tween the very similar allelozymes of alkaline phos-
phatase from human placenta (7, 8).
Competitive or Non-Competitive Immunoassay
A polyclonal antiserum is best suited for competitive
assays such äs the classical radioimmunoassay
(RIA), äs antiserum is diluted to such a high degree
in these assays, that only the highly affine i. e. specif-
ic antibodies still react with the desired enzyme and
the concurrent reaction of unspecific antibodies is to
a large extent suppressed. In comparison, in the non-
competitive assays, (e.g. immunometric proce-
dures), which work under conditions of an antibody
excess, the risk of such undesired cross reactions is
considerably greater. It is therefore especially im-
portant here to use a qualitatively high-grade i.e.
purified polyclonal or monoclonal antiserum. In con-
trast to the RIA, a labelled enzyme Standard is not
needed for the non-competitive immunoassay. This
is a considerable advantage äs radio-iodination can
change the immunological reactivity of an enzyme to
a high degree. As was shown using the RIA for pros-
täte acid phosphatase for example, this principal
source of error can be overcome by the careful selec-
tion and control of the radio-iodination technique
(9).
Determination of Enzyme by Catalytic Activity or
by Mass
In the immune complex, the catalytic activity of an
enzyme can be maintained unaltered; however often
steric or allosteric effects lead to varying degrees of
Inhibition but also less frequently rto an increase in
enzyme activity. In which way and to what extent the
catalytic properties of an enzyme are changed by an
immune reaction depends primarily on the amount
and quality (e.g. specificity, affinity, polyclonal or
monoclonal) of the anti-enzyme antibody used. In
this connection it is also extremely important wheth-
er this antibody reacts with the enzyme in soluble
form or — äs in a solid-phase immunoassay — in an
imiiiobilized form. Moreover, the catalytic activity of
an antibody-bound enzyme can be influenced by the
size of the Substrate. It is known that söme enzymes
— after binding on the antibodies — convert sub-
strates less effectively, the larger the Substrate mo-
lecular weight becomes (10, 11). On the other hand,
enzymes can be inhibited in their activity coiisidera^·
bly more by pre-incubation with the antibody than
they are if reaction with the antibody does not occur
until after addition of the Substrate. Here the sub-
strate quasi "proteets" the enzyme from the effect of
the antibody (12, 13, 14).
The choice of the type of immunoassay to be used
for a particular enzyme depends firstly on the cata-
lytic activity or mass concentration of this enzyme
and cross-reacting antigens (e. g. isoenzymes) in the
material to be examined and secondly on the preci-
sion, speed and practicability required of the assay in
reaching its diagnostic objective. Immunoassays
which utilize the antigenic äs well äs the catalytic
properties of an enzyme for its quantification are
suitable for the assay of enzymes with easily measu-
rable activity. After reaction with the specific anti-
enzyme antibodies (Separation step) the enzyme is
detected via its own catalytic activity. Precipitation,
Inhibition and adsorption procedures can be distin-
guished with respect to the Separation techniques
used. For the measurement of inactive enzyme fornis
(e. g. proenzymes) these methods are just äs unsuita-
ble äs they are for enzymes which are quickly inacti-
vated in diagnostically relevant body fluids or whose
activity is difficult to measure for technical reasons.
Such enzymes can only be qüantified by means of
their antigenic properties, i.e. their protein mass.
For this purpose, besides the RIA, immiunometric
assays in particular come into coiisideration.
The most important types of immunoassay which
have proved successful in clinicai enzyme diagnostics
are listed in table 1. They are e^emplified and de-
J. Clin. Chem. Clin. Biochem. / Vol. 22, 1984 / No. 12
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scribed in more detail choosing creatine kinases and
phosphatases.
Modifications of the Immunoassay
Immunoprecipitation
In figure l the immunological differentiation of the
dimerous cytoplasmic creatine kinase isoenzymes by
means of precipitating antibodies is shown schemati-
cally. In the first step of the reaction, a specific an-
tiserum directed against the M subunit of the enzyme
precipitates the isoenzymes MM and MB. The isoen-
zyme BB remains in the supernatant after centrifu-
gation and can be measured by its catalytic activity.
After a second, separate precipitation with an anti-B
subunit antiserum, the activity of the creatine ki-
nase-MM is determined. The catalytic activity of the
hybrid isoenzyme MB can only be calculated ma-
thematically; it results from the subtraction of the
activity of both homomeric isoenzymes from the to-
tal creatine kinase activity (15, 16, 17).
The immunoprecipitation renders a selective and
quantitative isoenzyme determination possible, if
carried out with reliable antibody excess and if the
anti-M or anti-B subunit antisera used show no cross
reactions with the respective other enzyme subunit.
The sensitivity of this method depends on whether
the catalytic concentration of the isoenzyme is mea-
sured spectrophotometrically (lower detection limit:
approx. 3 U/l (25 °C)) or by bioluminescenee (lower
detection limit: approx. 0.3 U/l (25 °C)) (18, 19,
20).
As the creatine kinase isoenzymes are determined
indirectly, i. e. by means of the activity remaining in
the supernatant, the precision of the method is par-
ticularly unsatisfactory in the case of low enzyme ac-
tivity. Interferences in the immunoprecipitation can
be caused by the occurrence of macromolecular
creatine kinase variants in the serum (21). These are
not precipitated by the antisera (macro-creatine ki-
nase type 2) or are only partially precipitated (ma-
cro-creatine kinase type 1). They remain in the su-
pernatant and lead to false results.
Immunoinhibi t ion
By contrast to immunoprecipitation, for which sev-
eral hours are usually required, the immunoirihibi-
tion of enzyme catalytic activity takes only a few
minutes. The "CK-MB Inhibition test" utilizes this
effect (fig. 2). Within 5 minutes an excess of specific
DD
Fig. 2. Determination of the creatine kinase isoenzyme MB by
immunoinhibition (22). The catalytic activity of the M
subunits is selectively blocked by polyclonal goat antibo-
dies (ABi), creatine kinase-MB is detected by its residual
B subunit catalytic activity.
@: M subunit of creatine kinase (inhibited)
D: B subunit of creatine kinase (active).
1stStep 2^ Step
Fig. 1. Differentiation of creatine kinase isoenzymes by immunoprecipitation (17). Catalytic activities of the BB (first step) and MM
(second step) isoenzymes are measured in the supernatants; the catalytic concentration of isoenzyme MB can be calculated by the
formula:
MB[U/1] = Total creatine kinase [U/l] - (BB[U/I] + MM[U/1]).
O: M subunit of creatine kinase
D: B subunit of creatine kinase
ABr. Antibody specific for M subunit
AB2: Antibody specific for B subunit
J. Clin. Chem. Clin. Biochem. / Vol. 22,1984 / No. 12
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antibodies inhibits all creatine kinase M subunits
in a serum sample. The activity of the B subunit of
creatine kinase-MB remains virtually uninfluenced.
As the isoenzyme BB only very rarely occurs in
blood in spectrophotometrically measurable activity
(i.e. >3 U/l), this test enables the isoenzymes MM
and MB to be differentiated quickly aind easily. After
total Inhibition of creatine kinase-MM, creatine ki-
nase-MB can be detected by means of its still active
B subunit without a Separation stage (e.g. centrifu-
gation) (22). Monoclonal antibodies are also able to
inhibit the activity of the creatine kinase M subunit
selectively and totally, however they appear to pos-
sess no definite advantages over polyclonal antibo-
dies in immunoinhibition tests (23).
In the determination of creatine kinase-MB in the
immunoinhibition test, interferences, i. e. false posi-
tive results, are caused by macromolecular creatine
kinases äs is also the case with immunoprecipitation
and furthermore by increased creatine kinase-BB
activities (21). In spite of this disadvantage the im-
munoinhibition test was proved especially successfül
in cardiac infarction diagnosis due to its rapidity and
easy application (24, 25).
Catalytically inactive enzyme molecules are not de-
tectable with the immunoprecipitation and Inhibition
1:501:100 1:150 1:200 1:300
Antiserum dilution
1:500
Fig. 3. Displacement of active creatine kinase-MM from a specif-
ic anti-creatine kinase-M antibody by inactive creatine ki-
nase-MM. Creatine kinase-MM was inactivated at 37 °C
in a pH-controlled serum matrix (pH 7.4 ± 0.1). Varying
concentrations of inactivated creatine kinase-MM were
mixed with a stepwise diluted antiserum containing inhib-
iting anti-creatine kinase-M antibodies. The mixtures
were pre-incubated for 20 h at 4 °C followed by addition
of catalytically active creatine kinase-MM (520 U/l). Af-
ter a second incubation for 3 h at room temperature en-
zyme catalytic activities were measured in triplicates.
Y-axis: Ratio of residual to initial catalytic activity.
Molar ratio of inactive to active creatine kinase-MM:
O-O-O: 0.0 (active enzyme only)
O-O-O: 4.8
- - : 12.1
- - : 24.2
procedures; however if they occur in a high concen-
tration and cross react with the antiserum, they may
cause interferences in the immune reaction of active
enzymes. As is shown in figure 3, such cross reac-
tions, e. g. between inactive creatine kinase-MM and
inhibitirig anti-creatine kinase-M antibodies, can be
verified in the displacement experiment and their
order of magnitude estimated.
Immunoadsorption
The immunoadsorption assay comprises three reac-
tion stages: the binding of the desired enzyme by
specific antibodies, the subseqUent Separation of the
resulting enzyme-antibody-complexes and the final
quantification of the complex associated enzyme ac-
tivity. Only those antibodies are suitable which do
not inhibit (26, 27) or only slightly inhibit (28, 29)
the enzyme catalytic activity. Antibodies which lead
to a stabilization (30, 31) and/or reactivation or acti-
vation (32, 33) of the enzyme are especially desira-
ble for the detectiqn of catalytically unstable en-
zymes such äs acid phosphatase. The Separation of
the enzyme-antibody-complexes is carried out by
means of precipitation with ammonium sulphate
(34) or polyethylene glycol (35). After centrifuga-
tion aiid washing it is possible to resuspend the en-
zyme complexes and to measure their activity. Solid-
phase assays in which the enzyme is bound to immo-
bilized antibodies are methodically more refined
(fig-4).
The immunoadsörption test detects an enzyme di-
rectly and thus offers some considerable advantages
over the precipitation and Inhibition methods. In ad-
dition its sensitivity can be increased by augmenting
the volume of the test sample: the enzyme activity is
enriched by the immunoadsorbent before it is mea-
sured (29). The obligatory Separation Step offers ad-
ditional advantages. It eliminates all potential inter-
ference factors in the test matrix before the actual
enzyme determination and thus improves the speci-
ficity of the assay.
Immunoadsorption assays are distinguished by a
wide measuring ränge (28, 38, 39) and a remarkably
high analytical sensitivity. As is shown in the pros-
tate acid phosphatase tests, they are able tö measure
catalytic concentrations of less than 0.1 U/l. This
corresponds to the enzyme mass concentration also
considered to be the lowest detectiori limit for ra-
dioimmunological and immunometric procedures
(tab. 1). As the immunoadsorption test is always car-
ried out with an antibody excess, interferences can
be caused by unspecific antibodips if polyclonal an-
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Fig. 4. Solid-phase immunoadsorbent assays for prostatic acid phosphatase (a) or placental alkaline phosphatase (b) (36, 37). A polysty-
rene-attached polyclonal antibody (AB, ABi) reacts directly or mediated by a monoclonal antibody (ABi) with the appropriate
enzyme (E). The amount of immunoreactive phosphatase is determined by its catalytic activity in the immune complex.
S: Substrate
P: product of catalytic activity
tiserum is used. This principal disadvantage can
however be eliminated by the introduction of mo-
noclonal antibodies (fig. 4b).
Radioimmunoassay
Problems associated with the determination of the
concentration of enzymes can be seen from the de-
scription of radioimmunoassays used to detect crea-
tine kinase MB (tab. 1).
It is not possible to obtain isoenzyme specific anti-
creatine kinase antisera by traditionäl immunization,
but only those which are specifically directed against
B or M subunits of creatine kinase. For this reason
only creatine kinase-B RIAs (assaying BB and MB)
or creatine kinase-M RIAs (assaying MM and MB)
are available (24, 40-44). The possibilities of inter-
ference in a radioimmunological creatine kinase-MB
determination in human seruni are thus already
predetermined: the creatine kinase-M RIA is gener-
ally unsuitable due to its cross reaction with the crea-
tine kinase-MM which occurs in a concentration
about 10 times greater; the creatine kinase-B RIA
(fig. 5) will only be uiiaffected by physiological crea-
tine kinase-BB concentrations if the creatine kinase-
MB concentration to be measured is considerably
higher than BB, i.e. if MB is clearly within the pa-
thological ränge. Due to this insufßcient specificity a
creatine kinase-B RIA, in spite of its greater sensi-
tivity, is not äble to detect the increase of creatine
kinase-MB in the serum of an infarction patient ear-
lier than the immunoinhibition test.
Another deeisive disadvantage of the radioimmu-
noassay is the long tixne it requires. Especially in the
diagnostics, e.g. of an acute cardiac infarction, it will
00
Fig. 5. Detection of creatine kinase-MB by radioimmunoassay.
Labelled creatine kinase-BB and unlabelled creatine ki-
nase-MB compete for the binding sites of a limited
amount of an anti-creatine kinase-B antibody (AB).
O: M subunit of creatine kinase
D: B subunit of creatine kinase
I: I25l-labelled B subunit
hardly reflect the current clinical condition of the pa-
tient. The analytical sensitivity of most creatine ki-
nase-B RIAs lies in the ränge l to 5 §/1 (tab. 1). For
active creatine kinase-BB or -MB with a specific ac-
tivity of ^400 U/mg protein (45), radioimmunoas-
says of this kind have a lower detection limit of ^0.4
U/l. If a lower specific activity (e.g. 10 U/mg) is tak-
en äs the basis, a test sensitivity which is too high will
inevitably be simulated (46). Thus, although these
RIAs are 10 times äs sensitive äs the immunoinhibi-
tion, they are by no means more sensitive than lumi-
nometric creatine kinase-B assays (18, 19, 20).
An interesting variant is a radioimmunoassay which
works with creatine kinase-BB binding autoantibo-
dies, isolated from patients' serum containing these
autoantibodies (47, 48). These highly affine antibo-
J. Clin. Chem. Clin. Biochem. / Vol. 22,1984 / No. 12
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dies (association constants: 1.4 x l O111/mol) show
no cross reactions with the isoenzymes MB and MM
under test conditions even when they are present in a
l O4 or l O5 times greater concentration than creatine
kinase-BB. This unparalleled isoenzyme specific
creatine kinase RIA is remarkably sensitive (detec-
tion limit: l §/ creatine kinase-BB), but can only
detect catalytically active enzyme.
The detection of inactive enzyme forms would be
particularly important in the case of an unstable en-
zyme such äs creatine kinase BB, which has more-
over been assigned a tumour associated marker (49).
Although cross reactions have been observed with
products of in vivo and in vitro enzyme degradation
in some creatine kinase-B RIAs, up to the present all
pinpointed attempts to quantify inactive creatine ki-
nase-B protein in human serum with an immunoas-
say have failed (40, 43, 50). Here, the excessively
high concentrations (15—198 mg/1 (!)) of inactive
creatine kinase-B protein measured in the serum of
healthy persons appear to be very doubtful (51, 52).
Immunometr ic assay
For the immunometric procedure, two antisera are
needed. Their antibodies must be capable of reacting
with the different respective epitopes of the enzyme
to be detected without impeding each other sterically
in the process. The antibodies of one of the antisera
are immobilized and separate the enzyme in the test
sample. The antibodies of the second antiserum are
labelled (radio iodine (IRMA), marker enzyme
(ELISA)) and identify the enzyme.
DO
DO:
Fig. 6; Immunometric assay for creatine kinase-MB. In the lst
step immobilized anti-creatine kinase-B antibodies (ABi)
only bind the isoenzymes BB and MB. In the 2nd step the
isoenzyme MB is then specifically detected by a 125I-la-
belled (53), respectively peroxidase conjugated (54) anti-
creatine kinase-M antibody (AB2)
I: label
In figure 6 an immunometric creatine kiiiase-MB as-
say is represented. In a first reaction phase the isoen-
zymes MB and BB are bound to immobilized crea-
tine kinase-B antibodies. After a Separation or wash-
ing step they are separated from the remaining crea-
tine kinases in the serum (MM, .macromolecular
creatine kinases). In the second reaction phase the
differentiation of both the antibody associated isoen-
zymes occurs: only creatine kinase-MB can bind la-
belled creatine kinase-M antibodies.
Such an assay can be very specific and the creatine
kinase-MB in a serum sample can be measured with-
out interference even in the case of a 1000-fold mo-
lar excess of the isoenzymes BB and MM (55). How-
ever, with a detection limit of 10 g/l of enzyme pro-
tein, the assay does not match the sensitivity of the
radioimmunoassay (tab. 1), even though it is just äs
time and labour consuming. By shortening the reac-
tion times and dispensing with the Separation stage
between both reaction phases, the immunometric as-
say is made more acceptable for clinical require-
ments, but at the same time, its änalytical specificity
and sensitivity are reduced (56). The extent to which
the introduction of monoclonal creatine kinase-B
and creatine kinase-M antibodies (57—59) is able to
overcome the weaknesses of the immunometric as-
say has yet to be clarified through further investiga-
tion.
Perspectives
The trend in clinical enzyme diagnostics away from
the "indirect" assay (e.g. immunoprecipitation) to-
wards the "direct" assay (e.g. immunoadsorption)
will continue and lead to a further improvement in
the specificity and sensitivity of immunological en-
zyme assays. For the same reasons the non-competi-
tive immunometric methods will replace the classical
competitive irnmunoassay.
The use of monoclonal antibodies should play a deci-
sive role in both these developments. Monoclonal
antibodies represent a defined homogeneous reagent
in terms of epitope, affinity and reactivity, which is
available in virtually unlimited quantities. Thus new
perspectives are being opened up for the standardi-
zation and application (e.g. differentiation of post-
synthetically altered and inactive enzyme forins) of
immunological enzyme tests. In the case of acute ill-
ness, such äs an acute myocardial infarctio», the
diagnosis has to be carried out under emergency
conditions. In addition to a quick and practicable
creatine kinase-MB test with limited specificity (im-
munoinhibition), highly specific, b t möre tiime and
J, Clin, Chem. Clin. Biochem. / Vol. 22, 1984 / No. 12
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labour consuming assays (tab. 1) are at present
available. It remains to be seen whether this dilem-
ma can be resolved by an acceleration of immune
reactions by means of sonication (acceleration factor
> 100(!)), äs has been demonstrated just recently
'{60).
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Summary: The introduction of immunohistochemical methods into pathological diagnostics has opened new
possibilities for combining the specificity of immunological methods with the selectivity of morphological
techniques. This considerable expansion of diagnostic possibilities has occurred since the introduction of
monoclonal antibodies. The basic conditions of immunohistochemical reactions (fixation, embedding), funda-
mental differences between the use of monoclonal antibodies and that of polyclonal antisera and possibilities
for increasing the sensitivity of diagnoses are discussed and illustrated by practical examples.
Immunhistochemische Methoden: Ihre Anwendung und Probleme
Zusammenfassung: Die Einführung immunhistochemischer Methoden in die diagnostische Pathologie hat
neue Möglichkeiten für die Kombination der Spezifität immunologischer Methoden mit der Selektivität mor-
phologischer Techniken eröffnet. Seit der Einführung monoklonaler Antikörper haben die diagnostischen
Möglichkeiten wesentlich zugenommen. Die Grundvoraussetzungen für die immunhistochemischen Reak-
tionen (Fixierung, Einbettung), grundsätzliche Unterschiede zwischen der Anwendung von monoklonalen
Antikörpern und der von Polyseren sowie die Möglichkeiten der Verbesserung der Empfindlichkeit diagno-
stischer Verfahren werden diskutiert und anhand praktischer Beispiele dargestellt.
Introduction
Pathological-anatomical diagnosis is, to a certain ex-
tent at least, subjective. It is based on the evaluation
of more or less selectively stained paraffin or frozen
sections, or, in the case of cytological diagnoses, cell
suspensions or smears. The reliability of the diagno-
sis depends above all on the experience of the inves-
tigator. The diagnostic difficulties increase even for
the experienced pathologist äs the morphological
picture becomes less chäracteristic or more "for-
eign". Nevertheless, the opinions and conclusions
from analogy of the inorphological observer often
form the basis from which therapeutical consequen-
ces of great weight äre drawn. The methodology of
morphological diagnostics depends on the ability to
recognize chäracteristic forms (1), and for a long
time such diagnoses <could not be verified by more
specific, functionally oriented techniques.
In the last few years immunohistochemistry has
brought about a revolution. It allows the investigator
to combine the remarkable specificity of immuno-
logical reactions with the extraordinary topographi-
cal resolution of light and electron microscopy and
thus to gain basic Information on the cellular and tis-
sular cömposition of objects under investigation. The
additional Information obtained in this way could
not be obtained with biochemical, immunochemical
or morphological techniques alone.
Since Coons (2, 3) first succeeded in visualizing
tissue constituents histologically by means of immu-
nofluorescence techniques in 1941, the popularity of
this technique has increased exponentially. Since the
preparation of monoclonal antibodies (4), this in-
crease may even be deemed explosive.
In the follöwing we wish to present the immunohis-
tochemical techniques that are in pathological-ana-
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tomical usage and to discuss their reliability and in-
formative value. The choice of procedures presented
here is based on our own experience.
Preparation of tissues for immiuiological investiga-
tions
In the following we will restrict the preseniation of
the technical procedures involved in immunohisto-
chemical investigations to the processing of formal-
in-fixed, paraffin-embedded tissue and cryostat sec-
tions of fresh tissue. Paraffin-embedded material has
the great advantage that it is possible to perform ret-
rospective evaluations of a large pathological ship-
ment. If one is limited to cryostat sections, only pro-
spective investigations can be performed, and there
are considerable problems involved in obtaining,
shipping and storing tissues.
Fixation
For all research-oriented problems and all known
antigens, the best, most exact and most reliable re-
sults are obtained in cryostat sections after brief fixa-
tion in organic solvents, such s acetone. How well
the structure is preserved depends on the length of
fixation time and on the avoidance of artefacts due
to freezing. The shock freezing technique via freon
or arcton s interphase with liquid nitrogen has
proved in practice to be the method that does the
least damage to the tissue. The frozen sections that
are prepared in this manner can be stored at —80 °C
and are fixed with acetone prior to immunohisto-
chemical staining. This procedure is adequate for
most antigens but is not applicable when immunohis-
tochemical procedures are planned for electron mi-
croscopy ((5), fig. 1). In this case short-term fixation
with various fixatives, such s glutaraldehyde, para-
formaldehyde and diluted Karnovsky's fixation me-
dium, is applied. This guarantees on the one hand
that the structure is preserved quite well, and on the
other hand many of the membrane antigens investi-
gated so far can be demonstrated. One must, howev-
er, expect a loss in sensitivity that varies from anti-
gen to antigen.
Embedding
Until only a few years ago immunohistochemical
techniques were held to be unfeasible and unreliable
for routine paraffin-embedded material. The dem-
onstration of immunoglobulins on routinely em-
bedded formalin-fixed material (6) was a decisive
turning point for immunohistochemical diagnostics.
In subsequent years advances were made in diverse
9<ϊ* ^1 V /Jferfc ΗΦ·'"&·*£> ; 4 \i ^ ·^ ν ' ^
Fig. 1. Immuno-electron microscopic localization of HLA-DR
oh an epithelial cell (E) of the thymic cortex. The immune
reaction is restricted to the outer cell membrane. Lympho*
cyte (L). 5700 x.
Tab. 1. Comparison of demonstration. of commonly used anti-
gens in paraffin-embedded tissue and in cryostat sections.
Paraffin
Post- stat
embedding
Cell membrane
Membrane-antigens and receptors — +
Lectin receptors + +
Cytoplasm
Secretion products
Hormones, mucus + — +
Immunoglobulins + +
Intennediary filaments
Actin, myosin, vimentin, desmin etc. -* -f +
Nuclear antigens
e. g. Tdt (Terminal deoxynucleotidyl- ^ +
transferase)
ANF (Antinuclear factors) -H· . +
Tumour associated antigens
CEA (Carcinoembryonic antigen) -H +
α-Foetoprotein + -f-
etc.
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areas, particularly with intracellular antigens, by in-
creasing the sensitivity of the techniques (tab. 1).
With adequate embedding, many antigen structures
can be demonstrated in embedded material. Better
preservation of the structure and increasing thinness
of the histological sections also improve the results.
It is generally recognized that particularly intracyto-
plasmie antigens with a relatively high antigen densi-
ty can be easily demonstrated in paraffin-embedded
material, provided the fixation is appropriate (fig. 2).
Examples of this are primarily immunoglobulins (7,
8), hormones, intracytoplasmic filaments and, under
appropriate conditions, certain intranuclear antigens
(9,10). In contrast, the demonstration of membrane
antigens is fraught with difficulties ((11), tab. 1). It
has not yet been possible to demonstrate the large
number of membrane antigens defined by monoclo-
nal antibodies reliably in paraffin-embedded mate-
rial. An exception to this are lectin receptors of the
cell membrane, i.e., sugar structures, which are not
altered by fixation and can thus be recognized op-
timally in paraffin sections (fig. 3).
The dream of the morphologist, to be able to com-
bine the specificity of immunohistochemical meth-
ods with the Optimum preservation of morphological
structure in plastic-embedded material, has only
been approximated so far. Immunoglobulins (fig. 4)
and hormones, in particular, can be demonstrated in
plastic-embedded material, under certain conditions
(12).
In practice immunohistological techniques have
been of particular significance for us for the identifi-
cation and specification of malignant lymphomas.
We have taken advantage of the difference in sensi-
tivity between paraffin-embedded material and fro-
zen sections, in order to distinguish between secreto-
ry immunoglobulins and membrane globulins (13).
Antibodies
The quality and specificity of immunological demon-
strations depend fundamentally on the type and
quality of antibodies used. The scientific and practi-
cal consequences of the breakthrough achieved with
the introduction of monoclonal antibodies (4) can-
not be appraised yet. There is no doubt that the in-
troduction of these highly specific and pure reagents
has initiated a revolutioü in the field of pathological-
histological and cytological diagnoses. Previously the
naming — recognition and description of the cells of
a tissue were reserved for a few, particularly expe-
rienced specialists. Now the immunochemical dem-
onstration of cell-specific, under certain conditions,
Fig. 2. Non-Hodgkin's lymphoma of high grade malignity (im-
munoblastic lymphoma). Demonstration of the light im-
munoglobulin chain kappa in a paraffin section using the
peroxidase-antiperoxidase (PAP) method according to
Sternberger. The tumour cells show a positive intracyto-
plasmic immune reaction. 370 x.
Fig. 3. Benign haemangioendothelioma. The endothelial cells of
the vessels show a positive reaction with Ulex europaeus
lectin (photo Dr. B. Borisch). 370 x.
Fig. 4. Demonstration of the light immunoglobulin chain lambda
in blast and plasma cells of the tonsil on semithin sections
by means of the peroxidase-antiperoxidase (PAP) meth-
od. 370 x.
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functionally specific, molecules has created possibi-
lites for bridging the gap between descriptive anato-
my and pathology, and the function (fig. 5). Let us
briefly discuss a few basic considerations on the anti-
genic structure of cell surfaces (14).
Fig. 5. Thymus of a 4 year old boy. T lymphocytes show a posi-
tive immune reaction with the monoclonal antibody
Leu-1. Mature medullar thymocytes react much more
strongly than cortical thymocytes do. Some of the latter
are negative. In the center of the picture a Hassairs body.
Frozen section. 250 x.
Aetigenic Structure of Cell Surfaces
When different animal species are immunized, dif-
ferent antigenic structures are recognized on cell sur-
faces, depending on which determinants of the cell
surf ace are recognized by the immunized animal spe-
cies äs foreign. If different animal species, e.g., räb-
bit, sheep, horse and monkey are used for the pro-
duction for antihuman lymphocyte sera, the different
spectra of the antisera reveal a very variable pattern
of reactivity with human lymphocytes and bone mar-
row cells, in spite of the similarity of the immunogen
and a comparable cytotoxic antilymphocyte titre
(15). Since thus far the only animal species available
for immunization for the production of monoclonal
antibodies are rat and mouse, it is quite conceivable
that particularly interesting antigenic structures and
determinants in certain experimental Systems, that
have already been defined with the aid of polyclonal
antibodies, are not yet demonstrablp with monoclo-
nal antibodies.
Monoclonal antibodies have found particular appli-
cation for the recognition of cell type-specific deter-
minants (16). We can assume that a particular de-
gree of cell type specificity has been achieved when-
ever molecules that are kiiown to be relevant to cell
functions are identified by means of immunohisto-
chemical procedures. When determinant specific
monoclonal antibodies are used, however, we must
expect to find considerable unexpected and func-
tionally irrelevant cross-reactivity and partial anti-
gen associations with other cells and structures. The
reason for this may lie in whät may be called riatüre's
economy principle, in the sense that cellular individ-
uality is not based on one single characteristic anti-
genic determinant, but on a pattern of different anti-
genic structures with variatiöns in their distribution
on the cells (17). This principle is familiär to all of us
from the polyinorphism of the HLA System or the
Kaufmann-White scheme of Salmonella. Why should
nature breach this tested principle when it comes to
cell type specificity?
For the practical demonstration of so-called cell
type-specific determinants by means of monoclonal
antibodies, this means that it is exactly these cross^
reactivities and partial antigen associatons that make
the application of monoclonal antibodies problemat-
ic. Let us explain this briefly in the following diagram
(fig. 6). A polyclonal antibody shows definite quan-
titative differences in its reactions with cells A, B,
and C, due to the varying determinant specificity.
These consideratioüs make it clear that the methods
used in conventional immunohistology, naniely, di-
lution to increase specificity, are of no value when
monoclonal antibodies are employed. On the con-
trary, it is important to recreate the antigen mosaic
demonstrated here by combining the demonstratiön
of different antigens via double labelling methods.
ImmunohistochemicaE Techniques
Almost äs mumerous äs the available antibodies with
their värying specificities are the immunohistochein-
ical techniques that are employed; moreover, their
specificity and sensitivity are being constantly in-
creased at the same time äs their application is being
simplified (18). Fluorescence procedures, which
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Monoclonal
arvtibody
("singte")
B
Av
M V
Polyclonat
antiserum
("fingerprint")
Fig. 6. Cell type specificity and cross-reactivity äs a problem of immunological cell recognition. In this example of a determinant-specific
reaction the raonoclonal antibody is not able to distinguish between cells A, B, and C, although all 3 cells types have very different
antigen patterns; this is clearly demonstrated by the polyclonal antiserum, which distinguishes the pattern of antigen associations
on the cell membrane.
(Reproducted with permission of Prof. Dr. Dr. W. Müller-Ruchholtz (14)).
were the first to be introduced, are equal to the later
peroxidase technique with regard to specificity and
sensitivity, but have certain decisive disadvantages.
For instance, specialized microscopy is needed; fresh
tissues must be used; morphology is poor, and fluo-
rescent stains are impermanent. For these reasons
we employ almost exclusively peroxidase and, more
recently, alkaline phosphatase immune labelling
techniques. The evaluations can then be performed
under a conventional light microscope, often on pa-
raffin sections, and the permanence of the immuno-
staining is excellent. Out of the multitude of immu-
nohistochemical techniques let us illustrate here
three of the most important methods, which are
probably also of the most practical significance
(fig. 7). In the direct peroxidase technique the tissue
is incubated with peroxidase-conjugated antibodies.
The applied antibody combines with the antigen to
be demonstrated and, after addition of diaminoben-
zidine äs Substrate, it is visüalized in the form of a
brown reaction product (19). Some disadvantages of
this simple method are: For each antigen one needs a
different peroxidase-conjugated antibody. Due to
the conjugation reaction between antibody and per-
oxidase, some of the antibody denatures and is thus
less specific for the antigen to be demonstrated. The
binding of antibody and peroxidase is never com-
plete, so that free excess antibody and free peroxi-
dase can lead to nonspecific reactions. An increase in
specificity, and thus a reduction of background stain-
ing is made possible by the indirect peroxidase meth-
od (20). In this method a primary antibody is applied
followed by a secondary peroxidase-conjugated anti-
body that is directed against the globulin fraction of
the primary antibody. Further progress was repre-
sented by the peroxidase technique according to
Sternberger et al. (21), which made peroxidase-anti-
body conjugation superfluous. In this procedure the
sections are incubated with the primary antibody and
then with a secondary antibody directed against the
globulin fraction of the primary antibody. This Step
is followed by the peroxidase-antiperoxidase com-
plex, which must be prepared in the same animal
species äs the primary antibody. For the visualization
of antigens on frozen sections, we find the indirect
peroxidase technique to be particularly appropriate,
and on paraffin sections, the peroxidase reaction ac-
Pecoxidase.
ant i peroxidase
Rabbit
antiperoxidase
Swine
anti- rabbit IgG
Rabbit ant i -A
A
Direct
B
Indirect Peroxidase-
antiperoxidase(PA P)
Fig. 7. Diagrammatic representation of antigen demonstration by
means of the direct immunoperoxidase method, the indi-
rect immunoperoxidase method and the peroxidasc-an-
tiperoxidase (PAP) method. antigen.
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cording to Sternberger. Independent of the method
employed, the specificity was increased by such
means äs
(1.) highly diluting the primary antibody and using
long incubation periods,
(2.) absorbing the secondary antisera with human se-
rum, and
(3.) proteolytic digestion of paraffin sections with
proteases (22), to mention only a few.
A procedure used more and more often recently is
the biotin-avidin System ((23), fig. 8). This is based
on the principle that the glycoprotein avidin has a
high affinity for biotin. Since avidin also has four
binding sites for biotin, avidin-biotin-peroxidase
complexes can be prepared that have the advantage
that an antigen is demonstrated not with one, but
with several peroxidase molecules, which leads to a
significant increase in the strength of the reaction.
In addition to the possibility of visualizing a single
antigen in the tissue, the desire soon arose to visual-
ize two or more antigens simultaneously. This led to
the development of a large number of double and
multiple labelling techniques (24). For instance, one
antigen is visualized with peroxidase, i.e., a brown
reaction product, and a second antigen is visualized
with alkaline phosphatase, which appears, e.g., red,
depending on the Substrate used, or with colloidal
Avidin- biotin-
peroxidase
complex
A v i d i n - b io t in -
peroxidase
complex
Biotinylated
b r i d g e ant ibody
Biotinylated
ant ibody
Fig. 8. Antigen demonstration by means of the biotin-avidin sys-
tem. Direct and indirect demonstration. D biotin, A anti-
gen, A^avidin (diagram according to Falini & Taylor (24),
modified.
gold, which also pf oduces a red stain. Meanwhile it is
also possible to perfonn double labelling with mo-
noclpnal antibodies (25).
If we observe immunological techniques from the
viewpoint of a cliiiical chemical test, we can formu-
late similar criteria of quality. The immüriohisto-
chemical procedures used today thus possess, äs de-
scribed in greater detail by Petrusz et al. (26), high
precision, sensitivity and specificity.
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Summary: Immunological rejection is still the most important problem in clinical organ transplantation re-
quiring the lifelong immuno-suppressive treatment of the allograft recipient. The clinical success rate however
can be improved by a variety of diagnostic procedures:
a) The reduction of the histocompatibility barrier between donor and recipient by HLA-typing and organ
exchange in order to obtain the best possibie match;
b) posttransplant monitoring of donor specific immune responsiveness towards donor antigens;
c) monitoring of T-cell subsets by monoclonal antibodies and cytofluometry.
T-cell subset monitoring is a rapidly developing new technique with great potential. With the presently availa-
ble first generation reagents already a detailed analysis of the major T-cell population in circulation is possi-
bie, which can markedly facilitate the diagnosis of rejection and viral infection. New monoclonal antibodies,
defining certain activation stages of T-cells or permitting a more refined differentiation of functionally distinct
subsets will leäd to increased relevance of this diagnostic approach. A particulary interesting aspect of mono-
clonal antibodies against T-cell differentiation antigens is their potential therapeutic use äs immunosuppres-
sive drugs with a highly selective action on defined T-cell subsets.
Immunologische Diagnostik bei Organtransplantationen: Histokompatibilitätstestung und T-Zell-Monitoring
Zusammenfassung: Die immunologische Abstoßung ist das zentrale Problem der klinischen Organtransplan-
tation. Neben der immunsuppressiven Therapie spielt die immunologische Diagnostik für die Herabsetzung
des Abstoßungsrisikos und die Früherkennung von Abstoßungsreaktionen und Infektionen eine wichtige
Rolle. Klinisch bedeutsame diagnostische Konzepte sind:
a) Die Reduktion der Histokompatibilitätsdifferenz zwischen Spender und Empfänger durch prospektive
Gewebetypisierung in Kombination mit überregionalem Organaustausch zur Erzielung einer möglichst
guten Gewebeübereinstimmung;
b) Untersuchungen der zellulären Immunaktivität gegen die inkompatiblen Antigene des Transplantates im
Verlauf nach der Transplantation;
c) die Überwachung der Konzentration der unterschiedlichen T-Zell-Subsets im Blut mit Hilfe von mono-
klonalen Antikörpern und Zytofluometrie.
Die Analyse von T-Zell-Subsets anhand von Differenzierungsmarkern, die durch monoklonale Antikörper
definiert sind, stellt eine sich schnell entwickelnde neue Technik dar, die im Bereich der Organtransplantation
zunehmend an Bedeutung gewinnt. Mit der jetzt verfügbaren ersten Generation von Antikörpern ist bereits
J) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
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eine gute Differenzierung zwischen Zellen mit Helferfunktion und zytotoxischen/supprimierenden T-Zellen
möglich. Die Bestimmung des relativen Anteils dieser T-Zell-Subsets im Blut kann die Differentialdiagnose
zwischen Abstoßung und Virusinfektion wesentlich erleichtern. Das zunehmende Verfügbarwerden von mo-
noklonalen Antikörpern, die bestimmte Aktivierungsstadien von Lymphocyten erfassen oder zu einer Ver-
feinerung der Subset-Differenzierung führen, dürfte diesen diagnostischen Ansatz schon bald weiter an Be-
deutung gewinnen lassen. Ein besonders interessanter Aspekt der monoklonalen Antikörpep gegen T-Zell-
Differenzierungsantigene ist ihr therapeutischer Einsatz als Immunsuppressiva mit hochselektiver Wirkung
gegen definierte Lymphocytenuntergruppen.
Introduction
Organ transplantation is a field of increasing clinical
relevance. Transplantation of the kidney has already
become a routine procedure for the treatment of
chronic renal failure and the transplantation of other
life sustaining organs such äs liver, heart and pan-
creas has also left the experimental stage and is cur-
rently rapidly expanding. The most important prob-
lem of this type of treatment however has remained
immunological rejection of the graft. It reflects the
response of the recipient's immune System towards
the incompatible alloantigens of the graft. Empiri-
cally developed immunosuppressive drug regimens
permit the effective control of the rejection process
in most but not all patients.
Clinically the rejection process manifests äs a deteri-
oration in graft function, finally leading to graft fail-
ure. In the hyperacute and acute types of rejection
this develops rapidly, in chronic rejection more slow-
ly over a period of months or even years. The most
important diagnostic procedures for detecting rejec-
tion are graft biopsy and follow up studies of graft
function. From the immunologists point of view, this
is unsatisfactory because it should be possible to de-
tect the rejection response on the level of the im-
mune system before graft damage has occurred. Fur-
thermore the testing of the transplantation antigens
of recipient and donor should even help to prevent
the occurrence of untreatable rejection processes. It
is the aim of this paper to review and evaluate the
current state of these diagnostic concepts in organ
transplantation.
Histocompatibility Testing
Histocompatibility or transplantation antigens are all
surface molecules which are able to induce allogfaft
rejection after transplantation in a recipient not pos-
sessing the same antigens. The aim of tissue typing
(histocompatibility testing) is the detection of these
antigens in donor and recipient and the subsequent
selection of the combination with the best match,
ideally füll compatibility between doiior and recip-
ient. Tissue typing has provided the basis for under-
standing the immunogenetics of transplantation and
is an established clinical procedure. The actual effect
on the clinical outcome of organ transplants however
has been liiiiited and depends on a number of addi-
tional factors.
In clinical practice tissue typing means typing for
HLA antigens. The HLA System represents the ma-
jor histocompatibility System (MHC), which is con-
trolled by a cluster of genes located on the short arm
of the sixth chromosome (l, 2). It codes for two
classes of cell surface proteins. HLA loci A, B and C
code for class I antigens consisting of a polymorphic
polypeptide chain of 44000 Dalton and an invariant
chain of 12000 Dalton representing cell surface
bound ßz-microglobulin. Class II antigens are con-
trolled by multiple loci in the D/DR, DC and SB
regions on the HLA chromosomal segment and cön-
sist of two polypeptide chains with molecular weights
of 28000 and 34000. Whereas'class I antigens are
present on all or nearly all cells, the expression of
class II antigens is more restricted (B cells, mäcro-
phages and a few more cell types). The outstanding
feature of the HLA system is the enormous allelic
Variation of its gene products (genetic polymor-
phism). There are more than 20 well defined A locus
alleles and more than 40 B locus alleles. This poly-
morphism is the cause of the tremendous variability
of individual HLA patterns (l, 2).
HLA antigens are called strong transplantation anti-
gens because they play a dominant role in the induc-
tion of rejection responses. It has recently become
obvious that this strong effect of the HLA antigens
in transplantation is a result of their role in antigen
recognition by T cells in general. It is now clear that
T lymphocytes can recognise antigen only when it is
presented in the eontext of HLA antigens (3). This
restriction of the antigen recognition process by
MHC antigens is one of the mechanisms by which
HLA antigens are involved in the regulation of im-
mune responses (Ir gene effect) and probably also
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the cause for the association of certain diseases with
particular HL A antigens (4, 5). These aspects of the
HLA System have raised a general interest in the sys-
tem going far beyond the transplant problem, but
have also contributed to a better insight into its par-
ticular role in organ transplantation.
The technical problems of HLA typing can be re-
garded äs essentially solved. The antigens coded for
by the three class I loci and the DR and DC class H
antigens are typed for by complement-dependent cy-
totoxicity with lymphocytes äs target eells and de-
fined monospecific typing sera (2). The antisera are
obtained from immunized human individuals (multi-
parous women, transfused patients and transplant
recipients). By this means in many instances com-
plete antigen patterns can be obtained. Besides HLA
typing, histocompatibility testing includes typing for
ABO blood group antigens and screening for the
presence of cytotoxic antibodies (tab. 1). Before the
transplantation is actually performed a cross-match
with recipient serum and donor lymphocytes is nec-
essary. In the presence of a positive cross-match with
a recent serum of the patient the transplantation
should not be performed because hyperacute rejec-
tion is impending (2).
Despite the advanced state of HLA typing the influ-
ence of tissue matching on transplant results is limit-
ed. Nevertheless it is worthwhile to consider what
HLA typing can contribute and what the reasons for
its limited impact are. Clear evidence for the domi-
nant role of the HLA System in organ transplanta-
tion has been derived from kidney transplants per-
formed in living related combinations particularly in
siblings. If siblings share all HLA antigens (two hap-
lotype identity) the organ graft survival is about
90%, if there is identity for antigens coded for by
one chromosome (orie haplotype identity) this is
75—80% and if there is a two haplotype mismatch it
is the same äs in unrelated combinations (6, 7).
Tab. 1. Tissue typing for organ transplantation.
1. Recipient
a) Typing for ABO
b) Typing for HLA
c) Screening for HLA antibodies
(indicating presensitization)
atthetimeofentry
in the waiting list
2. Donör
a) Typing for ABO
b) Typing for HLA
3. Cross-match
(complement-dependent cytotoxic assay with recipient serum
and donor lymphocytes)
For a long time it has been difficult to prove the
beneficial effect of matching in unrelated donor re-
'dpient combinations. Important reasons for this
were the incomplete knowledge of the HLA System
and its enormous polymorphism, rendering it very
difficult to find combinations with füll identity. Only
by an extensive organ exchange between transplant
centers has it become possible to achieve a sufficient
number of good matches and to collect enough data
to confirm the beneficial effect, even for the trans-
plantation of cadaver kidneys (8—10). In this coun-
try this has been achieved with the help of the Euro-
transplant Organization, in which all transplant cen-
ters in central Europe cooperate. According to the
Eurotransplant data, the difference in one year graft
survival between fullhouse matches and complete
mismatches is about 20% (8). This means that pa-
tients with a fully compatible graft derive true bene-
fit from tissue typing. Because of the enormous po-
lymorphism, however, such excellent matches are
achieved only for a minority of patients, which very
much limits the overall influence of HLA matching
on the clinical outcome.
The fact that in most patients füll compatibility can-
not be achieved raises the question äs to whether
there is a hierarchy in the clinical relevance of anti-
gens coded for by different loci. For nonsensitized
recipients of first cadaver kidney grafts there is
strong evidence that the HLA-DR antigens are par-
ticularly important (fig. 1). Therefore matching for
HLA-DR is now generally accepted to rank over
matching for HLA-ABC (8, 11). Of particular im-
1.00
0.80
a>
0.60
o
.
HLA-DR
mismatches
1 ( n = 15)
2 ( n = 167)
t [a]
Fig. 1. Effect of matching for HLA-DR antigeos on renai allo-
graft survival in 827 patients transplanted under the auspi-
ces of Eurotransplant (8). All patients received a kidney
from an unrelated cadaveric donor. Compatibility at the
DR löcus (group with 0 mismatches) clearly improves the
graft prognosis.
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portance are tissue typing and organ exchange for
patients who are sensitized from a previous graft or
after blood transfusions. If broadly cross-reactive
antibodies are present it can be very difficult to find
a cross-match negative graft at all. For all available
grafts in an organ exchange network it always has
first to be clarified whether or not the graft can be
given to one of the highly immunized patients on the
waiting list. With a suitable transplant the results in
these patients are äs good äs in unsensitized recip-
ients of first grafts (10).
The fact that even HLA identical living related kid-
ney transplants can be immunologically rejected
clearly points to the relevance of other antigenic Sys-
tems in addition to HLA. With the exception of the
ABO system these antigens are not typed for be-
cause they clearly rank below the HLA System in
clinical relevance. Nevertheless a clear statistical ef-
fect has been shown for the Lewis antigens (12, 13)
and for accumi^lated differences in other blood
group Systems (10). On the basis of animal experi-
ments in the mouse it has to be assumed that the
number of non-HLA loci which can function äs his-
tocompatibility loci is very high and probably ex-
ceeds one hundred.
For the clinical transplantation of heart and liver
even matching for HLA is extremely difficult be-
cause these organs cannot be preserved sufficiently
long to allow enough time for HLA typing of the
donor before transplantation. In contrast to kidneys
which can be preserved for up to 50 hours the con-
servation time for heart and liver grafts has to be
below 4 hours. Because there is no artificial Substitu-
tion for these organs such äs haemodialysis for pa-
tients with chronic renal failure, these transplanta-
tions always have to be performed urgently. There-
fore it is not possible to wait for a well matched do-
nor.
Monitoring of Antigen-Specific T Cell Responses
Since practically all organ grafts are transplanted
across some major histocompatibility barrier, graft
success depends on a delicate balance between im-
pending rejection on one side and drug-mediated
immunosuppression on the other. Disturbances of
this balance will either lead to graft damäge by rejec-
tion processes or overimmunosuppression with the
risk of severe or even fatal infection. In this Situation
there is an urgent need for methods monitoring the
reactivity of the recipient's immune System towards
the antigens of the graft.
In vitro techniques determining the reactivity of iso-
lated T lymphocytes of allograft recipients against
cultured cells of the graft donor are a suitable tool
for this purpose. By this means it is possible to test
whether the patient's T cell population contains anti-
gen-reactive clones against the dojjor antigens and
whether these clones have been stimulated or not.
Relevant techniques are the mixed lymphocyte cul-
ture (MLC) and the direct and indirect cell-mediated
cytotoxicity assay (direct and indirect CMC), In the
MLC test the proliferative reactivity of recipient T
cells indicates the presenee of T cell clones predomi^
nantly directed against donor HLA-DR antigens. In-
formation on the state of sensitisation of these clones
can be obtained from the kinetics of the prplifefätive
response. The indirect cytotoxicity assay demon-
strates the presence of cytotoxic precursör cell clones
to donor HLA-A, B, C antigens. Upon Stimulation
these precursor cells differentiate in vitro into effec-
tor cells and can be measured in a cell-mediated cy-
totoxicity assay (51Cr release assay). In vivo sensit-
ized cells can be measured without previous in vitro
Stimulation in a direct cell-mediated cytotoxicity as-
say using donor target cells.
For the detection of acute rejection the direct cyto-
toxicity assay caii be expected to be the appropriate
test. Indeed this assay has been demöiistrated to in-
dicate the occurrence of differentiated effector cells
in blood in close correlation with the development of
acüte rejection episodes (15, 16). However it is dis-
puted whether the occurrence of these cells is early
enough to predict impending rejectipn before clinical
Symptoms are present. Severe limitations are the re-
quirement for donor target cells which are difficult to
maintain in the cadaver donor Situation, and the
complicated nature of the assay which renders it not
very useful for routine purposes. Most attempts to
detect activated cells by spontaneous blastogenesis
of peripheral blood lymphocytes have been unsuc-
cessful (17). A promising new approach however is
the use of monoclonal antibodies, which detect dif-
ferentiation antigens present only on activated T
cells (see below).
During periods of clinical quiescence precursor cell
assays are of particular interest because they can
provide Information about the risk of the patient de-
veloping T cell-mediated immune reactions. Üsing
the indirect CMC assay it has been possible to show
that a number of patients possessing cytotoxic pre-
cursor cell clones against donor antigens before
transplantation loose these clones several months af-
ter transplantation (18, 19, tab. 2). Interestingly this
does not happen with proliferating helper cell clones.
It is not clear whether this represents clonal deletiön
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Tab. 2. Loss of donor-specific cytoioxic prccursor cells in pa-
tients with well tolerated kidney or liver allografts (dcvcl-
opcd by about 50% of patients with a good long tcrm re-
sult).
T cell response
to donor cells
Prolif- Cyto-
eration toxicity
T cell response
tothirdparty cells
Prolif- Cyto-
eration toxicity
Before transplantation
After transplantation + + + 0
of the cytotoxic cells, representing some type of par-
tial tolerance, or selective Inhibition of the cytotoxic
clones by suppressor cells. In any case this antigen-
specific defect shows that the recipient's immune
System can adapt to the continued presence of for-
eign histocompatibility antigens. Whereas assays for
rejection indicate when an increase in immunosup-
pressive treatment is required, studies of precursor
cell activity may indicate whether treatment can be
reduced or even withdrawn.
Monitoring of T Cell Subsets by Monoclonal Anti-
bodies
The analysis of T cell subsets by monoclonal antibo-
dies approaches the problem of monitoring T cell
reactivity at a different level. This most recent diag-
nostic concept assumes that the development of a re-
jection episode and the effects of immunosuppres-
sion are reflected in the T subset composition of the
blood. The subset model of the immune System orig-
inally has been based on functional tests which
showed that different T cell functions, such äs helper
or suppressor activity or the capability to kill other
cells, are mediated by distinct populations of T cells.
It is now clear that these subsets represent distinct
differentiation lines of T cells and differ not only in
• function but also in a number of cell surface proteins
which can be used äs subset specific markers. Mo-
noclonal antibodies against such "differentiation an-
tigens" have become the most important tools for
the definition of subsets, their quantitative analysis
and physical Separation (21, 22). Furthermore it is
likely that at least some T cell specific differentiation
antigens are involved in the mediation of subset spe-
cific functions (23).
The chemical and functional features of six human T
cell differentiation antigens defined by mouse mo-
noclonal antibodies are summarized in table 3. In-
cluded are antigens present only on intrathymic pre-
cursors of peripheral T cells (T6), antigens presented
on all peripheral T cells but not B cells (T3, TU,
T12) and finally true subset specific antigens (T4 and
T8). Originally T4 and T8 were thought to charac-
terize T cells strictly on the basis of function. Recent-
ly it has become clear that they define the class of
MHC antigens which restricts antigen recognition by
the particular subset. T4 positive cells are restricted
by class II antigens, T8 positive cells by class I anti-
gens (24). Since the majority of class II restricted
cells belongs to the helper cell pool and most class I
antigen restricted cells are cytotoxic, the original as-
sociation with function holds true in most instances.
A schematic representation of the complex associa-
tion between the specificity of MHC restriction and
the function of the T4 and T8 subsets is given in fig-
ure 2. Against these and several other T cell antigens
a variety of monoclonal antibodies have been pro-
duced in many different laboratories. The availabili-
ty of multiple antibodies detecting the same mole-
cule but reacting with different epitopes and possess-
ing different functions is very useful for analytical
Tab. 3. Human T lymphocyte surface antigens defined by monoclonal antibodies (adapted from Reinherz et al. (23).
Antigen Mr Monoclonal antibodies Expression on T cell lineage T subset specifity
T3
T4
T6
T8
TU
T12
20000
55000
49000
76000
55000
120000
OKT3
OKT4, Lcu3,
Anti-T4
OKT6, Leu6,
Anti-T6
OKT8, OKT5,
Leu2, Anti-T8
OKTll,Leu5,
Anti-Tll
Anti-T12
allmatureTcells
majority of thymocytes and
50-60% of peripheral T cells
70-80% of thymocytes
but not peripheral T cells
majority of thymocytes and
25-30% of peripheral T cells
all thymocytes and T cells
some thymocytes and all
peripheral T cells
none
predominantly T helper subset (T cells
restricted by class II antigens)
intrathymic precursor cells
predominantly cytotoxic/suppressor
subset (T cells restricted by class I
antigens)
none
none
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Antigen expression
T8
Tab. 4. Patterns of T subset shifts in transplänt patients.
Function ·
•c/s
Clinical state
Fig. 2. Functional characterization of T cell subsets defined by
monoclonal antibodies against the T cell differentiation
antigens T4 and T8. The expression of T4 and T8 corre-
lates better with the restriction of antigen recognition by
MHC (HLA) class I and class II determinants than with
the helper (TH) or cytotoxic/suppressor (Tc/s) function.
Most likely this good correlation is caused by a direct in-
volvement of the T4 and T8 molecules in the mediation of
restriction. Nevertheless for practical purposes they can be
regarded äs suitable markers of the helper and the cyto-
toxic suppressor subset.
MHC restriction: | | Class I, Class II.
purposes. An extensive comparison of T cell specific
monoclonal antibodies has been preformed in a re-
cent international workshop (25).
Monitoring relevant immunological events after or-
gan transplantation requires serial examinations of T
cell subsets in short intervals. In principle this can be
performed by fluorescence microscopy. More effi-
cient however is cytofluorography (26,27). This per-
mits not only the differentiation between positive
and negative cells but also the study of antigen densi-
ty and the correlation of fluorescent antibody stain-
ing with other cell parameters, e. g. forward and right
angle scatter giving Information on cell size and in-
ternal structure (26, 27). Furthermore the question,
whether two or more antigens are coexpressed on
the same cell can be analysed by staining with multi-
ple antibodies conjugated with different fluoro-
chromes (28). Relevant alterations in the T subset
composition of the blood, which can occur in trans-
plänt patients, are changes in the concentration of
individual subsets or the occurrence of subsets usual-
ly not present in the circulation (tab. 4).
Profound quantitative changes in the concentration
of the T4 subset have been reported after immuno-
suppression with azathioprin, corticosteroids and an-
tilymphocyte serum (29, 30, 31). Usually the T4
subset is markedly reduced. This indicates that this
frequently used drug combination has some selectiv-
ity for helper T cells. In patients treated with the new
immunosuppressive drug cyclosporine a similar drop
of the T4 population has not been observed, illus-
trating the different mode of action of this drug.
Characteristic subset patterns for the immunosup-
pression induced by cyclosporine remain to be estab-
lished.
T cell subsets Ratio
T4 T8 T4/T8
Immunological quiescence
Rejection
Viral infection
normal or J,
T
l
normal orjf
" l
T
l
T
i
The diagnosis of acute rejectioii by subset monitor-
ing was first discribed by Cosimi et al. in patients
treated with conventional immunosuppression (29).
They observed a sudden increase in the number of
T4 cells several days beföre the onset of clinical
Symptoms. Since the ratio of the number of T4 to T8
cells is normally about 1.3 to 1.8 the change in the
subset pattern elicited by conventional immunosup-
pression can be decribed äs a decrease in this ratio
below 1.0, whereas rejection is indicated by an in-
crease to normal of above normal values (tab. 3).
Since the immunosuppressive regimens used are
widely different between transplant groups, it is not
surprising that these findings have not been con-
firmed by all investigators (32). Furthermore, it has
to be pointed out that there is a wide Variation in the
number of T4 and T8 cells between individtials.
Therefore only serial examinations in the same pa-
tient during immunological quiescence and rejection
are truly informative. Because the rejection-prone
period is limited to the first three months after trans-
plantation this is the most important period for these
tests. The observation that the specific activation of a
very limited number of clones during a rejection re-
sponse can be accompanied by shifts of whole sub-
sets is unexpected. The underlying mechänism is not
understood. It's elucidation will require a better in-
sight into the regulatory processes that maintain the
normal homeostasis of the major T cell subsets in cir-
culation.
A different type of approach to the diagnosis of re-
jection using monoclonal antibodies and cytofluo-
rography is the demonstration of activated T cells in
the blood. The basis for this approach is the observa-
tion that activated T cells express a variety of cell
surface determinants not present on resting T cells.
These activation markers iüclude the receptor for
the T cell growth factor interleukiii 2, the transferrin
receptor and ä variety of other antigens which are
riot necessarily T cell specific. Mahy of these
markefs, however, are strongly expressed only dur-
ing the blast stage of T cells in the lymphatic tissue,
but to a much lesser degree when the activated cells
enter the circulation. Nevertheless preliminary datä
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indicate that the measurement of activation markers
can become a very powerful diagnostic tool (32, 33).
The detection of subsets or activation stages of T ,
cells normally not present in circulation is also possi-
ble by studying the coexpression of markers with two
or three colour immunofluorescence (28). Thus
HLA-DR antigens are usually restricted to B cells
and monocytes. They can be expressed however on
activated T cells. Studying the coexpression of T sub-
set markers and HLA-DR in transplant patients, van
Es et al. (34) have recently demonstrated an excel-
lent correlation between acute rejection and the oc-
currence of cells coexpressing T8 and HLA-DR. The
demonstration of activated cells in Wood probably is
much more sensitive than the diagnosis of rejection
on the basis of subset shifts alone (32).
Viral and bacterial infections resulting from over-
immunosuppression are a group of complications
which are even more endangering for the transplant
recipient than rejection. The diagnosis of infections
is particularly difficult because they are frequently
caused by agents such äs the cytomegalovirus, which
is not pathogenic in the immunologically uncom-
promised host. Furthermore the antiinflammatory
effect of conventional immunosuppression obscures
the typical clinical and laboratory signs, In this Situa-
tion it is of particular interest that several virus infec-
tions are accompanied by a drastic increase in the T8
and a reduction in the T4 cells resulting in a reduced
T4/T8 ratio (30, 34; tab. 2). Figure 3 depicts the
characteristic T subset pattern of severe viral infec-
tion in one of our liver transplant patients. The infec-
tion was diagnosed on the basis of the marked in-
crease in the T8 subset and was later confirmed by
virological tests. This diagnostic aspect of T subset
monitoring is probably äs important äs the diagnosis
of rejection.
A particülarly attractive trait from the poirit of im-
munosuppression is the fact that subset monitoring
defines changes in T cell reactivity at a level of the
immune System ät which therapeutic Intervention is
possible. Antigen-specific types of immunosuppres-
sion so far have not been clinically successful and
bear the risk of immunization instead of immuno-
suppression. Monoclonal antibodies against T cells
and T cell subsets, however, are also potentially
powerful tqols for immuno-suppression. Thus anti-
bodies against the T3 antigen and against T12 have
already been used clinically and have been reported
to reverse acute rejection episodes at least äs effec-
tively äs corticosteroids (29, 35). Since the immuno-
suppression mediated by these antibodies is nonspe-
cific, Takahashi et al. have used a monoclonal anti-
body reacting only with blast cells (36). This anti-
O K T 3
Control
0.76 T3+
Patient
0.83 T3+
OKT
"
o
0.39 0.26 U*
OKT 8
0.17 T8 0.57
Irctensity of fluorescence
Fig. 3. Analysis of T cell subsets in the blood of a healthy control
and a liver transplant patient 6 weeks after orthotopic liv-
er transplantation, suffering from acute cytomegalovirus
infection. The fraction of T cells was measured with the
OKT3 antibody, the helper subset with OKT 4 and the
cytotoxic/suppressor subset with OKT 8. Staining was
performed in whole blood using directly labelled antibo-
dies and the ORTHO SPECTRUM III cytofluorograph.
The number of cells is plotted versus fluorescence mea-
sured in arbitrarily defined units. Cells with a fluorescence
intensity above 25 units (indicated by the broken line) are
regarded äs positive. In the patient T4 cells are reduced
and T8 cells markedly increased. This is a typical pattern
for viral infections.
body was also effective without a demonstrable ef-
fect on normal resting T cells. This very nicely illus-
trates that the combined diagnostic and therapeutic
use of appropriate monoclonal antibodies can open
the way to an effective method of subset engineering
on the clinical level.
Conclusions
Immunological rejection elicited by the foreign his-*
tocompatibility antigens of the graft is the most im-
portant problem in clinical organ transplantation.
Histocompatibility testing attempts to prevent rejec-
tion by reducing the antigenic barrier between donor
and recipient. In kidney transplantation a limited but
significant effect of the presently available matching
techniques on the clinical outcome has unequivocally
been shown. Furthermore HLA typing and extensive
organ exchange represent the only possible means of
finding crossmatch-negative grafts for presensitized
patients with broadly cross-reacting antibodies
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against HLA-A, B, C antigens. The aim of post
transplant monitoring of the immune response is the
diagnosis of rejection by immunological means and
the recognition of states of overimmuno-suppression
and infection. This will render the necessary immu-
no-suppressive therapy both more efficient and less
dangerous. Relevant procedures are follow up stud-
ies of donor-specific immune responses and T sub-
set monitoring in peripheral blood using T cell-spe-
cific monoclonal antibodies. The latter technique is
presently in a state of rapid development and can be
expected to become increasingly important. Since
the presently available immunosuppressive proce-
dures to some degree have differential effects on T
subsets, this diagnostic approach deals with the im-
mune System on a level which lendß itself to thera-
peutic Intervention. T subset-speciric monoclonal
antibodies are likely to become therapeutically rele-
vant and to permit true subset engineering for the
manipulation of the immune response.
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Summary: The meaningful use of tumour markers for cancer diagnosis depends on the nature of the diagnos-
tic problem, on an adequate definition of positive and negative test results, and on the correct choice of the
patient group. Potential diagnostic applications lie in screening studies, diagnosis in patients with Symptoms,
staging and prognosis, diagnosis of local recurrence and distant metastases, and the monitoring of radio- and
chemotherapy. In quantitative tests, a positive or negative test result may be obtained by the establishment of
reference ranges in control groups, or by longitudinal studies in single patients. Usually, the monitoring of
therapy and the diagnosis of tumour progression are performed by following the concentration pattern of the
marker. When tumour marker determinations are performed in conjunction with other diagnostic tests, the
diagnostic sensitivity or specificity may be increased, depending on the particular test combination. The deter-
mination of tumour markers with limited diagnostic specificity should be performed in groups of patients with
a high prevalence of the disease, e.g. in the postoperative follow-up of patients with a high risk of tumour
recurrence. Tumour markers with high diagnostic specificity are also useful in differential diagnosis.
Diagnostische Empfindlichkeit, diagnostische Spezifität und prädiktiver Wert der Bestimmung von Tumor-
markern
Zusammenfassung: Der sinnvolle Einsatz des Tumormarker-Nachweises im Rahmen der Tumor-Diagnostik
hängt von der Fragestellung, einer adäquaten Definition des positiven bzw. negativen Testergebnisses sowie
von der richtigen Wahl der uiitersuchten Patientengruppe ab. Unter den potentiellen Fragestellungen lassen
sich Screening-Untersuchungen, die Diagnose nach Auftreten von Symptomen, Stadieneinteilung und Pro-
gnostik, Erkennung von lokalen Tumorrezidiven und Fernmetastasen sowie die Überwachung einer Radio-
oder Chemotherapie voneinander abgrenzen. Der Definition eines positiven bzw. negativen Testergebnisses
kann bei quantitativen Tests eine Transversal- und eine Longitudinal-Beurteilung zu Grunde liegen. Die
Abschätzung des Therapieerfolgs und die Diagnose der Progredienz einer malignen Erkrankung beruht in der
Regel auf einer Beurteilung des Konzentrationsverlaufs beim Einzel-Patienten. Durch eine sinnvolle Kombi-
nation des Marker-Nachweises mit anderen diagnostischen Tests lassen sich, je nach Art der Test-Verknüp-
fung, diagnostische Empfindlichkeit oder diagnostische Spezifität erhöhen. Die Bestimmung von Tumor-
markern mit begrenzter diagnostischer Spezifität ist nur in Personengruppen mit hoher Krankheitsprävalenz,
so z.B. im postoperätiven Verlauf von Patienten mit hohem Rezidiv- bzw. Metastasen-Risiko, angezeigt.
Tumormarker mit hoher diagnostischer Spezifität besitzen hingegen auch in der Differentialdiagnose einen
Stellenwert.
course of malignancies. In spite of this work, there is
Introduction
 stiH a | 0^ oj agreement concerning the diagnostic
A large number of publicätions have appeared in re- value of these determinations. This is connected with
cent years on the üse of tumour markers in the diag- the fact that only relatively few investigations have
nosis of naalignant tumours, and for monitoring the taken account of the necessary criteria for the eva-
J) Presented at the Kleinkonferenz „Immunologische Diagnostik" der Deutschen Gesellschaft für Klinische Chemie, Hamburg, Juni
1983.
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luation of a diagnostic test. For any test, data are
required on diagnostic sensitivity and specificity, on
the positive and negative predictive values, together
with the exact conditions under which the data are
obtained. In the absence of such Information, it is
not possible to define those clinical situations in
which the determination of tumour markers is mean^·
ingful, or to recognize those cases in which tumour
markers yield no more Information than already pro-
vided by established procedures. In the present ac-
count, the diagnostic value of various tumour
markers is critically evaluated, taking account of the
above test criteria. In this connection, particular at-
tention is paid to published investigations, in which
the diagnostic test criteria were considered, and the
exact conditions of the study were reported.
Diagnostic Test Criteria, with Special Consideration
of Tumour Markers
The value of a diagnostic test depends on its ability
to differentiate between the clinically normal and
abnormal, and between different groups of illnesses
or stages of an illness. The diagnostic relevance of a
test is based on the criteria of sensitivity, specificity
and efficiency (1) (fig. 1). For a qualitative test, diag-
nostic sensitivity represents the probability that the
presence of an illness will result in a positive test re-
sult, while diagnostic specificity represents the prob-
ability that the result will be negative in the absence
of a particular clinical condition. The probability of
achieving a correct test result in a mixed group of
normal and ill subjects is called the diagnostic effi-
ciency, and it is given by the proportion of the total
test results that are correctly positive or negative.
These diagnostic test parameters depend strongly on
the known medical history of the investigated group
of subjects. Diagnostic sensitivity is influenced main-
ly by the stage of the malignancy. If
 fthe stage defini-
tions of a malignancy are well established, then the
diagnostic sensitivity can serve äs a üseful test criter-
ion. Diagnostic specificity, however, can vary be-
tween wide limits, depending on the type and com-
Position of the control group.
The predictive value of positive or negative resülts is
of particular importatice in screening and in follow-
up investigations. Predictive values are derived from
the probability that a positive test result will truly be
associated with a case of illness, or the absence of
illness will be accompanied by a negative result (1).
Since the prevalence of the illness is included in the
calculation of the predictive value (fig. 1)^ the latter
depends on the ratio of ill to non-ill in the investigat-
ed group. Predictive values calculated from the
"Vierfelder table" are only generally applicable if
the investigated population is a repräsentative sam-
ple of the whole. For example, this may be a suffi-
ciently large sample of patients, iii which a tümour
marker is determined postoperatively for the detec-
tion of tumour recurrence. In such investigations
care müst be taken to ensure that the respective
stages of the malignancy are correctly recorded.
In quantitative methods for the determination of
tumour markers, the definition of a positive test re-
sult may be based on a transverse or a longitudinal
evaluation. For the transverse evaluation, it is neces-
Test positive T
Test negative T
Disease present
D
true positive = TD
false negativ = TD
Disease absent
D
false positive = TD
true negative = TD
TD
TD + TD" pos. Test
TD - - Predictive value
=-—==- = P(D/T)TD + TD neg. Test
P(D/T) ·.
P(D/T) =
P(D) · P(T/D)
P(D) - P(T/D) + P(D) · P(T/D)
P(D) - P(f/D)
P(D) - P(T/D) + P(D) · P(T/D)
. . PfT/r>\
TD + TD P(T/D)
Sensitivity
TD
 nf/DlTD + TD 1(T/ )
TD
TD + TD"
TD
TD + TD
Specificity
P(T/D)
P(T/ß)
Fig. 1. Results matrix and definitions of a qualitative test. Positive and negative predictive values are calculated with the aid of Bayes*
theorem (48).
D: illness present D: illness absent T: test result positive T: test result negative (according to Blittner (1)).
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sary to establish a reference ränge within a control
group. The resulting diagnostic parameters depend
on the composition of the control group and on the
Position of the cut-off point. If the cut-off point is
raised, the positive predietive value increases, and
there is a decrease in the proportion of false positive
test results; at the same time there is a decrease in
the negative predietive value, and an increased pro-
portion of false negatives. In choosing the reference
ränge, it must be decided whether a false positive or
a false negative test result presents the greater risk
for the patient. The risk depends primarily on the
extent to which the therapeutic decision is influenced
by the result of the individual test. For example, a
"second look" Operation may be performed if the
concentration of a tumour marker increases postop-
eratively.
A quantitative test also becomes a binary test when
it is used for the longitudinal evaluation of a tumour
marfcer in individual patients. In this case, a signifi-
cant increase in concentration is recorded äs a posi-
tive test result. In contrast to benign illnesses, which
can lead to false positive test results, the malign neo-
plasia shows progressive behaviour. This progression
is manifested äs a sustained increase in the serum
concentration of a tumour marker. A longitudinal
evaluation therefore permits an earlier recognition
of tumour development than is possible by a trans-
verse study. As a rule, a change in the concentration
of a tumour marker in one patient has greater diag-
nostic sensitivity and specificity than positive ör neg-
ative results obtained with the aid of a cut-off point.
The problem lies in the definition of a "significant
concentration increase".
In the literature there are frequent reports of the
measurement of various tumour parämeters in cer-
tain groups, and the result is considered to be posi-
tive if one of these test results is positive. If the cor-
relation coeffident between the individual tests is
less than unity, then such a linkage of test results in-
deed leäds to iacreäsed diagnostic sensitivity, where-
as the diagnostic specificity is decreased. Conversely,
the sensitivity is decreased and the specificity in-
creased if the declaration of a positive result requires
that each of the individual tests be positive. Finally,
the combined test results may be considered positive
or negative when eäch of the tests yields a positive or
negative result. The remaining cases are classified äs
inconclusive. In these cases, the final diagnosis must
be confirmed by invasive procedures, or by further
continuous observations (l, 2). The choice of test
coinbination depends on the clinical problem. If an
important therapeutic decision rests on the test re-
sult, then maximal specificity is required. On the the
other hand, if all possibly affected individuals are to
be detected, followed by invasive diagnosis, then the
' test combination should possess maximal sensitivity.
Examples of both cases are described below.
Screening
Figure 2 shows how diagnostic sensitivity and speci-
ficity are influenced by the choice of patient and con-
trol groups. This example shows the changes in the
sensitivity and specificity of the carcinoembryonic
antigen (CEA) determination in the course of var-
ious investigations between 1969 and 1972. In this
particular case, the upper limit of the reference
ränge corresponds to the normal ränge of 2.5 g/l.
According to the data of Thompson et al. (3), the
sensitivity and specificity of the CEA determination
are almost perfect. During subsequent investiga-
tions, the sensitivity of the test for colorectal carcino-
ma decreased continually, but there was an increase
in the proportion of elevated CEA values associated
with non-malignant complaints of the gastrointesti-
nal tract. It is very apparent that the reason for this
phenomenon lies in the selection of the patient
groups. Advanced colorectal carcinomas almost al-
ways lead to elevated CEA values. As a rule, howev-
100
so
B
Cn60
"
S 20
l
0 , 0 |
Thomson et öl., Lo Gert o et ., Ohor et öl.,
1969 (3) 1971 (50) 1972 (51)
Cotloborotive
study,
1972 (52)
Fig. 2. Results of the CEA test from various investigations of pa-
tients with colorectal carcinomas, non-enteric cancers and
non-malignant diseases of the gastrointestinal tract (ac-
cording to Bodansky (49)).
Q colorectal cancer
R>3 non-enteric cancer
[/2 non-malign g^strointestinaJ disease.
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er, non-malignant diseases of the gastrointestinal
tract, e.g. liver cirrhosis, are accompanied by ap-
preciable increases of CEA only during the active
phases of the illness.
Consideration of the data on the diagnostic sensitivi-
ty and specificity of the CEA determination, togeth-
er with the relatively low prevalence of colorectal
carcinomas in the normal population, leads to the
conclusion that the CEA determination is not suita-
ble for screening purposes. This was confirmed in an
Australian field study, which formed part of the
"Busselton study" (4). In 1969, serum samples were
taken from about 3500 inhabitants. Ninety percent
of these persons continued to take part in clinical in-
vestigations at regulär intervals. In 1973/74, the
CEA concentrations were determined in the sera of
2372 inhabitants, aged 40 and older. The sensitivity
of the CEA determination, i. e. the frequency of pos-
itive results for patients with malignant tumours, was
27%, while the specificity was 97%. Since the pre-
valence was 1.4%, a positive predictive value of
0.4% can be calculated, i.e. only one in 250 persons
with a positive test result actually had a malignant
tumour. Since the CEA determination detects ad-
vanced rather than early tumour stages, it is doubtful
whether a positive CEA result could have been fol-
lowed by effective curative therapy. In summary, the
CEA determination is therefore not suitable for
screening for malignancies in a normal population.
Similar considerations apply to other tumour
markers, whose diagnostic sensitivity and specificity
are comparable to those of CEA. The CEA determi-
nation is also unsuitable in a risk group, e. g. hospital
patients (5) or subjects with polyps of the large intes-
tine (6) or with colitis ulcerosa (7). This is because
an increased prevalence of disease with a possible
increase in diagnostic sensitivity is accompanied by a
decrease of diagnostic specificity.
The only tumour marker that can possibly be consi-
dered äs suitable for screening purposes is alpha-foe-
toprotein (AFP). Taking into account the time
course of the concentration, and by choosing a suita-
ble cut-off point, AFP measurement is relatively
specific for liver cell carcinoma (8). In addition, pa-
tients with liver cirrhosis represent a risk group in
which the prevalence of hepatocellular carcinoma is
about 5% according to clinical studies, or 10^-25%
according to autopsy studies (9). Diagnosis of liver
cell carcinoma by serum AFP measurement is, how-
ever, made difficult by the occurrence of intermit-
tent, short term concentration increases, which are
unrelated to the presence of carcinomas (10). These
short term increases do not, however, normally ex-
ceed 2000 §/1. In patients without hepatoma, the
concentration then decreases with a half life of 5—6
days, which corresponds to the normal half life of
serum AFP. In contrast, patients with liver carcino-
ma show a further increase. A positive test result can
therefore be defined äs follows: the AFP concentra-
tion must either exceed 2000 ^/ ^ lie above 50
g/l with subsequent increases in the course of the
disease. Thus, Lehmann & Wegener (10) reported
that 24 out of 27 cases of hepatocellular carcinoma
in a patient collective were diagnosed by AFP deter-
mination (89%), 17 of these before the appearance
of Symptoms (63%).
Differential Diagnosis after the Appearance of
Symptoms
For various reasons, CEA determination plays a se^
condary role in the differentiation of malignant tum-
ours. Colorectal carcinoma must inost frequently be
differentiated from benign illnesses of the gastroin-
testinal tract; but these same benign illnesses are ac^
companied by a relatively high frequency of false
positive increases in CEA concentration (11). This
means that the CEA test is not sufficieiitly specific to
serve äs a basis for differential diagnosis. By increas-
ing the upper limit of the refereiice ränge, the speci-
ficity of the diagnosis can be increased, but the de-
tected tumours are thän predominantly in an ad^
vanced stage. The CEA test is too insensitive for the
detection of localized carcinoma of the stoinach,
mammary gland, bronchial tract, ovary and cervix
(H, 12).
Despite the relatively low diagnostic sensitivity of
the CEA determination, it may be of value in the
differential diagnosis of those tumours that are slow
to produce Symptoms, and which caniiot be recog-
nized by present diagnostic procedure until a late
stage of development. This is the cäse for carcinoma
of the pancreas. The fange of CEA concentrations in
diagnosed pancreatic carcinoma is significantly dif-
ferent from that found in non-maligriant diseases of
the pancreas and gastrointestinal tract (13). For the
CEA determination to be of special diagnostic value,
however, its sensitivity and specificity should be
higher than those of other established procedures. In
a double blind study, the value of the CEA determi-
nation in differential diagnosis was studied in pa-
tients with suspected pancreatic carcinoma, where
immediate confirmation of the diagnosis had not
been possible (13) (tab. 1). In three out of nine cases
with later confirmed pancreatic carcinoma, CEA
concentrations were markedly eleväted on admission
to hospital. In these three cases, however, the diag-
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Tab. l. Initial plasma CEA level and interval before definite di-
agnosis, in patients suspected of carcinoma of the pan-
creas (according to the MRC Tumour Products Commit-
tee (13)).
Definite diagnosis
Pancreatitis Carcinoma of
or gallstones the pancreas
Othcr
malignancy
nosis
Other non-
malignant
disease
Days Initial Days Initial Days Initial Days Initial
to CEA to CEA to CEA to CEA
(pg/l) diag- ftig/l) diag- ( /1) diag-
nosis nosis
n = Total patients
nosis
1
11
120
123
164
193
215
13
21
17
8
11
6
11
3
7
8
18
28
28
90
230
956
100
50
191
32
14
10
21
11
12
7 17
7 82
461 26
un- 36
known
2
14
23
379
23
14
33
9
-, 100
ca.
c
v
Chorio- Invasive Hydatidiform
carcinoma mole mole
Fig. 3. Ratio of serum pregnancy specific ßi-glycoprotein to hu-
man ß-chorionic gonadotropin in patients with chorion-
carcinoma, invasive mole and hydatidiform mole. The
quotient was calculatecl from the concentrations in §/1
(according to Sakuragi (17)).
nosis was confirmed within a week by other estab-
lished procedures. In those cases that were not diag-
nosed until they were more advanced, the CEA de-
termination was not sensitive enough for a signifi-
cantly earlier diagnosis. In contrast, the measure-
ment of CEA is relatively sensitive for the diagnosis
of medullary thyroid carcinoma, although the deter-
mination of calcitonin is riiore sensitive and more
specific. Since there is a good correlation between
these two tests, the CEA determination does not ap-
pear to be capäble of yielding any essentially new
Information (14).
As already mentipned, the determination of AFP is a
useful aid to the diagnosis of hepatocellular carcino-
ma. On the other band, germ cell tumours of the
testes are diagnosed clinically by the local swelling.
The specific determination of human chorionic go-
nadotropin (HCG) has long been used for the diag-
nosis of hydatidiform mole and chorioncarcinoma
(15). These two malignancies can be differentiated
from one aiiother by the determination of pregnan-
cy-specific ß-1 glycoprotein (SP-1) and HCG (16) or
the fcsubimit of HCG (17) (fig. 3). In chorioncarci-
noma, the cpnceiitration of HCG-ß- is higher than
that of SP-1, whereas the converse is true for hydati-
diform mole. The fact that the SP-1/HCG-ß ratio in-
creases during pregnancy indicates that the change in
ratio is the result of an altered differentiation of the
cells of the trqphoblast (17).
Staging, Diagnosis of Metastases, Prognosis
Determination of the stage of neoplastic develop-
ment and the diagnosis of metastases may be based
on the result of one type of test, or on a combination
of various diagnostic procedures. In addition, the
time course of the concentration of a tumour marker
following therapeutic Intervention provides a matrix
of results. The use of tumour markers for staging and
for the diagnosis of metastases is closely related to
their importance in prognosis.
In patients with colorectal carcinoma, there is a sig-
nificant positive correlation between the preopera-
tive CEA concentration and the spread of the carci-
noma. Between Dukes' stages -D, there is an in-
crease in the concentration of CEA and an increase
in the proportion of cases showing elevated CEA.
Thus a relationship exists between preoperative
CEA concentrations and the prognosis. The higher
the concentration ränge, the higher the proportion of
patients with tumours in an advanced stage of devel-
opment (20—22). According to recent studies, how-
ever, CEA concentrations within each Dukes' stage
have little or no additional prognostic importance
(23—25). By determination of the time course of
CEA concentrations directly after surgical removal
of colorectal carcinomas, we were able to distinguish
between patients with CEA-secreting residual tum-
ours and those in which CEA-producing tissue had
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been removed, or in which no preoperative CEA in-
crease had been found (26). It was shown that CEA
concentrations greater than 20 \ig/l can also be
caused by the resectable primary tumour. We eon-
cluded from this that, after elimination of patients
with CEA-producing residual tumours, even a high
CEA serum concentration need not mean a poor
prognosis. This relationship has meanwhile been
confirmed by Persijn & Hart (24). If cases revealing
a residual tumour during Operation are excluded
from the follow up, there is no longer a significant
correlation between the preoperative CEA concen-
trations and the frequency of tumour recurrence. For
tumours sited away from the rectum or colon, how-
ever, CEA concentrations 8—10 fold higher than the
upper limit of the normal ränge indicate, with a high
degree of certainty, the presence of an extensive,
non-operable residual tumour or distant metastases
(27, 28).
Measurement qi CEA can serve äs a valuable sup-
plement to other procedures for the diagnosis of me-
tastases. In this connection, one study shoüld be not-
ed in which the combination of CEA measurement
and liver scintigraphy, showed a markedly higher
positive predictive value than the single test (29)
(fig. 4). The result was counted äs positive if both
tests were positive. The positive predictive value of
scintigraphy was 75%, and that of the CEA determi-
nation was 64%, whereas the combination of the two
resulted in a value of 100%. It is to be expected that
the diagnostic sensitivity of such a combination will
be lower than that of the single test. Thus, the diag-
nostic sensitivities are 42.1% + 14.0% = 56.1% for
the CEA determination, and 42.1% + 36.8% =
78.9% for liver scintigraphy, but only 42.1% for the
test combination (fig. 4). The consequence of com-
bining individual tests in this way is that fewer fälse
diagnoses are made, but the diagnosis at first re-
mains uncertaui for a larger number of patients.
These uncertain diagnoses must then be resolved by
further time course observations and/or alternative
diagnostic procedtires.
Preoperative measurement of AFP and HCG makes
a decisive contribution to the clinical staging of jion^
seminomatoüs germ cell tumours of the testes (30).
The importance of the determination of these tu-
mour markers is, however, relative, if staging is based
on pathological-anatomical criteria (31). This rela-
tionship is shown in täble2, where it is seen that
staging was improved by the determination of
markers only in stage A. As the tumour progressed
further, all cases showed tumour-associated in-
creases in the conceiiträtion of the tumour markers.
On the other hand, the AFP and HCG concentra-
tions are relatively insensitive indicators in the early
stages of lymph gland metastasis.
The existence of residual tumours and/or distant me-
tastases, following therapeutic Intervention, can also
be diagnosed by moiiitoring the time course of the
concentration of a tumour marker, providing the
D (57) 24/57 = 42,1%
D (320)
S (60)
CEA (50)
- S, CEA (24)
8,(3 (36)
S, CEA (26)
45/60 == 75%
D (45)
32/50 = 64%
24/24 = 100%
Not classified
*: S, CEA (391) 287/291=98·6%> (287)
CEA(327) -**1--*«* .5(302)
S(317) 30^7'^. 6(305)
Fig. 4. Diagnosis of liver metastases by liver scintigraphy (S) and CEA measurement (CEA). The iipper limit of the CEA reference
ränge was 3.6 times higher than the upper limit of the normal ränge. The presentation is according to Büttner (2), using data from
McCartney & Hoffer (29).
D: liver metastases confirmed in course of the illness. D: no liver metastases in follow-üp period. Si.positive scintigram S:
negative scintigram CEA: positive CEA test CEA: negative CEA test.
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Tab. 2. Frequency of elevated levels of human chorionic gonado-
tropin (HCG) and alpha-foetoprotein (AFP) in serum
samples obtained after orchiectomy but immediately be-
fore any other therapy in 142 patients with non-semi-
nomatous germ cell tumoursa (according to Skinner &
Scardino (31)).
Stageb
A
Bl
B2
B3
C
No.of
patients
67
15
23
6
31
HCG
(%)
7
29
52
83
84
AFP
(%)
9
33
43
75
60
Either
(%)
10
50
64
100
93
8
 These figures represent data collected since 1973 ftom a com-
bined group of patients treated at the Walter Reed Army Medi-
cal Center, the National Cancer Institute and UCLA.
b
 Stage A: disease confined to the scrotum.
Stage B1: metastases to <6 retroperitoneal nodes with no node
>2cm in diameter.
Stage B 2: metastases to ^6 retroperitoneal nodes or any me-
tastases >2cm in diameter.
Stage B 3: bulk abdominal disease.
Stage C: metastases above the diaphragm or to the viscera (liv-
same marker was elevated before the onset of ther-
apy. For tumour markers with a known biological
half life and a uniform pattern of elimination, a de-
layed decrease can be distinguished from a non-de-
layed decrease in concentration. At the moment this
is possible only for AFP (32). For other markers, a
complete fall in concentration is generally consi-
dered to be a negative result, and an incomplete de-
crease is counted äs positive.
Contradictory data have been reported for the speci-
ficity of the post-therapy diagnosis of residual tum-
ours and/or distänt metastases by monitoring the
time course of tujnqür markers. Many authors con-
sider a complete or -delayed decrease in marker
concentration tö be relatively certain evidence for
the complete elimination of tumour cells (32-34).
According to other stüdies, however, the diagnostic
specificity of a non-delayed ör complete concentra^
tion decrease is relatively low (35—37).
A decrease in CEA concentration to a stable but ele-
vated level may be observed when a non-malign ill-
ness is also present (36). The absence of any de-
crease, or an incomplete decrease of CEA with a
subsequent rise is, on the other hand, relatively cer-
tain evidence of a residual tumour (33). There is a
lack of agreement on the diagnostic value of an ex-
tended AFP half life (32, 35).
Diagnosis of Tumour Recurrences
After resection of a carcinoma, the rationale of rec-
ognizing renewed tumour growth is similar to that of
a screening investigation in a highly selected popula-
tion with a high frequency of illness; in patients with
resectioned colon carcinoma, for example, this fre-
quency is 30 to 40%. On the basis of this high fre-
quency of illness, the predictive value of a positive
tumour marker test is markedly higher than in a nor-
mal population or in patients with questionable diag-
noses. The result may be based on an individual test
or a combination of different tests, depending on the
clinical problem and the therapeutic consequences.
In both cases, the decision äs to whether a result is
positive or negative depends on the reference ränge,
which is established by a transverse study. Alterna-
tively, a result may be designated negative or posi-
tive on the basis of the time course of the marker
concentration in one particular patient. In this con-
nection, for the purpose of comparing different in-
vestigations, it is essential to establish the exact crite-
ria for a concentration increase.
The technique used by Martin et al. (38) for the de-
termination of a CEA increase takes into account
the variance of the method. Intra- and interassay
variance of the CEA determination were determined
in 9 different concentration ranges between l and 10
|ig/L These values were recorded on a nomogram
with calibration marks for the average value and the
95% confidence interval. If a significantly increased
value is measured, then both samples are analysed
again in a single assay. Thus, alterations of concen-
tration due to methodical variance are largely ex-
cluded. Alterations of CEA concentration caused by
non-malign conditions are not, however, excluded
by this method.
Steele et ai. (25) estimated the CEA increase by a
slope analysis, using at least four determiiiations to
calculate the slope. The logarithms of CEA concen-
trations are plotted against time, and the average
monthly concentration increase can be calculated
from the slope of the regression line. This method
permits an exact retrospective, statistical evaluation,
and provides a. quantitative assessment of malignant
growth. For diagnostic purposes and for therapeutic
decision making, however, a relatively long time is
required to obtain the positive test result. Other
workers regard the result äs positive if at least two
suecessive analyses show concentrations outside the
normal ränge (39), or if one value is several fold
higher than the upper limit of the normal ränge (40).
More complicated definitions of a concentration in-
crease are also used (21, 24).
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The diagnostic value of a postoperative CEA in-
crease can be assessed from the results of two colla-
borative studies using a large number of cases,
shown figure 5. Despite different working definitions
for the positive test result, the results of the two stu-
dies compare well with each other. The study repre-
sented in figure 5a was based on the äverage month-
ly increase in CEA (25), and was limited to patients
at Dukes' stages B2 and C, i.e. a high risk group for
tumour recurrence. A positive test result was re-
corded if the average CEA increase was greater than
3% per month. The diagnostic parameters are calcu-
lated from the "Vierfelder table". At 66.4%, the
positive predictive value of the CEA increase is rela-
tively low, especially if the possibility of a second-
look-operation is considered. In the quoted study,
the positive predictive value was, however, markedly
decreased by basing a positive test result on a single
CEA concentration, instead of ä concentration in-
crease. The predictive value was decreased, eveii if
the elevated concenträtion was more than four fold
higher than the upper limit of the normal ränge.
In the study represented in figure 5b, the test result
was positive if at least one postoperative CEA value
was 3.2 times higher than the upper limit of the nor^
mal ränge (40). The number of cases is similar to
that in the previpus investigation. Here also, the pre-
Monthlyrise>3%
Monthlyrise^3%
Recurrence
104
55
Np recurrence
52
388
P(D/T)
P(D/f)
104
"156"^
388
443
66,7%
87,6%
104P(T/D)= —= 65,4%
— — 388
— 88,2%
CEA >40 ng/1
CEA ^ 40 g/l
Recurrence
70
38
No recurrence
32
328
P(D/T)
P(D/T)
_ 70 _
~102~
__ 328 _
~366~"
68,6%
89,6%
TD + TD 398
N -468~85'0/° !
Diagnostic sensitivity of the CEA-rise äs first indicator of tumour progression:
CQ
P(T/D) = ^  = 54%
Fig. 5. Diagnostic sensitivity, specificity and efficiency, and the predictive value of the CEA concentration rise for the recognition of
tumour recurrence in patients with colorectal carcinoma.
a) Data from Steele et al. (25) for patients with colorectal carcinoma at Dukes* stages B2 and C. .
b) Data from Täte (40). . -
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dictive value of the positive test result is lower than
70%, whereas the predictive value of the negative
test result is approximately 90%. For more than half '
the patients with tumour recurrence, the elevated
CEA concentration was the first indicator that the
disease was still present.
There is no disagreement that the increase of CEA
in a certain percentage of the patients is an earlier
indicator of relapse than other diagnostic measures
or subjective Symptoms. With few exceptions, no
causal therapy is so far available for distant metasta-
ses of colorectal carcinoma. The time between an in-
crease of CEA concentration and the diagnosis of a
local recurrence is therefore of special importance.
A local recurrence is more amenable to surgery than
distant metastases. According to the data of Persijn
& Hart (24), about one quarter of local tumour re-
currences were first detected by an increased CEA
concentration.
The question arises äs to whether a second-look-op-
eration should be performed with the aim of resec-
tioning the residual tumour, solely on the basis of an
increased CEA concentration. In other words, what
is the predictive value of the CEA concentration in-
crease äs the first objective indication of a local tu-
mour recurrence in the absence of distant metastases?
The most optimistic study reported so far is by Min-
ton & Martin (41). In 40 patients showing preopera-
tive elevated CEA concentrations, which became
normalized after surgery, a second-look-operation
was subsequently performed solely on the basis of an
increased CEA concentration. CEA was determined
at three monthly intervals in 22 patients, and at
monthly intervals in 18 patients. The concentration
increases were confirmed by use of the previously
mentioned nomogram. The positive predictive value
of a CEA increäse for a local relapse was 48%. In
other studies, the predictive values for a local relapse
are, however, much lower. The value of 7% from the
investigations of Mach et al. (42) is comparable with
the resuits of Persijn & Hart (24). In the latter study,
an increäse of CEA at least 200 days before diagno-
sis of a local relapse showed a predictive value of
5%. The positive predictive value for a local relapse
may possibly be increased by slope analysis (43).
Distant metastases are more frequently accompan-
ied by steep cöncentration increases, whereas the in-
crease for a local relapse tends to be more graduaL
In a cömparison of patients with slow and steep CEA
concentration increases, Wood et al. (39) reported
twice äs many cases of relapse in the former group.
If, äs in the last example, a serious therapeutic deci-
sion must be made on the basis of a single diagnostic
test, then the predictive value of the positive test re-
sult becomes a factor of major importance in the es-
timation of the diagnostic value. In this case, the pro-
portion of false positive test resuits is critical. If,
however, a test or test combination is required that
will detect the greatest possible proportion of pa-
tients with tumour recurrence, then the negative pre-
dictive value is critical. In the latter Situation, the
Proportion of false negative test resuits should be
kept äs low äs possible. On the other hand, the false
positive resuits can be tolerated, because the diagno-
sis can be confirmed by invasive procedures, or by a
more exact monitoring of the patient. This is demon-
strated below by an example (tab. 3; (44)). A test
combination is required for the detection of distant
metastases, following the Operation for mammary
carcinoma. The tests should impose äs little strain äs
possible on the patients, and be capable of the earli-
est possible detection of the highest possible percen-
tage of distant metastases. Table 3 shows the resuits
of individual tests in cases of diagnosed distant me-
tastases. With respect to diagnostic specificity, the
CEA determination is superior to all other methods.
At least one of the tests marked with an asterisk was
positive for 46 out of 47 patients with distant meta-
stases. In one half of the cases, the positive test result
was obtained 3 months or more before the conclu-
sive clinical diagnosis. The and/or linkage of individ-
ual tests should result in a relatively low specificity
for the positive test result. Nevertheless, false posi-
tive resuits were recorded for only 3.5% of the pa-
tients. There are two reasons for this:
1. the upper limit of the CEA reference ränge was
three times higher than the normal ränge, and
2. the group in question is a very high risk group
with a metastasis prevalence of 33%.
Tab. 3. Abnormal biochemical and physical tests of first presen-
tation with metastases in 47 patients with breast cancer
(according to Coombes et al. (44)).
Test No. abnormal
Biochemical tests
Erythrocyte Sedimentation rate
-Glutamyl transpeptidase
AJkaline phosphatase
CEA
Hydroxyproline
Physical tests
Clinical examination
Chest X-ray
Bone scan
Liver scan
Liver ultrasound
Skeletal survey
Bone-marrow aspirate
5/31(16%)
9/30 (30%)*
15/46(32%)'
16/36(44%)*
8/32 (25%)
19/47(40%)*
19/44 (43%)'
15/44 (34%)
3/30(10%)
4/26(15%)
13/38(34%)
7/34(21%)
* Combination of these tests would have detected metastases in
46/47 patients.
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Monitoring of Radio- or Chemotherapy
Tumour markers are frequently the most sensitive
objective parameters for detecting the presence of
marker-producing tumours or portions of tumour
tissue that have resisted radio- or chemotherapy. In
patients with cervical carcinoma, providing the CEA
serum concentration is elevated before the Start of
radiotherapy, the success of the treatment can be
monitored by measuring the time course of the CEA
concentration (28). Determination of CEA provides
an objective assessment of the resistance to chemo-
therapy of CEA-producing mammary carcinomas
(about 50% are CEA producers) (45, 46). The che-
motherapy of non-seminomatous germ cell tumours
is monitored by the determination of AFP and HCG.
In the quoted example (47) (fig. 6), there is a dra-
matic fall in the AFP concentration at the Start of
chemotherapy, with a less pronounced decrease in
HCG. Tumour recurrence during chemotherapy is
detected earlier, by the occurrence of increased
marker concentrations than by other diagnostic
procedures. This example shows that a decrease in
the concentrations of a tumour marker during che-
motherapy only reflects the chemotherapeutic sensi-
tivity of a corresponding proportion of marker-pro-
ducing tissue. Unchanged concentrations of marker
do not exclude the possibility of the further growth
of marker-negative tissue. On the other band, in-
creasing concentrations are usually an indication of
continued or renewed tumour growth.
Resume
The effective use of tumour marker determinations
in tumour diagnosis depends ön an adequate defini-
tion of the positive or negative test result, and on the
correct choice of the pätient group to be investigät-
ed. The diagnostic potential of these tests should be
suited to the nature of the clinical problem. If they
are used in appropriate combinatiorts with other di-
agnostic procediires, and the time course of mafker
concentration is taken into account, then tumour
markers cän extend and expand the possibilities for
tumour diagnosis. Tumour markers are particularly
effective in the early recognition of local relapses
and metastases, and for the sensitive and objective
monitoring of radio- or chemotherapy.
10 12
t[months]
Fig. 6. Time course of serum concentrations of alpha-foetoprptein and human chorionic gonadotropin in a pätient with non-seminomat-
ous germ cell tumour (from Lange et al. (47)).
(1) Radical orchiectomy,
(2) retroperitoneal lymphadenectomy,
(3) start of chemotherapy,
(4) change of chemotherapeutic regime
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